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CHAPTER 1 
 
 
Introduction 
Platelets in CAD- Part 1 
10 
 
 
 
 
A long way has been moved from the introduction of percutaneous coronary interventions (PCI) in 
1977 to present days, where innovations in materials and technologies and the advances in new 
generations of drug eluting stents render PCI the best treatment option for coronary artery disease 
(CAD) (1,2). 
 
In fact, an escalation in complexity has been observed in PCI, extending the indication to 
percutaneous treatment to more extreme coronary lesions and higher-risk patients, that, however, 
might be exposed to an increased occurrence of periprocedural complications (3,4). 
 
Platelets certainly play a crucial role in such events, as these subcellular fragments are held 
responsible for the majority of haemostatic processes and for the pathogenesis of acute coronary 
syndromes and thrombotic events after coronary stent implantation (5). 
 
In these settings, achieving an adequate platelet inhibition represents the basis of pharmacological 
strategies, in order to prevent acute and long-term recurrent ischemic events (6). 
 
Therefore, several efforts have been accomplished in optimizing antiplatelet therapies and in the 
identification of humoral or genetic factors enhancing platelet reactivity. 
 
 
Periprocedural thrombotic complications in PCI 
 
 
Thrombotic complications, in patients undergoing coronary percutaneous coronary 
revascularization, represent a broad spectrum of events ranging from the most severe complete 
vessel occlusion, due to stent thrombosis, to more discrete microvascular events. Unfortunately, 
most of these events translate into an impaired myocardial perfusion, with a periprocedural 
myocardial injury. 
Periprocedural myocardial infarction (PMI) is defined as a release of cardiac enzymes (Troponines, 
Creatine-kinase) above 3-5 times the upper limit of normality indicating a myocardial damage 
consequence of PCI (7). Its incidence ranges from 3.6% to 48.8%, depending on the patients’ 
presentation, angiographic characteristics, and the adjunctive pharmacotherapy, with a negative 
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impact on outcomes (8). In a substudy of the ACUITY trial (9), in fact, PMI was associated with 
increased mortality at 1 year (6% vs 2.6%; P < 0.0001), and similarly the Cornell Angioplasty 
Registry (10) showed that troponin I levels greater than 5 times ULN were independently 
associated with a 1.8-fold increase of long-term (2-year) mortality. 
 
 
 
 
 
 
 
 
 
Figure 1.   Mechanisms involved in periprocedural myocardial infarction 
 
 
Flow-limiting complications, such as distal embolization, side branches loss or coronary dissection 
are macroscopic established causes of PMI, that, however has been reported even in apparently 
uncomplicated procedures (11). Microvascular obstruction by neutrophil and platelet plugs, local 
vasoconstriction and myocardial edema have been claimed for these silent events (12). Indeed, 
circulating mediators released after coronary stenting and pro-thrombotic conditions can favor 
these occurrences, by enhancing platelet reactivity, although the factors and biomarkers predicting 
the risk of periprocedural myonecrosis are still poorly understood. 
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Pro-thrombotic status in high-risk populations 
 
 
The prognosis of patients with coronary artery disease has significantly improved in the last 
decades, and especially in those admitted for ST-segment elevation acute coronary syndromes, 
further to the large widespread application of primary angioplasty (13). 
 
However, suboptimal results have been achieved so far in certain higher-risk populations, including 
patients with advanced age, cardiogenic shock, or diabetes mellitus (14,15). 
 
The incidence of diabetes in Western countries is raising epidemically, and subsequently the 
number of diabetic patients being treated for CAD (16). 
 
However, the prognostic difference in diabetic as compared to non diabetic patients is still relevant. 
Despite bypass surgery is still deemed as the best revascularization option in stable diabetics with 
multivessel coronary disease (17), a large quote of diabetic patients undergoes percutaneous 
procedures with stent implantation, especially in the context of acute myocardial, infarction, being 
exposed to a higher risk of periprocedural complications, stent thrombosis and repeated 
revascularization as compared to non diabetics (18). 
 
Diabetic patients certainly display a higher pro-thrombotic risk, as hyperglycemia and insulin 
resistance, in these patients induce an increase in oxygen radicals and other cytokines, favoring 
endothelial dysfunction, chronic low-grade inflammation and aggregation, especially in patients 
with poor glycemic control (19,20). 
In fact, platelet hyper-reactivity and reduced effectiveness of antiplatelet agents observed in 
diabetics, account for great part of these ischemic complications, thus justifying a more aggressive 
management and explaining the great efforts accomplished to establish an optimal antiplatelet 
treatment among these patients (21). 
 
Therefore, individualized antiplatelet strategies should be hypothesized for these subsets of 
patients, shifting the attention on the identification of adequate tools for the stratification of their 
thrombotic risk. 
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Definition of high-on treatment platelet reactivity 
 
 
In current clinical practice, several patients can experience recurrent ischemic events despite dual 
antiplatelet therapy (DAPT) and the underlying mechanism is often considered a poor response to 
antiplatelet agents, or “high-on treatment residual platelet reactivity” (HRPR) (22). 
 
Besides this clinical definition of HRPR, in case of thrombotic events, several platelet assays have 
been developed in order to identify those patients with enhanced platelet reactivity. However, while 
all these different whole blood “bedside” tests agreed on the prognostic impact of HRPR (23), the 
use of different cut-off values for the definition of antiplatelet agents resistance lead to a great 
uncertainty in identifying the prevalence and predictors of platelet hyper-reactivity (24). 
Only in a recent consensus, by Bonello et al. (25) attempted to set order in the definitions of 
resistance to antiplatelet agents, providing a validation for the selection of the cut-off points and the 
application of platelet function testing in clinical practice. 
 
Indeed, the first attempts of tailoring DAPT according to the results of aggregation assays have 
failed to provide any clinical benefit. In the GRAVITAS trial (26), the use of high-dose clopidogrel 
compared with standard-dose clopidogrel among patients with HRPR after PCI, did not reduce the 
incidence of death from cardiovascular causes, nonfatal myocardial infarction, or stent thrombosis, 
although slightly increasing the risk of bleedings. Similar results were obtained by Montalescot et 
al. in the ARCTIC trial (27). 
 
More recently, Multiple Electrode Aggregometry has emerged as the aggregation test best 
predicting the risk of MACE in a large cohort of 7,090 consecutive PCI-treated patients (28). 
Similar results were reported in the 416 clopidogrel treated patients of the PEGASUS-PCI (29) 
and, the same authors, subsequently demonstrated in the MADONNA trial (30) that tailoring 
antiplatelet therapy according to MEA-defined HRPR resulted in a significant reduction in ischemic 
events, whose benefits tended to increase over time. 
Therefore, future directions for platelet function testing can be considered in defining the best 
antiplatelet strategy option in patients with a high thrombotic risk. 
Platelets in CAD- Part 1 
14 
 
 
 
 
Platelet aggregation 
 
 
Antithrombotic pharmacological strategies 
 
 
Dual antiplatelet therapy with ASA and an ADP-antagonist represents the fundament of 
pharmacological therapy after PCI or an acute coronary syndrome, even in patients not undergoing 
invasive treatment. 
 
Fifteen years ago, the CURE trial (31) showed that 1-year administration of a dual antiplatelet 
therapy with ASA and clopidogrel provided significant benefits as compared to 1-month DAPT and 
subsequent ASA alone in patients with non-ST segment elevation acute coronary syndromes, 
reducing the risk of major cardiovascular events. 
 
However, delayed onset of antiplatelet effect and interindividual variability of response with a 
prevalence of poor responders of about 30% have emerged with clopidogrel (32), giving the need 
for the development of new ADP-antagonists. 
 
 
 
 
 
 
 
 
Figure 2. Principal pathways for platelet aggregation and mechanism of action of antiplatelet drugs (adapted from 
Vorcheimer et al. JAMA Apr 21 1999; 281: 15) 
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clopidogrel, providing a more powerful and predictable antiplatelet effect, and a faster onset of 
action, as their activation does not require complex metabolic pathway (33). In fact, in the PLATO 
trial (34), ticagrelor decreased the incidence of major adverse cardiovascular events (MACE) and 
total mortality in patients with ACS, thus being so far the only ADP-antagonist to achieve such a 
survival benefit. 
 
Similar advantages were expected to be found with cangrelor (35), an endovenous ADP- 
antagonist, reducing stent thrombosis and repeated revascularization, without significant increase 
in periprocedural bleedings, even in association to GPIIbIIIa inhibitors. 
 
Glycoprotein IIb-IIIa inhibitors are, in fact, the most potent antiplatelet agents, whose advantages 
has been clearly demonstrated in the early phases of acute myocardial infarction (36), preventing 
the problems of delayed onset of action or impaired gastrointestinal absorption of oral drugs. 
 
Certainly, more potent antithrombotic therapies are weighted by an intrinsic higher risk of bleeding 
complications, thus raising several concerns on the correct balance between ischemic prevention 
and hemorrhagic risk. 
 
Great expectations, in this sense, have been conveyed to bivalirudin, as an alternative to heparin 
for anticoagulation in patients undergoing percutaneous coronary interventions (PCI). However, 
despite several trials documented a reduction in major bleedings with bivalirudin, this translated 
into mortality benefits only in the HORIZON-AMI trial (37), where bivalirudin was compared with 
unfractionated heparin and routine GPIIb-IIIa inhibitors in STEMI patients, whereas no benefits in 
outcome were observed in several other trials, with even an increased risk of thrombotic 
complications. Similar findings have recently been observed in HEAT PPCI trial (38). Therefore, 
the real beneficial effects of bivalirudin in ACS patients are still to be elucidated. 
 
Beyond periprocedural antithrombotic strategies, anyway, the maintenance of a long-term oral dual 
antiplatelet therapy has the most relevant prognostic impact, as early interruption of DAPT for 
bleeding complications or comorbidities is associated with a poor outcome. However, optimal 
duration of dual antiplatelet therapy is still to be defined, since recent studies have suggested   that 
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a shorter DAPT duration could be safe with new generations of drug eluting stents, while a very 
prolonged treatment could increase the hemorrhagic risk. 
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THIS THESIS 
 
 
This thesis addresses multiple and different aspects of daily clinical practice in the management of 
antithrombotic strategies in patients with stable coronary artery disease or acute coronary 
syndromes, treated with percutaneous coronary revascularization, and the identification of factors 
contributing to the increased atherothrombotic profile of high-risk patients such as those with 
diabetes. 
 
Part 2 is focused on thrombotic complications during percutaneous coronary interventions and 
mainly on the pathogenesis of periprocedural myocardial infarction (PMI). Chapter 2  addresses 
the role of platelet size on the occurrence of periprocedural myocardial injury, whereas Chapter 3 
and Chapter 4 discusses the impact of PlA1/PlA2 single nucleotide polymorphism of platelet 
glycoprotein IIb-IIIa on PMI in elective patients and in the settings of acute coronary syndromes. 
 
Part 3 is centered on those subsets of patients at higher thrombotic risk, and especially on 
diabetics. Chapter 5 evaluates the differences in mean platelet volume in patients with and without 
diabetes mellitus, with a particular focus on coronary artery disease and platelet aggregation. 
Chapter 6 is dedicated to uric acid as a thrombotic marker in diabetic patients. Chapter 7 
evaluates the role of diabetes and glucose control on platelet function and the prevalence of high- 
on treatment platelet reactivity in ticagrelor treated patients. 
 
Part 4 is dedicated to pharmacological innovations in the field of antithrombotic therapies. Chapter 
8 addresses the benefits of new ADP-antagonists as compared to clopidogrel in a meta-analysis of 
randomized trials. In Chapter 9 we present an updated meta-analysis of randomized trials 
comparing bivalirudin with unfractionated heparin, with or without glycoprotein IIb-IIIa inhibitors 
during PCI. Chapter 10 addresses the debated issue of optimal duration of  dual antiplatelet 
therapy among patients receiving drug eluting stents implantation. 
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Abstract 
Background Periprocedural myocardial infarction (PMI) represents a relatively common 
complication of percutaneous coronary intervention (PCI). Mean platelet volume (MPV) has been 
proposed as a marker for platelet activation, as larger sized platelets have been associated with 
higher pro-thrombotic risk. 
Therefore, aim of the current study was to evaluate whether MPV is associated with increased risk 
of PMI after PCI. 
 
Methods We included 1056 consecutive patients undergoing PCI. We measured myonecrosis 
biomarkers at intervals from 6 to 48 h after PCI. Periprocedural myonecrosis was defined for 
troponin I increase by 3 times the ULN or by 50% if elevated at the time of the procedure. PMI was 
defined as CK-MB increase by 3 times the ULN or 50% if elevated at the time of the procedure. 
 
Results We grouped patients according to tertiles values of MPV (<10.4 fl; 10.5-11.3 fl; >11.4 fl). 
High MPV was associated with diabetes (p=0.025) and higher prevalence of cerebrovascular 
events (p=0.005). MPV significantly related with haemoglobin levels (p < 0.001), but inversely to 
platelet count (p < 0.001) and higher presence of thrombus (p = 0.03). Larger sized platelets did 
not increase risk of periprocedural myonecrosis (p=0.91; OR [95% CI]= 1.04 [0.90-1.2], p=0.64) or 
PMI (p=0.09; OR [95%CI]= 1.13 [0.93-1.37]; p=0.20). Subgroup analysis confirmed no impact of 
MPV on periprocedural MI also in high-risk subsets of patients, such as those with ACS at 
presentation (OR [95%CI] = 1.09 [0.87-1.38]; p=0.44), diabetes (OR [95% CI]= 1.02 [0.71-1.47], p= 
0.91), female gender (OR [95% CI] = 1.15 [0.78-1.71], p=0.48), elderly patients (age ≥ 75 years) 
(OR [95%CI] = 1.21 [0.87-1.69], p=0.25) or with renal failure (OR [95%CI] = 1.55 [0.91-2.61], 
p=0.1). 
 
Conclusions This study demonstrates that MPV does not predict the risk of PMI in patients 
undergoing PCI. 
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Background 
 
Periprocedural myocardial infarction (PMI) represents a relatively common complication of 
percutaneous intervention (PCI). In fact, despite several attempts to prevent myocardial injury after 
PCI, a significant elevation of biomarkers of myonecrosis occurs in 5-30% of patients (1). Several 
mechanisms are implied in PMI, including distal embolization, side-branch occlusion or coronary 
dissection, however myocardial injury can also occur after apparently uneventful PCI procedures in 
case of failure to obtain adequate myocardial perfusion (2, 3). Microvascular obstruction by 
neutrophil and platelet plugs, local vasoconstriction and myocardial edema have been claimed for 
these silent events. Several efforts have been focused in the last decades on new drugs and 
devices in order to prevent periprocedural complications in acute and elective setting (4-10). The 
improvements of drug-eluting stent have further contributed to reduce the risk of TVR and enlarge 
the indication of coronary angioplasty (11), with a larger proportion of high-risk patients and more 
complex coronary lesions, that might be at higher risk for periprocedural myonecrosis. Platelets 
certainly play a major role in complications in the acute and elective setting. Mean platelet volume 
(MPV) has been considered as a routinely available marker of platelet activity. In fact, larger sized 
platelets have been associated to enhanced reactivity and increased production of pro-aggregating 
mediators (12-15). Recent studies have reported higher values of MPV in patients with enhanced 
pro-thrombotic status, such as in diabetes mellitus, acute coronary syndromes and stroke and 
suggested MPV to predict the risk of future adverse coronary events after acute MI (16-20). 
Moreover, MPV has been associated with clinical and angiographic outcome after PCI, influencing 
coronary flow and myocardial perfusion in STEMI patients and increasing the risk of restenosis and 
events at long-term follow-up (20-22). 
 
The aim of our study was, therefore, to evaluate whether MPV is associated with the risk of 
periprocedural myocardial infarction after PCI. 
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Methods 
 
 
This is a single-center prospective study including patients undergoing PCI from January 2007 to 
January 2010. The study was approved by our local Ethical Committee. Coronary angioplasty was 
performed with standard techniques. Use of stents, type of stents and stent implantation techniques, 
as much as the use of directional or rotational atherectomy, IVUS, glycoprotein IIb-IIIa inhibitors, was 
left at the discretion of the operators. All patients received, according to guidelines, high-dose bolus 
of clopidogrel (600 mg) at the time of hospitalization or before angioplasty. Patients were clinically 
followed up to hospital discharge. 
 
Biochemical measurements 
 
Blood samples were drawn at admission in patients undergoing elective (following a fasting period of 
12 h) or urgent coronary angiography. Glucose, creatinine, and lipid profile were determined by 
standard methods. We measured MPV in a blood sample collected in tripotassium EDTA (7.2 mg) 
tubes. These blood samples were analyzed within 2 h of venipuncture by automatic blood counter (A 
Sysmex XE-2100) used for whole blood analysis. The expected values for MPV in  our laboratory 
ranged from 7.0 to 11.0 fl. The analytical Coefficient of Variation for MPV ranged from 
2.2 to 1.1 %. Cardiac biomarkers (Troponin I and CK-MB) were measured at baseline, before 
coronary revascularization, and later 6, 12, 24 and 48 h after PCI. 
 
Coronary angiography 
 
Coronary angiography was routinely performed by the Judkins technique using 6-French catheters. 
Quantitative coronary angiography was performed by experienced interventional cardiologists by 
an automatic edge-detection systems (Siemens Acom Quantcor QCA, Erlangen, Germany) (23). 
 
Study Endpoints 
 
Primary study endpoint was PMI defined as CK-MB mass release > 3 times ULN or increase by 
50% if already elevated at the time of the procedure. Secondary study endpoint was periprocedural 
increase in troponin I > 3 times ULN or increase by 50% if already elevated at the time of the 
procedure. 
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Statistical analysis 
 
 
Statistical analysis was performed using SPSS 15.0 statistical package. Continuous data are 
expressed as mean + SD and categorical data as percentage. Analysis of variance and the chi- 
square test (or Fisher-test) were used for continuous and categorical variables, respectively. Trend 
analysis was performed as previously described (24). Multiple logistic regression analysis was 
performed to evaluate the relationship between MPV and periprocedural myocardial necrosis or 
infarction, after correction for clinical and angiographic significant differences, that were entered in 
the model in block. 
 
Results 
 
 
Our population is represented by a total of 1056 patients undergoing coronary angioplasty Patients 
were divided in three groups according to tertiles values of MPV (< 10.4 fl, Group 1; 10.5-11.3 fl, 
Group 2; > 11.3 fl, Group 3). Patients’ characteristics are reported in Table 1. 
 
Most of the clinical and demographic features were similar between the 3 groups. Larger platelets 
were associated with higher prevalence of diabetes mellitus (p<0.001) and previous 
cerebrovascular events (p=0.005), higher rates of ARB (p<0.0001) and statin (p=0.01) therapy at 
admission. Platelet size was directly related to haemoglobin levels (p<0.0001) and WBC count 
(p=0.03) but inversely related to platelet count (p<0.0001). 
 
Mean platelet volume was not associated with the indication to coronary angiography, including 
acute coronary syndromes. 
 
Main angiographic and procedural findings and QCA parameters are listed in Table 2. No 
difference was found according to platelet size, except for higher presence of thrombus in patients 
within the lower tertile (p=0.03). 
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Table 1. Baseline Clinical Characteristics of patients according to mean platelet volume (MPV) 
tertiles 
 
Baseline Clinical 
Characteristics 
Group 1 
MPV I tert 
(<10.4) 
N=370 
Group 2 
MPV II tert 
(10.3-11.3) 
N=351 
Group 3 
MPV III tert 
(>11.3) 
N=334 
P value 
Age (meanrSD) 
Male Sex (%) 
Diabetes (%) 
Dyslipidemia ( %) 
 
Renal failure (%) 
Family history of CAD (%) 
Hyperomocystinemia ( %) 
Smoking (%) 
Active smoker 
Previous smoker 
Hypertension (%) 
History of MI (%) 
Previous PCI (%) 
Previous CABG (%) 
Previous CVA (%) 
Biochemistry 
Platelets (10^3/μl; rSD) 
Haemoglobin ( g/dlrSD) 
Creatinine (mg/dl rSD) 
Glycemia (mg/dlrSD) 
White Blood Cell (10^3/μl; rSD) 
Indication to angiography 
Stable angina or silent ischemia (%) 
Acute coronary syndrome (%) 
Arrhythmias/Valvulopathy/LV 
dysfunction (%) 
Therapy at admission 
ACE inhibitors (%) 
ARB (%) 
Beta blockers (%) 
Nitrates (%) 
Calcium antagonists (%) 
Diuretics (%) 
Statins (%) 
ASA (%) 
Clopidogrel (%) 
67.4 (r11.1) 67.6 (r11.5) 69 (r11.1) 0.10 
73.2 75.8 76.1 0.61 
24.9 30.6 34.1 0.025 
59.6 55.1 58.1 0.50 
16.5 15.5 18.9 0.47 
30.5 28.2 32 0.55 
66.4 60.7 64 0.32 
0.37 
22.6 25.6 
25.4  
24.5 24.8 29  
72.7 70 75.7 0.32 
24.6 24.8 29.6 0.24 
23.8 22 27.5 0.23 
14.6 10.5 12.9 0.26 
6.3 6.6 12.4 0.005 
 
228.2 (r62.9) 213.8 (r55.2) 196.8 (r61.7) <0.0001 
13.1 (r1.9) 13.6 (r1.6) 13.6(r1.7) <0.0001 
1.08 (r0.58) 1.16 (r0.80) 1.18 (r0.84) 0.23 
128.9 (r50.7) 134.9 (r63.9) 138.4 (r64.9) 0.10 
8 (r2.5) 7.9 (r2.5) 8.4 (r3.2) 0.03 
0.26 
14.7 16.5 15.5  
83.4 78.9 81.8  
1.9 4.6 2.7  
 
39.5 40.2 37.4 0.75 
15.1 16 27.8 <0.0001 
53.2 48.1 54.8 0.19 
37.8 38.7 45.2 0.10 
22.2 20.5 25.7 0.25 
26.8 25.4 27.5 0.81 
47.3 53 58.7 0.01 
57.3 63.2 65 0.09 
28.2 30.8 32.5 0.35 
 
MI= myocardial infarction; CVA= cerebrovascular accident; LV= left ventricle; WBC = white blood cells; 
ACE= angiotensin coverting enzyme; ARB= angiotensin receptor blockers. 
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Table 2. Angiographic and procedural characteristics according to mean platelet volume (MPV) 
tertiles 
 
 
Angioplasty features 
Group 1 Group 2 Group 3 
MPV I tert MPV II tert MPV III tert P value (<10.4) (10.3-11.3)  (>11.3) 
N=466 N=447 N=426 
Multivessel CAD 
1 
t2 
Severe CAD*(%) 
Gp IIb-IIIa inhibitors § 
Clopidogrel bolus > 6 hours before 
Multivessel PCI § 
N treated vessels § 
1 
2 
3 
Lesion length (mm ± SD) 
Target Vessel  diameter (mmrSD) 
% stenosis 
Target vessel (%) 
Right Coronary Artery (%) 
Left Main (%) 
Left Anterior Descending (%) 
Circumflex branch (%) 
Saphenous venous graft (%) 
Side branches (%) 
Type C lesions 
Calcifications (%) 
Thrombus (%) 
TIMI flow pre-PCI <3 (%) 
Instent restenosis (%) 
Chronic occlusion (%) 
Bifurcation (%) 
Direct stenting (%) 
Thrombectomy (%) 
Max balloon inflation (atmrSD) 
Kissing balloon (%) 
Slow flow (%) 
Distal embolization (%) 
Side branch loss (%) 
TIMI post PCI <3 
0.65 
40 42.2 40.1  
60 57.5 59.9  
31.4 29.9 30.5 0.92 
38.5 43.4 36.8 0.19 
33.4 32.8 29.2 0.53 
21.8 23.1 22.5 0.92 
0.87 
78.2 76.9 77.5  
18.6 18.8 17.7  
3.2 4.3 4.8  
19.7 (±12.7) 20.1 (±12.5) 19.7 (±12.6) 0.87 
3.1 (± 0.6) 3.1 (± 0.6) 3 (±0.6) 0.65 
89.7 89.1 88.9 0.49 
0.39 
34.7 33 29.1  
2.7 2.1 2.7  
27.5 33.9 31.1  
20.5 18.6 21.1  
3.2 1.9 3.6  
11.4 10.5 12.4  
25.9 27 28.7 0.65 
17.2 17.9 23 0.07 
11.8 9 6.5 0.03 
15.6 7.1 9.8 0.06 
6.2 4.9 5.8 0.69 
9.8 7.2 10.1 0.26 
18.8 20.1 15.9 0.28 
26.6 28.2 24.6 0.07 
3.7 3.8 1.8 0.18 
20.9 (±3.8) 20.7 (±4.1) 20.6 (±4) 0.48 
8.1 9.6 8.6 0.78 
1.4 2.4 1.3 0.42 
1 0.7 0.5 0.77 
0.2 1.5 0.5 0.10 
5.6 3.3 1.8 0.13 
 
 
*Defined as 3-vessel disease and/or left main disease; CAD= coronary artery disease; 
§ per patient definition 
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No difference was observed between the groups in terms of PMI (Fig. 1) and periprocedural 
myonecrosis (Fig. 2). The results were confirmed after correction for baseline confounding factors 
for both PMI (Adjusted OR [95% CI] = 1.13 [0.93-1.37], p= 0.20) and periprocedural myonecrosis 
(Adjusted OR [95% CI] = 1.04 [0.90- 1.2], p=0.64). 
 
Figure 1 
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Figure 1. Bar graphs show the relationship between mean platelet volume (MPV) and periprocedural myocardial 
infarction (MI) ; ACS = Acute Coronary Syndrome. 
 
Figure 2 
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Figure  2. Bar graphs show the relationship between mean platelet volume (MPV) and periprocedural myonecrosis; 
ACS = Acute Coronary Syndrome. 
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Similar results were found when the analysis was conducted according to the ULN of  MPV (>  11 
fl; n= 411 or ≤ 11fl; n=645). In fact, PMI was observed in 20.5% of patients with normal MPV as 
compared to 15.2% in patients with high MPV (adjusted OR[95%IC]= 0.90 [0.65-1.25],p= 0.52), 
whereas periprocedural myonecrosis was observed in 53.1% and 55.3% of patients, respectively 
(adjusted OR[95%IC]= 1.07 [0.84-1.36],p= 0.59). The results did not change even when we 
compared patients with very low MPV (lowest quintile, < 10 fl, n = 255) vs patients into the highest 
quintile (n = 295), with therefore very high MPV (>  11.6 fl), in terms of both PMI (21.1 % vs 14.4 
%, Adjusted OR [95% CI ] =0.89 [0.55-1.5], p = 0.65 ) or myonecrosis ( 56.3 % vs 54.9%, Adjusted 
OR [95% CI ] = 1.1 [0.76-1.56], p = 0.65). 
 
As shown in Figure 3, lack of association between MPV and PMI was confirmed in subgroup 
analyses, including high-risk subsets of patients such as those with, such as those with ACS at 
presentation (OR [95%CI]= 1.09 [0.87-1.38]; p=0.44), diabetes (OR [95% CI] = 1.02 [0.71-1.47], 
p=0.91), female gender (OR [95% CI] =1.15 [0.78-1.71],p=0.48), elderly patients (age > 75   years) 
 
(OR [95%CI]= 1.21 [0.87-1.69],p=0.25) or with renal failure (OR [95%CI]= 1.55  [0.91-2.61],p=0.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure   3. 
 
Odds ratio for periprocedural myocardial infarction (MI) at logistic regression in overall cohort and in subgroups of 
patients; ACS = Acute Coronary Syndrome; CKD= chronic kidney disease. 
All patients (n = 1056)
Elective (n = 463)
ACS (n = 593)
Diabetes (n = 315)
No diabetes (n = 741)
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Figure 3
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Finally, Table 3 shows differences in clinical, angiographic characteristics and MPV between 
patients with or without periprocedural MI. 
 
Table 3. Main clinical features of patients with periprocedural MI. 
 
Baseline Clinical Characteristics No periprocedural MI 
N= 879 
Periprocedural MI 
N=177 
 
P value 
Age (meanrSD) 
Male Sex (%) 
Diabetes (%) 
Dyslipidemia ( %) 
 
Renal failure (%) 
Active smoking (%) 
Arterial hypertension (%) 
History of MI (%) 
Previous PCI (%) 
Previous CABG (%) 
Previous CVA (%) 
Acute coronary syndrome at presentation (%) 
Biochemistry 
Platelets (10^3/μl; rSD) 
Haemoglobin ( g/dlrSD) 
Creatinine (mg/dl rSD) 
Glycemia (mg/dlrSD) 
MPV  (fL; rSD) 
Therapy 
ACE inhibitors (%) 
ARB (%) 
Beta blockers (%) 
Nitrates (%) 
Calcium antagonists (%) 
Diuretics (%) 
Statins (%) 
ASA (%) 
Clopidogrel (%) 
Intraprocedural GPIIbIIIa administration (%) 
Clopidogrel bolus > 24hours (%) 
Angiography 
Multivessel disease (%) 
Multivessel PCI (%) 
Type C lesions (%) ‡ 
Thrombus (%)‡ 
Restenosis (%)‡ 
Direct stenting (%)‡ 
Kissing balloon (%)‡ 
Slow flow (%)‡ 
Side branch occlusion (%)‡ 
68 ± 10.6 67.8 ± 11.6 0.76 
75.3 73.6 0.63 
30.7 26 0.22 
60.4 42 0.17 
18.6 12.1 0.04 
23.1 28.2 0.06 
72.6 74 0.41 
28.8 18.1 0.004 
26.1 16.9 0.01 
13.8 6.8 0.01 
9.2 7.3 0.43 
79 89.9 0.002 
 
211.6 (r62.6) 217.3 (r53.6) 0.26 
13.3 (r1.8) 13.6 (r1.7) 0.09 
1.2 (r0.81) 1.1 (r0.63) 0.35 
133.6 (r62.3) 134.6 (r48.9) 0.85 
10.9 (r0.96) 10.7 (r0.99) 0.11 
 
40.5 38.4 0.61 
20.6 15.8 0.15 
54,7 39.5 <0.001 
43.9 27.7 <0.001 
23.8 18.6 0.14 
28.3 24.9 0.35 
50.6 40.1 <0.001 
65.5 52 0.001 
33.8 18.5 <0.001 
36.6 54.4 <0.001 
32.3 30.1 0.38 
 
59.6 62.1 0.75 
37.1 45.4 0.02 
25.2 33.8 0.01 
6.8 18 <0.001 
6.7 1.3 0.002 
64.5 67.2 0.60 
7.6 16.2 <0.001 
0.6 5.1 <0.001 
0.7 1.4 0.31 
‡ per lesion definition ( n=971 and n=238 respectively) 
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PMI was associated with ACS at presentation, (p=0.002), multivessel PCI (p=0.02), GPIIbIIIa 
inhibitors administration (p<0.001), higher thrombus burden (p<0.001) and more complex type C 
lesions, kissing balloon (p<0.001) and post-procedural slow-flow (p<0.001). On the contrary, PMI 
inversely related with renal failure (p=0.04), previous MI (p=0.004) previous PCI or CABG (p=0.01), 
restenosis (p=0.002) and specific treatment with beta-blockers, nitrates, statins, clopidogrel 
(p<0.001) and ASA (p=0.001), while no difference was observed in absolute values of MPV (10.9 
vs 10.7 fl, p = 0.11). 
 
 
Discussion 
 
The main finding of the present study is that MPV does not affect the risk of PMI in both elective or 
ACS patients undergoing coronary angioplasty. 
MPV has been reported to influence prognosis and angiographic results in patients with acute 
myocardial infarction and after PCI (20-22, 25). However, no study has so far evaluated the effect of 
MPV on PCI. Distal embolization, side branches loss and coronary dissection are well defined 
causes of myocardial injury, however PMI has been reported even in apparently uncomplicated 
procedures (1-4). Previous studies reported important role of no-reflow or “low  reflow” phenomenon 
in such events, meaning inadequate myocardial perfusion in absence of mechanical coronary 
obstruction. Microvascular obstruction by white cells and platelets plugging, so far as 
vasoconstriction due to platelets release of tromboxanes and other mediators, have been claimed as 
possible mechanisms (25, 26). Enhanced platelet reactivity, such as in acute coronary syndromes or 
in diabetes mellitus, has in fact been reported to increase the risk of PMI (27). 
Large interest has been focused on the role of MPV as prognostic marker in patients with coronary 
artery disease and in patients undergoing PCI, due to the fact that some reports showed a 
relationship between MPV and platelet reactivity. However, so far contrasting results have been 
reported. 
Goncalves et al. (21) recently reported in a large cohort of patients undergoing PCI, an increased 
incidence of death and myocardial infarction at 1 year follow-up in patients with highest values of 
MPV. Same long-term results were reported by Huczek (20) in STEMI survivors. In these patients, 
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the authors reported, moreover, a strong relationship between platelet size and no reflow or “low 
reflow”, displaying a strong correlation between higher MPV and corrected TIMI frame count 
(CTFC). 
In a previous report we did not find any relationship between MPV and the extent of CAD and 
platelet aggregation (28). In accordance with these data, Tavil et al (29), did not observe any 
difference among patients with or without significant coronary artery disease. Similar findings were 
observed by Halbmayer et al (30). 
No study has investigated so far the relationship between MPV and the risk of PMI in patients 
undergoing PCI. In our study, including 1056 patients, we found no association between high 
platelet size and the risk of PMI in both elective or ACS patients undergoing PCI. The results were 
confirmed in major high-risk subsets of patients. 
Several factors may contribute to explain our findings. In our study we included a large cohort of 
consecutive, unselected, patients, in order to obtain MPV values distribution closest to general 
population and to evaluate clinical impact of MPV in a condition reflecting everyday practice, ideal 
for a biomarker aimed to be routinely used to predict risk of PMI. 
MPV values in our patients were, then, far higher than those reported by previous studies; and 
applying the same limits used in those studies relating platelets size to angiographic results even 
subjects in our lower tertile (<10.3 fl) would have been considered as having high MPV. Therefore, 
lack of identifying differences between the 3 groups, in present study, could be explained if patients 
belonged all to the same “large sized platelets” category. However, our results were confirmed 
when the analysis comparing patients with very low MPV value vs very high MPV values (lowest vs 
highest quintile). 
In addition, extensive use of antiplatelet agents, such as pre-treatment with clopidogrel or GPIIbIIIa 
administration, could have prevented PMI in patients with higher platelet reactivity. In fact, ISAR- 
REACT 2 trial demonstrated important reduction of myonecrosis in patients with high risk ACS by 
GPIIbIIIa inhibitors treatment in association with clopidogrel (31). In ARMYDA trial, clopidogrel 
loading dose before PCI (600 mg) proved effective in preventing periprocedural complications in 
elective patients as much as statins pretreatment (32). 
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Furthermore, angiotensin II has been suggested to increase platelet size and to induce platelet 
shape change and activation, binding a specific receptor located on platelets surface. 
Pharmacological blockade of this pathway, by angiotensin receptor blockers (ARB), has been 
associated to reduced platelet aggregation both in vitro and in vivo (33,34). In our study, patients 
with larger sized platelets were more frequently receiving ARB as anti-hypertensive drugs, thus 
possibly preventing increased platelet reactivity in these subjects. However, no impact of MPV on 
periprocedural MI was confirmed after correction for baseline clinical differences. 
Furthermore, large MPV may not imply higher platelet reactivity. In fact, we previously found no 
relationship between MPV and platelet aggregation (28). In fact, the increase in MPV may be a 
process driven by increased production of bone marrow derived larger circulating reticulated 
platelets within the blood stream. In fact, in accordance with previous reports, we observed that 
MPV was inversely correlated with the total platelet count, which could even suggest the 
consumption of small platelets and a compensatory production of larger reticulated platelets. 
Indeed, MPV has been shown to correlate with both megakaryocyte ploidy and with the percentage 
of circulating reticulated platelets (35). Furthermore, a positive correlation between thrombopoietin 
(a key thrombopoietic hormone) levels and MPV values has been demonstrated in CAD (36). 
Thus, larger MPV may not imply higher platelet reactivity, that has been shown to be related to the 
extent and complexity of CAD (37), but may be associated with even reduced aggregation since 
larger platelets may be precursor and not fully mature platelets. In fact, Van der Planken and 
colleagues (38) did not find any relationship between platelet prothrombinase activity (PPA), a final 
pathway platelet procoagulant activity of type 1 diabetic platelets, and mean  platelet volume 
(MPV). 
Finally, as shown by previous reports, MPV may be associated with other prognostic factors, such 
as smoking (17) diabetes (18), obesity (39), hypertension (40), that may primarily affect 
periprocedural complications and PMI. In accordance with these data, we observed that diabetes 
and previous CVA were significantly associated with larger platelets. 
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Study limitations 
 
Quantification of the reticulated platelets, the most active fraction of platelets, as much  as 
functional evaluation of platelet reactivity and drugs response and availability of more accurate and 
validated direct markers of platelet activation such as P-selectin or CD40L, would have certainly 
improved the results our study, allowing better classification of patients according to platelet 
reactivity and the thrombotic risk. Furthermore, we did not collect long term follow-up data, and 
therefore cannot exclude a potential prognostic role of MPV in terms of thrombotic complications 
and restenosis. Finally, we evaluated MPV only at admission and, then, such analysis was not 
repeated after clopidogrel bolus. However, we have recently reported no significant impact of high- 
dose bolus of clopidogrel on MPV in ACS patients (41). 
 
 
Conclusion 
 
This study demonstrates that MPV is not associated to periprocedural myonecrosis and PMI in 
patients undergoing PCI and, therefore, cannot be used a marker for risk stratification of PMI. 
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Abstract 
 
 
Periprocedural myocardial infarction (PMI) represents a relatively common complication of percutaneous 
coronary intervention (PCI) and large interests have been focused on platelets in order to prevent such a 
complication. The single nucleotide polymorphism Leu33Pro of platelet glycoprotein IIIa has been related to 
an increased platelet reactivity, a lower response to antiplatelet agents and higher risk of stent restenosis. 
Therefore, aim of our study was to evaluate the impact of this polymorphism on PMI in elective patients 
undergoing PCI. Our population is represented by 422 consecutive patients with cardiac biomarkers within 
normality undergoing elective PCI. We measured cardiac biomarkers (CK-MB and Troponin I) at baseline, 
and 8, 24 and 48 hours after the procedure. For all subjects, we performed genetic analysis to assess the 
presence of Leu33Pro polymorphism. 
 
A total of 136 patients (32.2%) were polymorphic. Those patients were younger (p=0.03) and more often 
dislypidemic (p=0.01). Angiographic features did not differ according to genetic status. Pharmacological 
treatment pre and during angioplasty was similar. PCI-related complications did not differ according to 
genotype, with the only exception of higher rate of distal embolization in polymorphic patients. However, 
Leu33Pro polymorphism was not associated with increased risk of periprocedural myonecrosis and  PMI even 
after correction for baseline differences, (respectively OR=1.22 [0.81-1.84], p=0.34 for myonecrosis and 
OR=1.66 [0.85-3.23]; p=0.14 for PMI). At subgroup analysis, the Leu33Pro substitution was associated with 
higher risk of PMI only among diabetics (adjusted OR=4.46 [1.12-17.76], p=0.03). 
 
Among patients undergoing elective PCI, the polymorphism Leu33Pro of platelet glycoprotein IIIa is 
associated with increased risk of PMI only in diabetic patients 
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Introduction 
 
Percutaneous coronary intervention (PCI) currently represents the largest applied revascularization 
therapy among patients with coronary artery disease. Periprocedural myocardial infarction (PMI) 
still represents a relatively common complication of PCI, occurring in a range between 5 to 20% of 
patients (1). Several efforts have been focused in the last decades on new drugs and devices in 
order to prevent periprocedural complications in both acute and elective setting (2-6). However, as 
the new generations of drug-eluting stent have further enlarged the indication of coronary 
angioplasty, percutaneous treatment has been addressed to high-risk patients and more complex 
coronary lesions, that might be at higher risk for PMI. Several mechanisms are implied in PMI, 
including distal embolization, side-branch occlusion or coronary dissection, however myocardial 
injury can also occur after apparently uneventful PCI procedures in case of failure to obtain 
adequate myocardial perfusion (7, 8). Microvascular obstruction by neutrophil and platelet plugs, 
local vasoconstriction and myocardial edema have been claimed for these silent events. Platelets 
certainly play a major role in complications in the acute and elective setting. 
The polymorphism Leu33Pro of glycoprotein Gp IIIa (HPA-1 a/HPA-1 b platelet antigen), platelet 
fibrinogen receptor, is due to a single nucleotide substitution. The HPA-1 b mutation has been 
related to increased risk of severe CAD, in-stent restenosis and enhanced platelet function, with a 
lower threshold for activation and higher prevalence of resistance to most common antiplatelet 
drugs, with particular attention to clopidogrel and GPIIbIIIa inhibitors. (9-15). More recent studies, 
however, have not confirmed previous findings on this allele neither for the extent of CAD nor for 
platelet function. (16,17). 
Therefore, the aim of our study was, therefore, to evaluate whether the polymorphism Leu33Pro of 
platelet glycoprotein Gp IIIa is associated with increased risk of PMI among patient undergoing 
elective PCI. 
 
Methods 
 
 
Our population is represented by 422 patients undergoing elective coronary angioplasty at the 
Azienda Ospedaliera-Universitaria, “Maggiore della Carità”, Novara, Italy between March 2007 and 
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June 2010. The study was approved by our local Ethical Committee and all patients signed 
informed consent. For all patients we collected before the revascularization all clinical data and a 
fasting blood sample for routine chemistry, genetics and cardiac biomarkers (Troponin I and CK- 
MB). We excluded all subjects with elevated troponin I and CK-MB at baseline (above 0,04 μg/l 
and 5,00 ng/ml, respectively). The diagnosis of diabetes was based on previous history of diabetes 
treated with or without drug therapies, fasting glucose > 126 g/dl or HbA1 > 6,5 %. 
 
Coronary angioplasty was performed with standard techniques. Use of stents, type of stents and 
stent implantation techniques, as much as the use of directional or rotational atherectomy, IVUS, 
glycoprotein IIb-IIIa inhibitors, was left at the discretion of the operators. All patients received, 
according to guidelines, high-dose bolus of clopidogrel (600 mg) at the time of hospitalization or 
before angioplasty. Patients were clinically followed up to hospital discharge. 
 
Coronary angiography was routinely performed by the Judkins technique using 6-French right and 
left heart catheters. Quantitative coronary angiography (Siemens Acom Quantcor QCA, Erlangen, 
Germany) was performed by two experienced cardiologists who had no knowledge of the patients' 
clinical information (18). Significant coronary artery disease was defined as at least 1 coronary 
stenosis more than 50%. Severe multivessel disease was defined as three-vessel disease and/or 
left main disease. 
 
Biochemical measurements 
 
Blood samples were drawn at admission, in patients undergoing elective coronary angiography, 
after a fasting period of 12 h. Glucose, creatinine, and lipid profile were determined by standard 
methods. Cardiac biomarkers (Troponin I and CK-MB) were measured at baseline, before coronary 
revascularization, and at 6, 12, 24 and 48 h after PCI. 
 
Genetic analysis 
 
 
In all patients we performed genetic analysis to define the presence of Leu33Pro polymorphism. 
Genomic DNA was obtained from 200 μl of whole blood through a dedicated kit (GenElute™ Blood 
Genomic DNA, Sigma Aldrich ). The region of GPIIIa gene (17q21.32) containing the nucleotidic 
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substitution for Leu33Pro polymorphism was amplified by polymerase chain reaction (PCR) using 
as templates a forward primer (5'-TTG ACT TCT CTT TGG GCT CCT GAC TTAC-3 ' ) and a 
reverse primer (5'-CGA TGG ATT CTG GGG CAC AGT TATC-3’). 1 μl of genomic DNA was 
amplified in 19 μl of mix composed by 4 μl of Green Buffer, MgCl2 25mM, 5% DMSO and 0,03 u/μl 
of GoTaq® Hot Start Polymerase (Promega); resulting in a fragment of 106 bp. A negative control 
containing no genomic DNA was added for every PCR. 10 μl of amplified product were incubated 
at 37°C for 3 h with the restriction enzyme MspI, which divided 2 fragments of 66 and 40 bp if the 
Leu33Pro polymorphism (HPA-1 b antigen) was present. The digestion products were separated 
with electrophoretic run on a 4,5% High Resolution agarose gel containing 5% Gel Red. 
 
Study endpoints 
 
 
Primary study endpoint was the occurrence of PMI defined as post-procedural CK-MB increase  by 
 
3 times above the upper limit of normal (ULN), whereas secondary study endpoint was the 
occurrence of periprocedural myonecrosis, defined as postprocedural troponin I increase by 3 
times above the ULN. 
 
Statistical analysis 
 
 
Continuous data were expressed as mean ± SD and categorical data as percentage. Chi-Square 
test and ANOVA test were used to compare polymorphic and non polymorphic subjects concerning 
clinical and angiographic characteristics and procedural features. Multiple logistic regression was 
use to define the relationship between Leu33Pro polymorphism and periprocedural myocardial 
infarction for subgroup analysis and after correction for baseline confounding factors, that were 
entered in the model in block. 
 
Results 
 
 
Among the 422 patients, 136 carried the Leu33Pro substitution (HPA-1 b allele), 8 of them in 
homozygosis. Baseline demographic and clinical features are shown in Table 1 and 2. 
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Table 1. Clinical and demographic features according to HPA-1 aHPA-1 a/HPA-1 b alleles 
 
Baseline Clinical Characteristics HPA-1 a/HPA-1 a 
(n=286) 
HPA-1 b carriers 
(n= 136) 
 
P value 
Age (meanrSD) 
Male Sex (%) 
Diabetes (%) 
Hypercholesterolemia ( %) 
 
Renal failure (%) 
Family history of CAD (%) 
Smokers (%) 
Active smokers 
Previous smoker 
Hypertension (%) 
History of MI (%) 
Previous PCI (%) 
Previous CABG (%) 
Previous CVA (%) 
Indication to angiography 
Stable angina (%) 
Recent ACS (%) 
Arrhythmias/Valvulopathy/LV dysfunction (%) 
EF < 35% (%) 
Therapy at admission 
ACE inhibitors (%) 
ARB (%) 
Beta blockers (%) 
Nitrates (%) 
Calcium antagonists (%) 
Diuretics (%) 
Statins (%) 
ASA (%) 
Clopidogrel (%) 
68.1 (r10.4) 65.9 (r10.8) 0.03 
78 77.8 0.95 
32.4 33.3 0.85 
58.2 71.9 0.01 
17.1 16.3 0.84 
31 34.8 0.44 
0.95 
21.3 20  
30.3 31.1  
75.3 75.6 0.95 
33.8 28.9 0.31 
34.6 34.1 0.91 
15 16.9 0.59 
8.7 9 0.93 
0.12 
41.5 32.6  
53.3 58.8  
5.2 8.9  
11.3 15.7 0.22 
 
41.6 41.5 0.98 
24.5 27.4 0.52 
65.4 66.7 0.68 
50.3 53.3 0.57 
28.7 27.4 0.79 
26.9 25.9 0.83 
62.9 61.5 0.77 
76.2 77.8 0.73 
33.6 37 0.49 
 
CAD= coronary artery disease MI= myocardial infarction; CVA= cerebrovascular accident; ACS= 
acute coronary syndrome; LV= left ventricle; EF = ejection fraction; ACE= angiotensin converting 
enzyme;  ARB= angiotensin receptor blockers; ASA= acetylsalicylic acid. 
 
 
HPA-1 b carriers were younger than wild-type (p=0.03) and had higher prevalence of dyslipidemia 
(p=0.01), with lower HDL values (36.6 vs 38.7 mg/dl; p=0.05), whereas no differences were 
observed for other variables. 
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Table 2 Biochemistry parameters according to HPA-1 a/HPA-1 b alleles 
 
Biochemisty Parameters HPA-1 a/HPA-1 a 
(n=286) 
HPA-1 b carriers 
(n= 136) 
 
P value 
Fasting Glucose (mg/dl ± SD) 
Glycosylated Haemoglobin (%± SD) 
Creatinine (mg/dl ± SD) 
Uric Acid (mg/dl ± SD) 
Total Cholesterol (mg/dl± SD) 
LDL Cholesterol (mg/dl ± SD) 
HDL cholesterol (mg/dlrSD) 
Haemoglobin (g/dl ± SD) 
White Blood Cells Count (10^3/μl ± SD) 
Platelet Count ( 10^3/μl ± SD) 
133.6 (+ 67.7) 134.9 (+ 56.4) 0.84 
6.5(± 2.5) 6.4 (±1.2) 0.59 
1.1(± 0.3) 1.1 (+ 0.8) 0.31 
6.4 (+ 4.8) 5.9 (+ 1.5) 0.27 
155.2 (±37.3) 150.8 (± 33.8) 0.25 
103.1 (+ 53.4) 102 (+ 54.9) 0.85 
38.7 (r10.9) 36.6 (r9.4) 0.05 
13.7 (r1.6) 13.5 (r1.5) 0.27 
6.1 (r4.3) 4.6 (r4) 0.47 
212.1 (r54.3) 213.7 (r56.7) 0.79 
 
 
Procedural features are shown in Table 3. No difference was found in terms of QCA parameters, 
target vessel, number of vessels, adjunctive drugs administration and procedure related 
complications. However, distal embolization was more frequent in presence of HPA-1  b 
substitution (p=0.04). 
 
As shown in Figure 1, PMI was observed in 8.3% of procedures, with no relationship with the 
genotype (Fig. 1). Periprocedural myonecrosis was observed in approximately 60% of patients, 
with no difference according to presence of PlA polymorphism (Fig. 2). Similar results were 
observed by using higher cut-offs such as Tn I increase by 5 times (54.4% vs 57.1%, adjusted OR 
[95% CI] = 1.25 [0.84- 1.85], p=0.27) or 10 times above the ULN (40.9% vs 40.6%; adjusted OR 
[95% CI] = 0.99 [0.66-1.47], p=0.96). 
 
Leu3Pro polymorphism confirmed no association with the risk of myonecrosis or periprocedural 
myocardial infarction also after correction for baseline confounding factors (younger age, 
prevalence of previous cerebrovascular events) (OR [95% CI] = 1.66 [0.85- 3.23], p=0.14 and 1.22 
[0.81- 1.84], p= 0.34, for PMI and  myonecrosis, respectively) . 
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Table 3. Angiographic and procedural features according to HPA-1 a/HPA-1 b alleles 
 
Procedural features HPA-1 a/HPA-1 a 
(n=353) 
HPA-1 b carriers 
(n= 180) 
P value 
Severe CAD (%)§ Gp 
IIb-IIIa inhibitors § 
Clopidogrel bolus > 6 h pre-PCI § 
Multivessel PCI § 
N treated vessels § 
1 
2 
3 
Lesion length (mm ± SD) 
Reference diameter (mm± SD) 
% stenosis 
Target vessel (%) 
RCA (%) 
LM (%) 
LAD (%) 
CX (%) 
SVG (%) 
AL (%) 
Type C lesions 
Calcifications (%) 
Thrombus (%) 
TIMI flow pre-PCI <3 (%) 
Instent restenosis (%) 
Chronical occlusion (%) 
Bifurcations (%) 
Predilatation(%) 
Direct stenting (%) 
Max balloon inflation (atm ± SD) 
Kissing balloon (%) 
Thrombectomy (%) 
Any dissection (%) 
Slow flow (%) 
Distal embolization (%) 
Additional stent required (%) 
Side branch loss (%) 
TIMI post PCI <3 
35.4 31.9 0.47 
38.4 32.3 0.23 
28.4 27.1 0.96 
19.9 26.7 0.11 
0.21 
80.1 73.3  
16.7 20.7  
3.1 5.9  
20.2 (± 12.5) 18.9 (±13.7) 0.34 
3.1 (± 1.1) 3 (±1.0) 0.54 
88.5 (±10) 88.2 (±10.7) 0.80 
0.25 
35.6 29.9  
0.9 2.4  
29.1 32.9  
17.6 22.8  
2.4 1.8  
14.4 10.2  
25.8 29.7 0.42 
23.5 18.8 0.23 
3.2 3.0 0.88 
18.5 20.2 0.26 
7.7 9.7 0.43 
10 13.2 0.28 
17.9 13.8 0.24 
62.6 64.8 0.85 
28.9 29.6 0.34 
16.2 ± 3 16.3 ±2.9 0.61 
8.4 5.4 0.29 
0.9 1.8 0.4 
2.8 0.6 0.21 
0.9 1.9 0.39 
0.0 1.8 0.04 
1.3 0.6 0.51 
0.9 1.2 0.77 
4.4 5.4 0.38 
 
§ per patient definition 
 
CAD = Coronary Artery Disease; PCI = Percutaneous Coronary Intervention. RCA= right coronary 
artery, LM = left main; LAD = Left Anterior descending; CX = Circumflex Artery; SVG = Saphenous 
venous Graft; AL = Anterolateral Branch. 
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Figure 1  Periprocedural myocardial infarction according to HPA-1 a/HPA-1 b alleles 
 
Figure 2 
 
 
70 
60 
50 
40 
30 
20 
10 
0 
 
 
 
P=0.52 
 
 
HPA-1 a/ HPA-1 a 
HPA-1 b carriers 
 
 
Figure 2  Myonecrosis prevalence according to Leu33Pro polymorphism 
 
 
Finally we performed subgroup analysis in major high-risk subsets of patients (Figure 3). No impact 
of the Leu33Pro polymorphism on PMI was observed according to age (> 70 years (OR [95% CI] = 
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1.18 [0.34-4.06]; p =0.79) or < 70 years (OR [95% CI] =  1.34 [0.45-4]; p =0.28), male gender  (OR 
 
[95% CI] =  0.86 [0.78 – 4.42], p =0.16) or in females (OR [95% CI] =  0.59 [0.1-3,5]; p =0.56); 
 
previous MI (OR [95% CI] =  0.85 [0.24-3.06], p= 0.81) or no history of MI (OR [95% CI] =  1.7 
[0.64- 4.4]; p =0.30); statins treatment (OR [95% CI] = 1.63 [0.62- 4.28], p=0.32) or no statins (OR 
[95% CI] = 1.27 [0.33-4.9], p=0.27) and GPIIbIIIa inhibitors administration during PCI (OR [95% CI] 
= 1.32 [0.48-3.67], p=0.59) or no GPIs (OR [95% CI] =  2.48 [073-8.36], p=0.14). However, diabetic 
 
patients carrying the HPA-1 b allele had a significant increased rate of periprocedural MI (18.4 vs 
4.8% for HPA-1 a/HPA-1 a, OR [95% CI] = 3.9[1.3-11.5], p=0.02), whereas no difference was 
observed among non diabetic patients (11.5% vs 10.9%, OR [95% CI] = 0.94 [0.44-1.99], p=0.87; p 
Interaction=0.006). The impact of the Leu33Pro substitution on PMI among diabetic patients 
persisted after correction for baseline differences (adjusted OR [95% CI] = 4.46 [1.12 –17.76], p= 
0.03). 
 
 
 
 
Figure 3 Impact of the polymorphism HPA-1 of Gp IIIa on periprocedural myocardial infarction (PMI) in 
major subgroups of patients; MI= myocardial infarction, GPIs= GP IIbIIIa inhibitors 
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Discussion 
 
 
Our study represents one of the largest attempts to investigate the impact of platelet GpIIIa 
polymorphism on PMI. The major finding is that this polymorphism does not affect the occurrence 
of PMI and periprocedural myonecrosis in elective patients undergoing PCI. However, a significant 
impact was observed among diabetic patients. 
 
PMI has been shown in over 10% of patients undergoing PCI, mainly related to angiographically 
documented complications such as distal macroembolization, flow-limiting dissections or branch 
occlusions, however myonecrosis has been identified also in apparently uncomplicated PCI, 
therefore influencing prognosis (19-20). Although the definition of periprocedural myocardial 
infarction is still debated, an increase of cardiac biomarkers over 3x ULN has been related to a 
doubling of risk of major cardiac adverse events, both for troponin (OR 2.25, 95% CI 1.26 to 4.00, 
p=0.006) (21)  or CK-MB (RR 2,82, p = 0.03) (22). 
 
Many factors have been showed to impact on such occurrence, such as diabetes mellitus, acute 
clinical presentation and complex angiographic lesions. In fact, the release of prothrombotic factors 
can cause microvascular thrombosis, platelet plugging, vasoconstriction and slow-flow or no-reflow 
phenomenon (23-26). 
 
Large attention has been paid in the last decades to adjunctive therapies in order to prevent 
periprocedural complications in both acute and elective setting (2-6, 27-28), with particular 
attention to antithrombotic therapies, especially in the era of DES. 
 
In the ARMYDA 2 trial, optimal clopidogrel preloading reduced the occurrence of early MI; (19,20). 
GP IIb-IIIa inhibitors, for their rapid onset and great platelet inactivation, demonstrated a protection 
from PMI, with an important role in ACS (29-30) and complex high risk PCI, while their advantage 
seems reduced, according to ISAR-REACT trial, in elective patients after clopidogrel loading dose 
(31-33)..However, a recent small randomized trial (prematurely discontinued for slow recruitment), 
showed a trend in benefits in terms of periprocedural CK-MB release from the administration of Gp 
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IIb-IIIa inhibitors (eptifibatide) among patients undergoing complex intervention requiring extensive 
stenting (more than 33 mm) (28). 
 
Polymorphism Leu33Pro depends on the substitution of aminoacid 33, (leucine) with proline, due 
to a T ÆC transition in exon 2 (34). The allele with proline (HPA-1 b) is present in about 15% of 
the Caucasian population (35) and has been reported to increase in vitro platelet reactivity, 
receptor binding to fibrinogen and thrombin formation, allowing platelet activation for lower stimuli 
(36-37). In vivo studies suggested earlier onset of spontaneous myocardial infarction and 
increased risk of in stent restenosis and thrombosis, although other studies did not confirm these 
findings (12, 15-16, 38). Only one large study was conducted to evaluate the impact of this 
polymorphism on PCI complication and short term outcome (39) which did not find any association. 
However stenting was applied in only 280 patients and the introduction of new devices could have 
modified this result. Wheeler reported occurrence of PMI, only in few non polymorphic patients, 
only due to extremely complex PCI such as SVG revascularization (35). More recently, among 
patients undergoing primary angioplasty for STEMI, Verschuren et al (17) did not find any impact of 
Gp IIIa polymorphism on periprocedural and long-term outcome. 
 
In our study we evaluated the impact of the polymorphism Leu33Pro on PMI in patients undergoing 
elective PCI. Even though, this polymorphisms did not affect the risk of PMI in the overall 
population, we found a significant relationship of such allelic variant with PMI in diabetic patients. 
 
Diabetics, in fact, are known to have higher platelet reactivity. A recent study on 285 patients 
undergoing elective PCI demonstrated enhanced platelet activation despite clopidogrel pre- 
treatment (600mg), thus influencing periprocedural MI (odds ratio 8.34, 95% confidence interval 
2.60 to 26.76, p = 0.0003) (40). 
 
Moreover, Tschoepe found increased prevalence of Leu33Pro polymorphism in diabetics 
suggesting this genetic variant to be directly related to diabetes and only secondarily influencing 
the macrovascular prognosis of these patients (41). Primary genetically-dependent link between 
diabetes  and  platelet physiology,  thus,  had  already been  suggested  in  murine models,  where 
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insulin deficiency induced GPIIb IIIa hyper expression and changes in DNA-content of the 
megakaryocytic precursors (42). Functional changes in platelet interaction via glycoprotein GPIIb 
IIIa induced by the polymorphism could be, then, enhanced in diabetes mellitus (41-42). Findings 
of the present study indirectly confirm such hypothesis. 
 
Lack of identifying a role of the polymorphism in other patients subgroups could be due to the 
extensive use antiplatelet drugs, such as abciximab and other GP IIb-IIIa inhibitors, effective in 
preventing the risk of periprocedural complications, whereas in diabetic patients carrying the HPA- 
1 b allele, common pharmacological treatment offered inadequate protection, thus suggesting need 
of new targeted strategies to prevent PMI in such patients. Additional large studies are certainly 
needed to confirm our findings, and to evaluate whether a more aggressive antiplatelet therapy 
may reduce the risk of PMI in diabetic patients carrying the  Leu33Pro polymorphism. 
 
Study limitations 
 
We used a definition of PMI as a CK MB increase 3xULN, that may certainly have limited the 
identification of PMI. In fact, by excluding periprocedural cardiac enzymes increase by 1-3x ULN, 
we aimed at the identification of only those cases with significant myonecrosis, that impacts on 
prognosis. Moreover, we did not consider clinical features of PMI such as chest pain or ECG 
modifications post-PCI, whose role has been recently pointed out (20). 
 
Another limitation to our study is the lack of clinical follow-up data, and therefore we could not 
exclude an impact of this polymorphism on short or long term outcome. Furthermore, we did not 
routinely evaluated platelet reactivity. Exploration of the SNPs in CYP19C gene polymorphism 
would have provided additional important information. In fact, despite the recent introduction of 
new oral ADP-antagonists prasugrel and ticagrelor, that have finally overcome clopidogrel 
resistance, the benefits of their use in elective patients has not been investigated and therefore not 
approved yet. Finally, it must be recognized that the significant impact of the polymorphism in 
diabetic patients observed in our study, especially in consideration of the relatively small sample 
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size, is only hypothesis-generation and further large studies are certainly needed to further confirm 
this finding. 
 
Conclusions 
 
 
The present study showed that among patients undergoing elective PCI, the polymorphism 
Leu33Pro of platelet glycoprotein IIbIIIa was associated with increased risk of PMI among diabetic 
patients. 
53 
Platelets in CAD – Part 2 
 
 
 
 
References 
 
1. Califf RM, Abdelmeguid AE, Kuntz RE, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol 
1998;31:241e51. 
2. De Luca G, Suryapranata H, Chiariello M. Prevention of distal embolization in patients undergoing mechanical 
revascularization for acute myocardial infarction. A review of current status. Thromb Haemost 2006; 96: 700-10. 
3. De Luca G, Bellandi F, Huber K, Noc M, Petronio AS, Arntz HR, Maioli M, Gabriel HM, Zorman S, DE Carlo M, 
Rakowski T, Gyongyosi M, Dudek D. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty-abciximab long- 
term results (EGYPT-ALT) cooperation: individual patient's data meta-analysis. J Thromb Haemost 2011; 9: 
2361-70. 
4. De Luca G, Smit JJ, Ernst N, Suryapranata H, Ottervanger JP, Hoorntje JC, Dambrink JH, Gosslink AT, de Boer 
MJ, van 't Hof AW. Impact of adjunctive tirofiban administration on myocardial perfusion and mortality in patients 
undergoing primary angioplasty for ST-segment elevation myocardial infarction. Thromb Haemost 2005; 93: 
820-3. 
5. De Luca G, Cassetti E, Verdoia M, Marino P. Bivalirudin as compared to unfractionated heparin among patients 
undergoing coronary angioplasty: A meta-analysis of randomised trials. Thromb Haemost 2009; 102: 428-36. 
6. De Luca G, Navarese EP, Suryapranata H. A meta-analytic overview of thrombectomy during primary 
angioplasty. Int J Cardiol. 2012 Jan 28. [Epub ahead of print] 
7. De Luca G, Maas AC, Suryapranata H, Ottervanger JP, Hoorntje JC, Gosselink AT, Dambrink JH, de Boer MJ, 
van 't Hof AW. Prognostic significance of residual cumulative ST-segment deviation after mechanical 
reperfusion in patients with ST-segment elevation myocardial infarction. Am Heart J 2005; 150: 1248-54. 
8. De Luca G, van 't Hof AW, Ottervanger JP, Hoorntje JC, Gosselink AT, Dambrink JH, Zijlstra F, de Boer MJ, 
Suryapranata H. Unsuccessful reperfusion in patients with ST-segment elevation myocardial infarction  treated 
by primary angioplasty.Am Heart J. 2005; 150: 557-62. 
9. Michelson AD, Furman MI, Goldschmidt-Clermont P, et al. Platelet GP IIIa PlA polymorphisms display different 
sensitivity to agonists. Circulation 2000; 101: 1013-8. 
 
10. Kastrati A, Schomig A, Seyfarth M, et al. PlA polymorphism of platelet glycoprotein IIIa and risk of restenosis 
after coronary stent placement. Circulation 1999; 99: 1005-10. 
 
11. Di Castelnuovo A, de Gaetano G, Donati MB, Iacoviello L. Platelet glycoprotein receptor IIIa polymorphism 
PLA1/PLA2 and coronary risk: a meta-analysis. Thromb Haemost 2001; 85: 626-33. 
 
12. Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, Weiss JL, Gerstenblith G, Goldschmidt- 
Clermont PJ. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary 
thrombosis. N Engl J Med 1996; 334: 1090 –1094 
 
13. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Sabaté M, Fernández C, Stranieri C, Trabetti E, 
Pignatti PF, Macaya C. PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients 
undergoing coronary stent implantation. Blood Coagul Fibrinolysis. 2004; 15: 89-93. 
 
14. Böttiger C, Kastrati A, Koch W, Mehilli J, Seidl H, Schömig K, von Beckerath N, Schömig A. HPA-1 and HPA-3 
polymorphisms of the platelet fibrinogen receptor and coronary artery disease and myocardial infarction. 
Thromb Haemost. 2000 Apr;83(4):559-62. 
 
15. Verschuren JJ, Boden H, Wessels JA, van der Hoeven BL, Trompet S, Heijmans BT, Putter H, Guchelaar HJ, 
Schalij MJ, Jukema JW. Value of platelet pharmacogenetics in common clinical practice of patients with ST- 
segment elevation myocardial infarction. Int J Cardiol 2012 Aug 29 [Epub ahead of print] 
 
16. Ye Z, Liu EH, Higgins JP, Keavney BD, Lowe GD, Collins R, Danesh J. Seven haemostatic gene 
polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet. 2006 Feb 
25;367(9511):651-8 
 
17. Weber AA, Jacobs C, Meila D, Weber S, Zotz RB, Scharf RE, Kelm M, Strauer BE, Schrör K. No evidence for 
an influence of the human platelet antigen-1 polymorphism on the antiplatelet effects of glycoprotein IIb/IIIa 
inhibitors. Pharmacogenetics. 2002 Oct;12(7):581-3 
 
18. De Luca G, Santagostino M, Secco GG, Cassetti E, Giuliani L, Franchi E, Coppo L, Iorio S, Venegoni L, 
Rondano E, Dell'Era G, Rizzo C, Pergolini P, Monaco F, Bellomo G, Marino P. Mean platelet volume and the 
54 
Platelets in CAD – Part 2 
 
 
 
 
extent of coronary artery disease: results from a large prospective study. Atherosclerosis. 2009 Sep;206(1):292- 
7. 
 
19. Cuculi F, Lim CC, Banning AP. Periprocedural myocardial injury during elective percutaneous coronary 
intervention: is it important and how can it be prevented? Heart. 2010 May;96(10):736-40. Review. 
 
20. Hanna EB, Hennebry TA. Periprocedural myocardial infarction: review and classification. Clin Cardiol. 2010 
Aug;33(8):476-83. Review. 
21. Testa L, Van Gaal WJ, Biondi Zoccai GG, et al. Myocardial infarction after percutaneous coronary intervention: 
a meta-analysis of troponin elevation applying the new universal definition. QJM 2009;102:369e78 
 
22. Roe MT, Mahaffey KW, Kilaru R, et al. Creatine kinase-MB elevation after percutaneous coronary intervention 
predicts adverse outcomes in patients with acute coronary syndromes. Eur Heart J. 2004;25:313–321 
 
23. Michaels AD, Gibson CM, Barron HV. Microvascular dysfunction in acute myocardial infarction: focus on the 
roles of platelet and inflammatory mediators in the no-reflow phenomenon. Am J Cardiol. 2000; 85:50b–60b. 
 
24. Herrmann J Peri-procedural myocardial injury: 2005 update. Eur Heart J. 2005;26:2493–2519 
 
25. Mallat Z, Hugel B, Ohan J, et al. Shed membrane microparticles with procoagulant potential in human 
atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation. 1999;99:348–353. 
 
26. De Luca G, Gibson CM, Bellandi F, Noc M, Maioli M, Zorman S, Zeymer U, Gabriel HM, Emre A, Cutlip D, Arntz 
HR, Dudek D, Rakowski T, Gyongyosi M, Huber K, van't Hof AW. Impact of distal embolization on myocardial 
perfusion and survival among patients undergoing primary angioplasty with glycoprotein IIb-IIIa inhibitors: 
insights from the EGYPT cooperation. J Thromb Thrombolysis 2010; 30: 23-8. 
 
27. De Luca G, Iorio S, Venegoni L, Marino P. Evaluation of intracoronary adenosine to prevent periprocedural 
myonecrosis in elective percutaneous coronary intervention (from the PREVENT-ICARUS Trial). Am J Cardiol. 
2012; 109: 202-7. 
 
28. Biondi-Zoccai G, Valgimigli M, Margheri M, Marzocchi A, Lettieri C, Stabile A, Petronio AS, Binetti G, Bolognese 
L, Bellone P, Sardella G, Contarini M, Sheiban I, Marra S, Piscione F, Romeo F, Colombo A, Sangiorgi G. 
Assessing the role of eptifibatide in patients with diffuse coronary disease undergoing drug-eluting stenting: the 
INtegrilin plus STenting to Avoid myocardial Necrosis Trial. Am Heart J 2012; 163: 835.e1-7. 
29. De Luca G, Navarese E, Marino P. Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST- 
segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of 
randomized trials. Eur Heart J. 2009 Nov;30(22):2705-13. 
 
30. De Luca G, Ucci G, Cassetti E, Marino P.Benefits from small molecule administration as compared with 
abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a 
meta-analysis. J Am Coll Cardiol. 2009 May 5;53(18):1668-73 
 
31. Mangiacapra F, Barbato E, Patti G, Gatto L, Vizzi V, Ricottini E, D'Ambrosio A, Wijns W, Di Sciascio G. Point-of- 
care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing 
percutaneous coronary intervention. JACC Cardiovasc Interv. 2010 Mar;3(3):318-23. 
 
32. Campo G, Fileti L, de Cesare N, Meliga E, Furgieri A, Russo F, Colangelo S, Brugaletta S, Ferrari R, Valgimigli 
M; 3T/2R Investigators. Long-term clinical outcome based on aspirin and clopidogrel responsiveness status 
after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing 
resistance to aspirin and/or resistance to clopidogrel) trial substudy. J Am Coll Cardiol. 2010 Oct 
26;56(18):1447-55. 
 
33. Kastrati A, Mehilli J, Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing 
percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA. 
2006;295:1531–1538. 
 
34. Newman PJ, Derbes RS, Aster RH. The human platelet alloantigens, PlA1 and PlA2, are associated with a 
leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA 
typing. J Clin Invest. 1989 May;83(5):1778-81. 
55 
Platelets in CAD – Part 2 
 
 
 
 
35. Wheeler GL, Braden GA, Bray PF, Marciniak SJ, Mascelli MA, Sane DC. Reduced inhibition by abciximab in 
platelets with the PlA2 polymorphism. Am Heart J. 2002 Jan; 143(1):76-82 
36. Feng D, Lindpaintner K, Larson MG, et al. Increased platelet aggregability associated with platelet GP IIIa PlA2 
polymorphism: the Framingham offspring study. Arterioscler Thromb Vasc Biol 1999; 19:1142-7. 
 
37. Loncar R, Stoldt V, Hellmig S, Zotz RB, Mihalj M, Scharf RE. HPA-1 polymorphism of alphaIIbbeta3 modulates 
platelet adhesion onto immobilized fibrinogen in an in-vitro flow system. Thromb J. 2007 Feb 19;5:2. 
 
38. Park S, Park HY, Park C, Ko YG, Im EK, Jo I, Shin C, Lee JB, Shim WH, Cho SY, Jang Y. Association of the 
gene polymorphisms of platelet Glycoprotein Ia e IIb/IIIa with myocardial infarction and extent of coronary artery 
disease in the Korean population. Yonsei Med J, vol 45, 2004, No 3, pp 428-434 
 
39. Laule M, Cascorbi I, Stangl V, Bielecke C, Wernecke KD, Mrozikiewicz PM, Felix SB, Roots I, Baumann G, 
Stangl K. A1/A2 polymorphism of glycoprotein IIIa and association with excess procedural risk for coronary 
catheter interventions: a case-controlled study. Lancet. 1999 Feb 27;353(9154):708-12. 
 
40. Mangiacapra F, Patti G, Peace A, Gatto L, Vizzi V, Ricottini E, D'Ambrosio A, Muller O, Barbato E, Di Sciascio 
G. Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes 
mellitus and treated with clopidogrel and percutaneous coronary intervention. Am J Cardiol. 2010 Sep 
1;106(5):619-23. 
 
41. Tschoepe D, Menart B, Ferber P, Altmann C, Haude M, Haastert B, Roesen P. Genetic variation of the platelet- 
surface integrin GPIIb-IIIa (PIA1/A2-SNP) shows a high association with Type 2 diabetes mellitus. Diabetologia. 
2003 Jul;46(7):984-9. 
42. Tschoepe D, Schwippert B, Schettler B, Kiesel U, Rothe H, Roesen P (1992) Increased GPIIBIIIA expression 
and altered DNA-ploidy pattern in megakaryocytes of diabetic BB-rats. Eur J Clin Invest 22:591–598 
56 
Platelets in CAD – Part 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
57 
Platelets in CAD – Part 2 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 4 
 
 
Platelet PIA1/PIA2 polymorphism and the risk of periprocedural 
myocardial infarction in patients with acute coronary 
syndromes undergoing coronary angioplasty 
 
 
Monica Verdoia, Gioel Gabrio Secco; Ettore Cassetti; Alon Schaffer; Lucia Barbieri; Pasquale 
Perrone - Filardi;  Paolo Marino, Harry Suryapranata, Fabiola Sinigaglia; Giuseppe De Luca, 
on behalf of the Novara Atherosclerosis Study Group (NAS) 
 
 
Division of Cardiology, Azienda Ospedaliera-Universitaria “Maggiore della Carità”, Eastern Piedmont 
University, Novara, Italy; (MV, GGS, LB, EC, AS, PM, GDL); Division of Cardiology "Azienda Ospedaliera 
Marche Nord", Pesaro, Italy (GGS); Biochemistry, Department of Medicine, Cardiovascular and 
Immunological Sciences, University of Naples Federico II, Naples, Italy (PPF); Department of Translational 
Medicine, Eastern Piedmont University, Novara, Italy (FS); Department of Cardiology, UMC St Radboud, 
Nijmegen, The Netherlands (HS) 
 
 
 
 
 
 
 
 
 
 
Blood Coagul Fibrinolysis. 2014;25:107-13 
58 
Platelets in CAD – Part 2 
 
 
 
Abstract 
 
 
Acute coronary syndromes (ACSs) represent a high-risk condition, as enhanced platelet reactivity 
importantly influences myocardial perfusion and procedural results after percutaneous coronary 
intervention (PCI). In fact, higher rate of periprocedural myocardial infarction (PMI) and reduced 
event-free survival have been reported in these patients. The single nucleotide polymorphism 
Leu33Pro of platelet glycoprotein IIIa has been related to an increased platelet reactivity, a lower 
response to antiplatelet agents and higher risk of stent restenosis. Therefore, our aim was to 
evaluate the impact of this polymorphism on PMI in patients undergoing PCI for non-ST-segment 
elevation MI (NSTEMI). 
 
Our population is represented by 478 consecutive patients undergoing coronary angioplasty for 
NSTEMI. Cardiac biomarkers were monitored at intervals from 8 to 48h after the procedure. 
Genetic analysis was performed to assess the presence of Leu33Pro polymorphism. A total of 156 
patients (32.6%) were polymorphic. Clinical features did not differ according to genetic status, 
neither pharmacological treatment pre and during angioplasty. PlA carriers had lower rate of 
calcifications (P=0.01) and higher coronary tortuosity (P=0.03) at angiography and underwent 
more frequently to thrombectomy (P=0.05). PCI-related complications did not differ according to 
genotype. Leu33Pro polymorphism was not associated with increased risk of periprocedural 
myonecrosis and PMI even after correction for baseline differences, [odds ratio (OR) (95% 
confidence interval (CI)=0.70 (0.44-1.13), P=0.15 for PMI and OR (95% CI)=0.77 (0.53-1.11), 
P=0.17 for myonecrosis, respectively]. Results were confirmed in high-risk subgroups of patients. 
 
In conclusion, among patients undergoing PCI for ACS, the polymorphism Leu33Pro of platelet 
glycoprotein IIIa is not associated with increased risk of PMI. 
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Introduction 
 
In the last decades, the introduction of drug-eluted stents (DESs) and strong antiplatelet treatment 
have largely expanded the indication to percutaneous coronary revascularization, allowing the 
treatment of more complex lesions and improving outcome even in high-risk subsets of patients, 
such as those with acute myocardial infarction [1-5]. Despite improvements, however, still 5-20 % 
of procedures is complicated by periprocedural myocardial infarction (PMI) [6], with more severe 
impact on prognosis especially in acute coronary syndromes patients [7-8]. Procedural 
complications have been advocated to explain PMI, including distal embolization, side-branch 
occlusion or coronary dissection [9-10], however myocardial injury can also occur after apparently 
uneventful PCI procedures. Platelets certainly play a major role in such cases, causing the 
formation of cellular plugs occluding microvascular circulation, therefore preventing adequate 
myocardial perfusion in particular in acute setting, where platelet reactivity is enhanced [11-13]. 
 
The polymorphism Leu33Pro of glycoprotein Gp IIIa (PlA1/PlA2 platelet  antigen), platelet 
fibrinogen receptor, is due to a single nucleotide substitution. The PlA2 mutation has been related 
to increased risk of severe coronary artery disease (CAD), in-stent restenosis and enhanced 
platelet function, with a lower threshold for activation and higher prevalence of resistance to most 
common antiplatelet drugs, with particular attention to clopidogrel and GPIIbIIIa inhibitors, although 
more recent studies have not confirmed these findings [14-20]. 
 
Therefore, the aim of our study was to evaluate whether the polymorphism Leu33Pro of platelet 
glycoprotein Gp IIIa is associated with increased risk of PMI among patients with non-ST segment 
elevation myocardial infarction (NSTEMI) undergoing PCI. 
 
 
Methods 
 
Our population is represented by 478 patients undergoing coronary angioplasty for NSTEMI at 
Azienda Ospedaliera Universitaria, “Maggiore della Carità”, Novara, Italy between March 2007 and 
June  2010.  The  study  was  approved  by  our  local  Ethical  Committee  and  all  patients signed 
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informed consent. For all patients we collected before the revascularization all clinical data and a 
fasting blood sample for routine chemistry, genetics and cardiac biomarkers (Troponin I and CK 
MB). NSTEMI was defined as chest pain lasting more than 5 minutes, associated with elevation of 
cardiac biomarkers beyond the upper limit of normal (ULN) (respectively 0,04 μg/l for Troponin I 
and 5,00 ng/ml for CK-MB), with or without ECG changes. The diagnosis of diabetes was  based 
on previous history of diabetes treated with or without drug therapies, fasting glucose > 126 g/dl or 
HbA1c > 6.5 %. 
 
Coronary angiography was routinely performed by the Judkins technique using 6-French right and 
left heart catheters. Quantitative coronary angiography (Siemens Acom Quantcor QCA, Erlangen, 
Germany) was performed by two experienced cardiologists who had no knowledge of the patients' 
clinical information. Severe multivessel disease was defined as three-vessel disease and/or left 
main disease. 
 
Coronary angioplasty was performed with standard techniques. Use of stents, type of stents and 
stent implantation techniques, as much as the use of directional or rotational atherectomy, 
intravascular ultrasound (IVUS), glycoprotein IIb-IIIa inhibitors, was left at the discretion of the 
operators. All patients received, according to guidelines, high-dose bolus of clopidogrel (600 mg) at 
the time of hospitalization or before angioplasty. Patients were clinically followed-up to hospital 
discharge. 
 
Biochemical measurements 
 
Blood samples were drawn at admission in patients undergoing elective (following a fasting period 
of 12 h) or urgent coronary angiography. Glucose, creatinine, and lipid profile were determined by 
standard methods. Cardiac biomarkers (Troponin I and CK MB) were measured at baseline, before 
coronary revascularization, and at 6, 12, 24 and 48 h after PCI. 
 
Genetic analysis 
 
 
In all patients we performed genetic analysis to define the presence of Leu33Pro polymorphism. 
Genomic DNA was obtained from 200 μl of whole blood through a dedicated kit (GenElute™ Blood 
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Genomic DNA, Sigma Aldrich Co., St Louis, Missouri, USA). The region of GPIIIa gene (17q21.32) 
containing the nucleotidic substitution for Leu33Pro polymorphism was amplified by polymerase 
chain reaction (PCR) using as templates a forward primer (5'-TTG ACT TCT CTT TGG GCT CCT 
GAC TTAC-3 ' ) and a reverse primer (5'-CGA TGG ATT CTG GGG CAC AGT TATC-3’). 1 μl of 
genomic DNA was amplified in 19 μl of mix composed by 4 μl of Green Buffer, MgCl2 25mM, 5% 
DMSO and 0,03 u/μl of GoTaq® Hot Start Polymerase (Promega Co., Southampton,  UK); 
resulting in a fragment of 106 bp. A negative control containing no genomic DNA was added for 
every PCR. 10 μl of amplified product were incubated at 37°C for 3 h with the restriction enzyme 
MspI, which divided 2 fragments of 66 and 40 bp if the Leu33Pro polymorphism (PlA2 antigen) 
was present. The digestion products were separated with electrophoretic run on a 4,5% High 
Resolution agarose gel containing 5% Gel Red (Biotium Hayward, California, USA). 
 
Study endpoints 
 
 
Primary study endpoint was the occurrence of PMI defined as documentation of post-procedural 
fall and rise of CK-MB by 50% of baseline value, whereas secondary study endpoint was the 
occurrence of periprocedural myonecrosis, defined as post-procedural troponin I reduction and 
successive increase by 50% of pre-procedural levels. 
 
Statistical analysis 
 
 
Continuous data were expressed as mean ± SD and categorical data as percentage. Chi-Square 
test and ANOVA test were used to compare polymorphic and non polymorphic subjects concerning 
clinical and angiographic characteristics and procedural features. Multiple logistic regression was 
use to define the relationship between Leu33Pro polymorphism and periprocedural myocardial 
infarction for subgroup analysis and after correction for baseline confounding factors, that were 
entered in the model in block. 
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Table 1. Clinical and demographic features according to PlA1/PlA2 alleles 
 
Baseline Clinical Characteristics 
ACS Group 
PlA1/PlA1 
(n= 322) 
PlA2 carriers 
(n= 156) 
 
P value 
Age (meanrSD) 
Male Sex (%) 
Diabetes (%) 
Hypercholesterolemia (%) 
Renal failure (%) 
Family history of CAD (%) 
Smokers (%) 
 
 
 
 
Hypertension (%) 
Previous MI (%) 
Previous PCI (%) 
Previous CABG (%) 
Previous CVA ( %) 
EF <  35 % (%) 
Therapy at admission 
 
ACE inhibitors (%) 
ARB (%) 
Beta blockers (%) 
Nitrates (%) 
Calcium antagonists (%) 
Diuretics (%) 
Statins (%) 
ASA (%) 
Clopidogrel (%) 
 
 
 
 
 
 
 
 
 
 
 
 
Active smokers 
Previous smoker 
68.7(r11.1) 69.3 (r11.1) 0.61 
71.7 70.5 0.43 
29 26.9 0.64 
53.6 51.9 0.40 
18.1 16 0.34 
26.5 26.9 0.50 
0.32 
27.1 28.2  
24 17.9  
71 71.2 0.54 
22.4 20.6 0.43 
18.1 14.1 0.17 
10.6 12.2 0.35 
10 5.8 0.08 
15.2 13.5 0.12 
 
 
39.3 
 
39.7 
 
0.50 
15.9 16.7 0.46 
46.4 41 0.16 
34.3 38.5 0.21 
18.7 21.2 0.30 
29 28.2 0.48 
47.4 48.1 0.48 
53.3 55.8 0.34 
32 30.1 0.71 
 
 
CAD= coronary artery disease MI= myocardial infarction; CVA= cerebrovascular accident; ACS= 
acute coronary syndrome; EF = ejection fraction; ACE= angiotensin converting enzyme; ARB= 
angiotensin receptor blockers; ASA= acetylsalicylic acid. 
 
 
 
Results 
 
 
Among the 478 patients, 156 (32.6%) carried the Leu33Pro substitution (PlA2 allele), 12 of them in 
homozygosis. The allelic distribution was consistent with Hardy-Weinberg equilibrium (p=0.38). As 
shown in Table 1 and 2, baseline demographic and clinical features did not differ significantly 
according to genotype. 
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Table 2. Biochemistry parameters according to PlA1/PlA2 alleles 
 
 
Biochemisty Parameters 
 
PlA1/PlA1 
(n=322) 
PlA2 carriers 
(n= 156) 
 
P value 
Fasting Glucose (mg/dl ±SD) 
Glycosilated Haemoglobin (%±SD) 
Creatinine (mg/dl ±SD) 
Uric Acid (mg/dl ±SD) 
 
Total Cholesterol (mg/ dl ±SD) 
LDL Cholesterol (mg/dl ±SD) 
HDL cholesterol (mg/dlrSD ±SD) 
Haemoglobin (g/dl ±SD) 
Mean Platelet Volume (fl ±SD) 
White blood cells (10^3/μl ±SD) 
Platelets ( 10^3/μl ±SD) 
135.2 (± 63.1) 129.3 (± 46.4) 0.31 
6.4(± 1.5) 6.3 (±1.3) 0.76 
1.2(± 0.9) 1.2 (± 1) 0.73 
6.7 (± 7.8) 7 (± 10) 0.75 
163 (± 41) 157.1(± 41) 0.14 
112.1 (± 60.4) 103.1 (± 47.8) 0.11 
36.3 (r10) 36. 7(r10) 0.65 
13.2 (r1.7) 13.1 (r1.9) 0.34 
10.8 (r0.9) 10.8 (r0.9) 0.99 
8.8 (r4) 8.3 (r2.8) 0.22 
215.2 (r63.8) 205.8 (r60.8) 0.13 
 
 
Angiographic and procedural features are shown in Table 3. PlA2 polymorphism was associated 
with less coronary calcifications (p=0.01), and higher prevalence of proximal vessel tortuosity 
(p=0.03), and larger use of thrombectomy (p=0.05). No difference was found in terms of QCA 
parameters, target vessel, number of vessels, adjunctive drugs administration and procedure 
related complications. 
 
As shown in Figure 1, PMI was observed respectively in 23.7 and 19.9% of procedures, (OR 
[95%CI]=0.81[0.49-1.33], p= 0.39) with no relationship with the genotype (Fig. 1). Periprocedural 
myonecrosis was observed in approximately 50% of patients, with no difference according to 
presence of PlA polymorphism (53.4 % vs 46.8%, OR [95% CI]= 0.77[0.52-1.14], p = 0.19). Similar 
results were observed by using lower cut-offs such as Tn I increase by > 20% of baseline levels 
(60% vs 53.2%, OR [95% CI]=0.85[0.54-1.34], p=0.48). 
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Table 3. Angiographic and procedural features according to PlA1/PlA2 alleles 
 
 
Angioplasty features ACS 
PlA1/PlA1 
(n=418) 
PlA2 carriers 
(n= 188) 
 
P value 
Severe CAD (%)§ 
Critical atheromasic vessels § 
1 
t2 
 
Gp IIb-IIIa inhibitors (%) § 
Clopidogrel bolus pre- PCI > 6 h § 
Multivessel PCI (%) § 
N vessels § 
1 
2 
3 
Lesion length (mm ± SD) 
Target Vessel  diameter (mm ± SD) 
% stenosis (± SD) 
Target vessel (%) 
RCA (%) 
LM (%) 
Left anterior descending (%) 
Circumflex branch (%) 
SVG (%) 
AL (%) 
Type C lesions (%) 
Calcifications (%) 
Proximal vessel tortuosity (%) 
Thrombus (%) 
TIMI flow pre-PCI <3 (%) 
Instent restenosis (%) 
Chronical occlusion (%) 
Bifurcations (%) 
Predilatation (%) 
Max inflation (atm ± SD) 
Kissing balloon (%) 
Thrombectomy (%) 
Any dissection (%) 
Slow flow (%) 
Distal embolization (%) 
Additional stent required (%) 
Side branch loss (%) 
TIMI post PCI <3 
28.1 25 0.27 
0.35 
43.4 41  
56.6 59  
37.9 46.3 0.09 
40.7 39.4 0.59 
24.5 17.3 0.05 
0.19 
75.5 82.7  
19.3 14.1  
5.3 3.2  
18.9 (±12) 17.9 (±12.1) 0.40 
3 (±0.56) 3.1 (±0.61) 0.08 
89.2 (±10.5) 90.7 (±9.1) 0.08 
0.56 
29.2 30.9  
4.1 2.1  
29.2 26.6  
18.7 23.4  
3.8 2.1  
10.8 9.6  
22.3 26.4 0.17 
19.1 11.2 0.01 
4.5 8.9 0.03 
11.4 15.6 0.10 
16.8 22.9 0.34 
3.0 6.2 0.06 
4.9 7.3 0.17 
19.5 18.4 0.43 
68.4 70.2 0.46 
20.2 ± 4.1 20.1 ±3.6 0.89 
7.4 11.5 0.18 
2.8 6.2 0.05 
2.2 1.2 0.45 
2.2 0.6 0.18 
1.3 0.0 0.16 
2.1 0.6 0.17 
0.3 0.6 0.52 
2.3 3.4 0.57 
§ per patient definition 
 
CAD = Coronary Artery Disease; PCI = Percutaneous Coronary Intervention. RCA= right coronary artery, LM = left main; 
AL = Anterolateral; SVG= saphenous vein graft. 
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Figure 1 
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Figure 1  Periprocedural myocardial infarction (PMI) according to PlA1/PlA2 alleles 
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Figure 2  Myonecrosis prevalence according to Leu33Pro polymorphism 
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factors (adjusted OR[95% IC]= 0.70[0.44- 1.13],p=0.15 for PMI; adjusted OR[95% IC]= 0.77[0.53- 
1.11],p=0.17 for myonecrosis). 
 
Similar results were observed when the analysis was performed in major high-risk subsets of 
patients (Figure 3), according to age (> 70 years: OR [95% CI] = 0.75 [0.40-1.40]; p =0.37; < 70 
years: OR [95% CI] =  0.70 [0.34-1.45]; p =0.34), gender (males: OR [95% CI] = 0.60 [0.35 – 1.05], 
 
p =0.08; females: OR [95% CI] = 1.29 [0.53-3,15]; p =0.56), diabetes status (diabetic patients:  OR 
 
[95% CI] =   0.99 [0.39-2.6], p= 0.99; non diabetic patients: OR [95% CI] =   0.62 [0.35- 1.1]; p 
 
=0.19), renal function (Chronic Kidney Disease: OR [95% CI] =  0.38 [0.03-5.2], p= 0.47; normal 
 
renal function (OR [95% CI] = 1.06 [0.58-1.9], p= 0.56), statin use (Statin: OR [95% CI] =         0.69 
 
[0.35-1.4], p= 0.32; no statin: OR [95% CI] = 0.59 [0.48-1.6], p= 0.72) and periprocedural 
administration of GpIIbIIIa inhibitors (GPIs: OR [95% CI] = 0.79 [0.42-1.5], p= 0.45; no GPIs: OR 
[95% CI] = 0.75 [0.37-1.5], p=0.42). 
 
Figure 3 
 
 
All patients (n= 478) 
Age <70 (n=219) 
Age > 70 (n=259) 
Diabetes (n= 143) 
No diabetes (n=335) 
Male sex (n= 332) 
Female sex (n=146) 
CKD (n=388) 
No CKD (n=90) 
Statins (n=238) 
No statins (n=246) 
GpIIbIIIa inhibitors (n=272) 
No GPIs (n=206) 
 
RISK of PMI 
OR [95% IC] 
 
 
 
 
P value 
P= 0.15 
P= 0.34 
P= 0.37 
P= 0.99 
P=0.19 
P=0.08 
P=0.56 
P=0.56 
P=0.47 
P=0.32 
P=0.72 
P=0.45 
P=0.42 
 
 
 
 
P interaction 
 
 
 
P= 0.41 
 
 
P= 0.66 
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P=0.50 
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Figure 3 Impact of the polymorphism HPA-1 of Gp IIIa on periprocedural myocardial infarction (PMI) in 
major subgroups of patients; MI= myocardial infarction, GPIs= GP IIbIIIa inhibitors 
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Discussion 
 
 
The present study represents one of the largest attempts to investigate the impact of a genetic 
variant of platelet GpIIIa on PMI in NSTEMI treated by coronary angioplasty. Our major finding is 
that this polymorphism does not affect the occurrence of PMI and periprocedural myonecrosis. 
 
PMI represents a relatively common complication of coronary angioplasty in the setting of NSTEMI. 
It is mainly related to angiographically documented complications such as distal 
macroembolization, flow-limiting dissections or branch occlusions [21]. However, myocardial 
damage has been identified also in apparently uncomplicated PCI, therefore influencing long-term 
outcome [7-8, 22-25], especially in acute settings, mainly due to the release of prothrombotic 
factors can cause platelet hyper-activation, leading to microvascular thrombosis, platelet plugging, 
vasoconstriction [24-27] further compromising myocardial perfusion. 
 
In fact, large attention has been paid in the last decades to adjunctive therapies in order to prevent 
periprocedural complications in both acute and elective setting [28-29], with particular attention to 
antithrombotic therapies, especially in the era of drug eluted stents (DES). 
 
The introduction of new oral antiplatelet agents, such as prasugrel and ticagrelor, with earlier onset 
of action and lower rate of poor responders than clopidogrel, has allowed to reduce both 
periprocedural and long term recurrences of ischemic event in ACS patients undergoing early 
invasive strategy [13, 30]. Moreover, GP IIb-IIIa inhibitors, for their rapid onset and great platelet 
inactivation, have demonstrated greatest protection from PMI, mainly in acute settings [31-32] and 
complex high risk PCI. In fact, even in the era of new oral antiplatelet compounds, due to its delay 
in reaching the peak effects when peri-procedurally administrated, only Gp IIb-IIIa inhbitors can 
guarantee optimal platelet inhibition [33-35]. Large interests have been focused in the last decades 
on the role of platelet Gp IIIa polymorphism. In fact, this receptor represents a key element in the 
final aggregation. The single nucleotide polymorphism Leu33Pro depends on a point mutation TÆ C 
 
transition in exon 2 of GPIIIa gene, resulting in the substitution of aminoacid 33, (leucine) with 
proline [36].  The allele with proline (PlA2) has about 15% frequency in the Caucasian population 
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[37] and has been associated to higher receptor binding to fibrinogen, enhanced thrombin 
formation and platelet reactivity, with lower threshold of activation (38-39). 
 
In vivo studies suggested earlier onset of spontaneous myocardial infarction and increased risk of 
in stent restenosis and thrombosis for PlA2 carriers, although other studies did not confirm these 
findings [15, 18-19, 40]. Laule et al [41] evaluated the impact of this polymorphism on PCI 
complication and outcome and found no association. However, stenting was applied in only 280 
patients and the introduction of new devices could have modified this result. More recently, among 
patients undergoing primary angioplasty for STEMI, Verschuren et al [20] did not find any impact of 
Gp IIIa polymorphism on periprocedural and long-term outcome. Similarly, Cayla et al. [42] in 123 
patients experiencing acute stent thrombosis, reported no risk difference according to the carriage 
of the PlA polymorphism (OR [95%IC]=0.52[0.28-0.95]). 
 
In our study we evaluated the impact of the polymorphism Leu33Pro on PMI in patients undergoing 
PCI for NSTEMI. Confirming previous reports, we found that this polymorphisms did not affect the 
risk of PMI in the overall population, nor at subgroup analysis in high-risk subsets of patients such 
as in diabetics, elderly or patients with renal failure. 
 
It may be argued that the lack of a role of the polymorphism in our study could be due to the 
extensive use antiplatelet drugs, such as abciximab and other GP IIb-IIIa inhibitors. However, a 
previous in-vitro study reported that antiplatelet effect of GpIIIa blockers is not modified by the 
presence of PlA polymorphism both in vitro and in vivo [43]. 
 
Similar findings have been observed in our recent in-vivo study [44] including 80 patients 
undergoing coronary revascularization and receiving Gp IIb-IIIa inhibitors (bolus and endovenous 
infusion of abciximab (n = 40) or small molecules (n = 40). The aggregation tests were performed 
at baseline and after 10 min, 1 h and 4 h, through Multiplate impedance aggregometry. The 
Leu33Pro substitution did not influence platelet response after Gp IIb-IIIa administration, which was 
confirmed for both abciximab and small molecules. 
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Study limitations 
 
 
A potential limitation to our study is that we did not consider clinical features of PMI such as chest 
pain or ECG modifications post-PCI, whose role has been recently pointed out [20]. In addition, we 
did not collect follow-up data, and therefore we cannot exclude an impact of this polymorphism on 
short or long term outcome. Finally, we did not routinely evaluate platelet reactivity, nor receptor 
fibrinogen binding or other parameters of platelet activation. 
 
 
 
Conclusions 
 
 
Among patients undergoing PCI for NSTEMI, the polymorphism Leu33Pro of platelet glycoprotein 
IIIa is not associated with increased risk of periprocedural myocardial damage  and therefore 
cannot be considered a risk factor for PMI. 
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Abstract 
 
 
Platelets play a central role in the pathogenesis of coronary artery disease (CAD). Mean platelet 
volume (MPV) is an indicator of platelet activation, and has been demonstrated to be correlated 
with platelet reactivity. Diabetic patients have been shown to have larger MPV, that may 
contribute to higher platelet reactivity and atherothrombotic complications observed in these 
patients. Therefore, the aim of the current study was to investigate whether MPV is associated 
with platelet reactivity and the extent of CAD among diabetic patients. We performed a cohort 
study including 1016 consecutive diabetic patients undergoing coronary angiography at the 
University Hospital 'Maggiore della Carita', Novara, Italy. CAD is defined as stenosis above 50% 
in at least one coronary vessel at coronary angiography. Platelet reactivity was evaluated in 50 
diabetic patients without history of CAD and who were free (in the past month) from medications 
which may affect platelet aggregation. Platelet aggregation was evaluated by light transmission 
aggregometry after stimulation with 1 μg/ml collagen type I. We additionally evaluated platelet 
surface expression of P-selectin after stimulation with U46619 (a stable synthetic analogue of 
the prostaglandin PGH2) and plasma concentration of thromboxane B2 (TxB2). Patients were 
grouped according to tertile values of MPV (<10.6 fl, group 1; 10.6-11.3 fl, group 2; >11.4 fl, group 
3). MPV was associated with age (P=0.011), baseline fasting glucose (P=0.044), glycosylated 
haemoglobin (P=0.005), creatinine (P=0.052) and haemoglobin (P=0.003), but inversely related to 
platelet count (P<0.001) and triglycerides (P=0.031). Larger MPV was associated with therapy with 
statins (P=0.012) and diuretics (P=0.021). CAD was observed in 826 patients (81.3%). MPV was 
not associated with the prevalence of CAD [odds ratio (OR), 0.85 (0.7-1.03), P=0.11]. The results 
were confirmed in terms of severe CAD [OR, 1.03 (0.88-1.21), P=0.7]. The absence of any 
significant relationship between MPV and CAD was confirmed after correction for baseline 
confounding factors [OR, 0.9 (0.75-1.08), P=0.19]. Finally, MPV was not related to platelet 
reactivity. This is the first study showing that in diabetic patients MPV is not related to platelet 
reactivity and the prevalence and extent of CAD. Therefore, MPV may not be considered a risk 
factor for CAD among diabetic patients. 
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Introduction 
 
Coronary artery disease is a leading cause of mortality among developed countries (1). Diabetes is 
a major risk factor for coronary artery disease, and a higher platelet reactivity and pro-thrombotic 
status have been advocated as major determinants (1), that contributes to explain the worst 
outcome observed with these patients especially in the setting of ST- segment elevation myocardial 
infarction (2-3). In fact, diabetes has been associated with higher occurrence of distal 
embolization and impaired myocardial reperfusion (4-5). Mean platelet volume (MPV) has been 
shown to be an indicator of platelet activation, that plays a pivotal role in the pathophysiology of 
atherosclerotic disease (6,7). It has been reported that elevated values of MPV are associated with 
cardiovascular diseases (8,9). 
 
Several reports have demonstrated that there is a close relationship between MPV and 
cardiovascular risk factors, such as, impaired fasting glucose, diabetes mellitus, hypertension, 
hypercholesterolemia, and obesity (10-15). So far few data have been reported on the relationship 
between MPV and CAD, especially among diabetic patients. Thus, the aim of the current study 
was to evaluate the impact of MPV on platelet aggregation and coronary artery disease in a 
consecutive cohort of diabetic patients undergoing coronary angiography. 
 
Methods 
 
 
Our population is represented by a total of 1016 consecutive diabetic patients undergoing coronary 
angiography between January 2007 and December 2010 at the Ospedale “Maggiore della Carita”, 
Novara, Italy. Informed consent was obtained by all patients before angiography. The protocol 
was approved by our local Ethical Committee. All demographic and clinical data were 
prospectively collected in a dedicated database. Hypertension was defined as systolic pressure 
> 140 mm Hg and/or diastolic pressure was > 90 mm Hg or if the individual was taking 
antihypertensive medications. The diagnosis of diabetes was based on 1) previous history of 
diabetes treated with or without drug therapies; 2) fasting glycaemia > 126 mg/dl); 3) random 
glycaemia (> 200 mg/dl) 4) HbA1c ≥ 6.5%. No exclusion criteria were applied. 
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Biochemical measurements 
 
 
Blood samples were drawn at admission in patients undergoing elective (following a fasting period 
of 12 h) or urgent coronary angiography. Glucose, creatinine, and lipid profile were determined 
by standard methods. We measured MPV in a blood sample collected in tripotassium EDTA (7.2 
mg) tubes. These blood samples were analyzed within 2 h of venipuncture by automatic blood 
counter (A Sysmex XE-2100) used for whole  blood analysis. The expected values for MPV in 
our laboratory ranged from 7.0 to 11.0 fl. The analytical CV for MPV ranged from 2.2 to 1.1 %. 
 
Preparation of platelets-rich plasma (PRP) and platelets-poor plasma (PPP) 
 
 
Blood was withdrawn from patients in 0.32% sodium citrate. Platelet-rich plasma (PRP) was 
prepared by centrifugation of blood at 200 x g for 15 minutes at room temperature. 0.5 ml of PRP 
were centrifuged at 1500 x g for 10 minutes to obtained platelet-poor plasma (PPP). PPPs were 
frozen and stored at -80C for further analysis. 
 
Evaluation of platelet aggregation 
 
 
Platelet-rich plasma (0.25 ml) were prewarmed at 37°C in a Chronolog aggregometer for 2 min, 
and then stimulated with 1 μg/ml collagen type I (Chronolog Corporation, Havertown, PA, USA). 
Aggregation was monitored continuously for at least 5 min. 
 
Flow Cytometry 
 
 
At rrom temperature in the dark, 2.5 μl of PRP (5 × 105 platelets/samples) stimulated or not with 10 
μM U46619 (a stable synthetic analog of the prostaglandin PGH2) were incubated with PE-
CD62P (P-selectin) or an isotype match control for 20 min at room temperature in the dark. The 
reaction was stopped by adding 1 ml of PBS. The cells were analyzed using a BD Bioscience 
FACSCalibur flow cytometer by acquiring 10000 events of the gated platelet population. 
 
Measurement of thromboxane B2 in plasma 
 
 
Thromboxane B2 was purified from thawed PPP samples by solid phase extraction on C-18  
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columns. The extracts were quantified with a TxB2 EIA kit (Cayman Chemicals, Ann Arbor, MI, 
USA) following the manufacturer’s instructions. 
 
Coronary angiography 
 
 
Coronary angiography was routinely performed by the Judkins technique using 6-French right 
and left heart catheters. Quantitative coronary angiography was performed by two experienced 
cardiologists who had no knowledge of the patients’ clinical information. Significant coronary artery 
disease was defined as at least 1 coronary stenosis more than 50%. 
 
Statistical analysis 
 
 
Continuous data were expressed as mean + SD and categorical data as  percentage. Analysis of 
variance and the chi-square test were used for continuous and categorical variables, respectively. A 
trend analysis was performed as previously described (16). Multiple logistic regression analysis 
was performed to evaluate the relationship between MPV and coronary artery disease, after 
correction for baseline confounding factors, that were entered in the model in block. Linear 
regression analysis was used to evaluate the relationship between MPV, TxB2, and platelet 
aggregation. Statistical analysis was performed using the SPSS 15.0 statistical package Results 
were considered statistically significant at two-sided p< 0.05. 
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Results 
 
Table 1. Baseline characteristics according to tertiles of mean platelet volume. 
 
Demographic and clinical 
characteristics 
I tertile 
(< 10.6 fl) 
n = 326 
II tertile 
(10.6-11.3 fl) 
n = 334 
III tertile 
(> 11.4 fl) 
n = 356 
 
p value 
Age (mean + SD) 67.9 (±11.3) 69.4 (±9.7) 69.9 (±9.7) 0.03* 
Height (cm) 163.1 (± 20.1) 163.2 (±18,2) 163.5 (±19.3) 0.97 
Abdominal waist (cm) 100.6 (±19.3) 100.3 (±19.3) 102.2 (±19.4) 0.46 
Male gender (%) 66.6 68.9 68.9 0.77 
Hypercholesterolemia (%) 56.5 55.0 55.7 0.93 
Smoking (%) 32.8 27.3 33.5 0.41 
Family history of cad (%) 27.5   20.4  24.0 0.12 
Renal failure(%) 22.8 17.1 27.0 0.01* 
Hypertension (%) 75 77.5 76.7 0.75 
Previous mi (%) 25.5 29.0 31.5 0.23 
Previous pci (%) 21.8 24.9 19.4 0.22 
Previous cabg (%) 14.8 14.1 16.6 0.64 
Previous cva (%) 6.5 9.6 10.7 0.14 
Indication for angiography    0.32 
Stable angina (%) 23.7 28.4 23.0  
CMP or valvular disease (%) 15.7 19.2 20.2 
ACS (%) 58.8 50.6 54.2  
Baseline chemistry     
Cholesterol (mg/dl) 163.7 (± 43.2) 158.1 (±39.2) 159.8 (±41.2) 0.24 
LDL- cholesterol (mg/dl) 111.9 (± 63.0) 106.9 (± 77.7) 108.7 (±60.9) 0.66 
HDL-cholesterol (mg/dl) 37.9 (±0.7) 38.8 (±1,0) 38.0 (± 0.7) 0.72 
Triglycerides (mg/dl) 156.8 (±7.9) 144.8 (±5.5) 137.9 (±4.9) 0.09 
Uric acid (mg/dl) 6.3 (±1.9 6.1 (±1.8) 6.5 (±2.1) 0.01* 
Fasting glucose (mg/dl) 150.1 (±63.4) 161.5 (±70.9) 159.8 (± 71.5) 0.04* 
Glycosylated haemoglobin 6.9 (±1.6) 7.1 (±1.4) 7.4 (±2.6) 0.01* 
Creatinine (mg/dl) 1.3( ± 0.7) 1.2 (±0.6) 1.3(±0.8) 0.06 
Platelet count (x103/μl) 234.1 (± 75.9) 222.4 (± 60.5) 199.5 (±60.3) <0.001* 
WBC (x103/μl) 8.3 (±4.4) 8.1 (±3.0) 8.2 (± 2.7) 0.85 
RBC (x106/μl) 4.5 (±0,6) 4.6 (±0.6) 4.6 (±0.6) 0.01* 
Haemoglobin (g/dl) 12.9 (±1.9) 13.3 (±1.9) 13.4 (±1.7) 0.01* 
MCV (fl) 88.0 (± 5.5) 87.4 (±6.5) 89.4 (±5.1) <0.001* 
Fibrinogen (mg/dl) 475.4 (± 136.5) 483.5 (±169.5) 484.5 (± 155.5) 0.72 
Homocysteine (nmol/ml) 18.3 (± 9.5) 17.5(±8.4) 18.5 (±8.2) 0.41 
Therapy at admission     
Statins (%) 44.3 48.5 53.9 0.04* 
ASA (%) 67.1 72.5 71.7 0.33 
Nitrates (%) 42.8 42.8 43.0 0.99 
Beta-blockers (%) 53.2 49.1 53.4 0.45 
ACE-inhibitors (%) 40.3 38.0 44.4 0.23 
Angiotensin-receptor 
antagonist (%) 
 
21.2 
 
22.2 
 
19.9 
 
0.77 
Diurectis (%) 33.8 31.4 42.1 0.09 
CA-antagonists (%) 26.5 21.6 22.5 0.29 
Clopidogrel (%) 33.6 36.4 34.6 0.79 
Ticlopidine (%) 5.2 8.7 7.1 0.22 
ASA= acetylsalicylic acid, CABG= coronary artery bypass grafting, CMP= cardiomyopathy, CVA= cerebrovascular 
accidents; MPV= mean platelet volume; PCI= percutaneous coronary interventions; RBC= red blood cells; WBC = 
white blood cells 
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Patients were grouped according to tertiles values of MPV (< 10.6 fl, Group 1; 10.6-11.3 fl, 
Group 2; > 11.4 fl, Group 3). Baseline characteristics according to MPV are reported on 
Table 1. 
 
Patients with larger platelet volume were older (p = 0.011), MPV was associated  with baseline 
fasting glucose (p=0.044), glycosilated haemoglobin (p = 0.005), creatinine (p = 0.052), 
haemoglobin (p = 0.003), but inversely related to platelet count (p < 0.001) and 
triglycerides (p = 0.031). Larger MPV was associated with therapy with statins (p = 0.012) 
and diuretics (p = 0.021). 
 
Table 2. Angiographic characteristics according to tertiles of mean platelet volume. 
 
Variable I Tertile 
(< 10.6 Fl) 
II Tertile 
(10.6-11.3 Fl) 
III Tertile 
(> 11.4 Fl) 
P Value 
CAD (%) 83.13 82.6 78.4 0.21 
Multivessel Disease (%) 53.1 53.0 51.4 0.44 
LM - Trivessel Disease (%) 34.7 31.1 36 0.39 
LM Vessel Disease (%) 15.1 11.1 15.2 0.001* 
AD Branch Disease (%) 67.4 69.3 64.9 0.04* 
Cx Branch Disease (%) 56.3 57.2 58.5 0.46 
RCA Disease (%) 55.7 53.3 54.3 0.40 
Type C Lesion (%) 28.3 31.4 32.7 0.03* 
Plaque Distribution Eccentric 81.6 81.8 80.1 0.31 
Lesion Length (Mm) 18.0 (± 12.5) 18.5(±12.1) 18.41 (±12.2) 0.60 
% Stenosis (Mean + SD) 85.6  (± 16.5) 85.3 (± 16.5) 85.5 (± 15.4) 0.13 
Reference Diameter (mm) 2.9 (± 0.62) 2.9 (± 0.62) 2.9 (± 0.64) 0.19 
Calcifications (%) 23.0 27.5 25.5 0.02* 
Proximal Vessel Tortuosity (%) 4.7 3.9 4.9 0.40 
Restenosis (%) 3.5 4.8 3.7 0.14 
Bifurcation (%) 19.2 16.7 16.2 0.07 
Thrombus (%) 6.2 5.5 4.3 0.06 
Chronic Occlusion (%) 14.3 16.3 16.6 0.27 
Dissection (%) 0.5 0.1 0.3 0.17 
TIMI Flow (%)    0.13 
LM= left main coronary; AD= anterior descending; Cx = circumflex 
 
MPV and CAD 
 
 
CAD was observed in 826 patients (81.3 %). As shown in Figure 1, MPV was not associated with 
the prevalence of CAD (OR = 0.85 [0.7-1.03], p = 0.11). The results were confirmed with 
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severe CAD (as defined by the prevalence of 3-vessel disease and/or left main disease, in 
fig.2) (OR = 1.03 [0.88- 1.21], p = 0.7). 
 
 
 
 
Figure 1. Bar graph showing the relationship between Mean Platelet Volume (MVP) and the prevalence 
of coronary artery disease (CAD). 
 
 
 
 
Figure 2. Bar graph showing the relationship between Mean Platelet Volume (MVP) and the prevalence 
of severe coronary artery disease (CAD), as defined by three vessel disease and/or left main disease). 
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However, MPV related to the prevalence of Type C lesions (p = 0.01) but inversely related to the 
prevalence of bifurcation lesions (p = 0.03) and presence of thrombus (p = 0.02), as in Table 
2. Lack of association between MPV and CAD was confirmed after correction for baseline 
confounding factors (OR = 0.9 [0.75- 1.08], p = 0.19). 
 
MPV and platelet aggregation. 
 
 
We analysed the relationship between MPV and platelet reactivity in 50 additional diabetic 
patients without history of coronary artery disease and who were not taken any therapy 
(within the last month) with known and proved effects on platelet aggregation. We firstly 
analysed platelet aggregation by LTA. No significant relationship was found between MPV 
and  platelet  aggregation  as  evaluated  by LTA when  stimulated  with  1  μg/ml  collagen (r 
=0.22, p = 0.13; Figure 3A). These data were confirmed by the absence of any relationship 
between MPV and fold increase in the expression of P-Selectin (r =0.24, p = 0.11; Figure 3B) 
after stimulation with U46619. Finally, MPV was not related to the plasma TxB2 levels (r = 
0.078, p = 0.61; Figure 3C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Linear regression analysis showing the absence of relationship between Mean Platelet 
Volume (MVP) and platelet aggregation as evaluated by LTA (after stimulation with 1 μg/ml collagen 
type I) (A), fold increase in P-Selectin (B) and plasma TbX2 levels (C) 
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Discussion 
 
This is the largest study so far conducted to investigate the relationship between MPV and 
coronary artery disease in diabetic patients. We found that MPV is not associated with the 
prevalence and the extent of CAD. In addition, no relationship was found between MPV and platelet 
reactivity. 
 
Platelets are enucleate cells of 1–2 μm in length with average life span of 7-8 days, generated by 
bone-marrow derived megakaryocytes after cytoplasmic fragmentation, and play a pivotal role in 
the process of atherosclerosis (17). Large interest has been directed towards an improved 
understanding of platelet physiology, the assessment of platelet function and the development of 
improved anti-platelet treatment with faster and stronger activity. It has been observed a large 
variability in baseline platelet reactivity and effects of antiplatelet therapies, that may potentially 
due to variability in platelet size. In fact, larger platelets have a greater mass and are both 
metabolically and enzymatically more active than smaller platelets. Indeed, they have a greater 
prothrombotic potential, with higher levels of intracellular thromboxane A2, and βTG levels, as 
well as increased levels of procoagulant surface proteins (e.g. P selectin, GpIIb/IIIa) (18). 
Hemostatically reactive platelets, larger platelets, have more granules and adhesion receptors that 
have resulted in decreased bleeding time showing increased activation (19). Also an increase in 
MPV may be due to the usage of small platelets during acute ischemia (8-20). On these 
grounds, MPV could be accepted as a parameter of platelet activity and has been proposed as 
prognostic factor in coronary heart disease (21-22). Confirming the importance of MPV, several  
additional reports have demonstrated that MPV was associated with impaired myocardial perfusion 
(23- 24) and clinical outcome after primary angioplasty (25). However, opposite findings have 
been observed by Tavil et al (26), who did not observe any difference among patients with or 
without significant coronary artery disease.  Similar findings were observed by Halbmayer et al (27). 
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Diabetic patients have been shown to have larger MPV (6-9), that may contribute to higher 
platelet reactivity and atherothrombotic complications observed in these patients. However, so far 
no study has investigated the impact of MPV on coronary artery disease among diabetic patients. 
No relationship was found between MPV and the prevalence and extent of CAD. Some factors may 
contribute to explain our findings. The increase in MPV may be a process driven by increased 
production of bone marrow derived larger circulating reticulated platelets within the blood stream. 
In fact, in accordance with a previous report (28), we observed that MPV was inversely 
correlated with the total platelet count but linearly related to PDW and P-LCR, which could suggest 
the consumption of small platelets and a compensatory production of larger reticulated platelets. 
Indeed, the MPV has been shown to correlate with both megakaryocyte ploidy and with the 
percentage of circulating reticulated platelets (29). 
 
Furthermore, a positive correlation between thrombopoietin (a key thrombopoietic hormone) levels 
and MPV values has been demonstrated in CAD (30). Thus, larger MPV may not imply higher 
platelet reactivity, but may be associated with even reduced aggregation since larger platelets may 
be precursor and not fully mature platelets, not influencing the risk of CAD, as observed in our 
study. In our study, we did not find any relationship between MPV and platelet reactivity, as 
evaluated by LTA after stimulation with 1 μg/ml collagen, confirmed by the absence of any 
relationship between MPV and fold increase in P-Selection after stimulation with an analogue of 
prostaglandin PGH2. In addition, the absence of any relationship between MPV and plasma TxB2 
levels may indirectly discard the hypothesis that larger MPV contain more TxB2 synthase activity. 
Supporting our data, van der Planken and colleagues (31) did not find any relationship between 
platelet prothrombinase activity (PPA), a final pathway platelet procoagulant activity of type 1 
diabetic platelets, and mean platelet volume (MPV). 
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Limitations 
 
 
A major limitation is that the diagnosis of diabetes was based on medical history or fasting 
glycaemia, whereas OGTT would have certainly improved the identification of diabetic patients.  
In conclusion is the first study showing that among diabetic patients MPV does not affect 
platelet reactivity and does not correlate with the prevalence and extent of CAD. Therefore, MPV 
may not be considered a risk factors for CAD among diabetic patients. 
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Abstract 
 
Background. Serum uric acid (SUA) elevation has been associated with the main determinants of 
atherosclerosis and metabolic syndrome, although an independent relationship between SUA and 
coronary artery disease (CAD) has never been confirmed. Recent reports suggested a central 
role of SUA in diabetic patients, possibly being an early marker of impaired glucose metabolism 
and best predicting the risk of cardiovascular events in these patients. Aim of current study was to 
evaluate the relationship between diabetes and uric acid and its association with the extent of CAD 
and platelet aggregation  among diabetics. 
 
Methods. Diabetes was observed in 1173 out of 3280 (35.7%) patients undergoing coronary 
angiography. Fasting samples were collected for uric acid levels assessment. Coronary disease 
was defined for at least 1 vessel stenosis > 50% as evaluated by QCA. 
 
Results. Diabetes was related to age, hypercholesterolemia, hypertension, BMI,  renal failure, 
previous MI or coronary revascularization (p<0.001, respectively) and smoking (p=0.001). 
Diabetics were more frequently treated with ACE-inhibitors, ARBs, b-blockers, calcium-
antagonists, diuretics, statins (p<0.001, respectively), and ASA (p=0.004). Diabetics displayed 
higher glycemia and HbA1c (p<0.001), higher creatinine and  triglycerides (p<0.001) but lower total 
and HDL cholesterol (p<0.001) and haemoglobin (p<0.001). 
 
No significant difference was found in SUA levels between diabetic and non diabetic patients 
(p=0.09). In fact, we identified age, renal failure, hypertension, smoking, BMI, use  of diuretics, 
statins, haemoglobin, triglycerides and HDL cholesterol levels as independent predictors of higher 
levels of uric acid (3rd tertile, ≥ 6.7 mg/dl or 0.39 mmol/l). 
 
Among diabetic patients, no relationship was found between uric acid and the extent of 
coronary artery disease (p=0.27; adjusted OR [95%CI] = 0.93 [0.76-1.1], p = 0.48), or severe (LM-
trivessel) CAD (P=0.05; adjusted OR [95%CI] = 1.01 [0.86-1.18], p = 0.94). Furthermore, SUA 
levels did not influence platelet aggregation. 
 
Conclusion. Ageing, BMI, renal failure, hypertension, smoking, use of statins and diuretics, 
haemoglobin, HDL cholesterol and tryglicerides levels but not diabetes or glycemic control are 
independent predictors of hyperuricemia. Among diabetic patients, higher SUA is not 
independently associated with the extent of CAD or with platelet aggregation. 
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Background 
 
 
Cardiovascular disease represents the leading cause of mortality in developed countries. 
Despite the great reduction in mortality achieved by the improvement in myocardial 
revascularization techniques (1-2), the results are still unsatisfactory in high-risk subgroups, 
especially in diabetic patients (3-4). Therefore, much interest has been recently focused on the 
identification of new risk factors for CAD and its prevention. 
 
Serum uric acid (SUA), a degradation metabolite of purines, has been extensively addressed in the 
past years as a possible risk factor for cardiovascular disease (5-7). In fact, hyperuricemia has 
been associated with higher mortality and higher rate of cardiovascular events, as it might 
promote atherosclerosis progression by inducing oxidative stress, endothelial dysfunction and 
smooth muscle cells proliferation (8-11). However, till now contrasting results have been reported 
on SUA as an independent predictor  of cardiovascular disease. On the contrary, a stronger 
relationship has been found between SUA and main determinants of coronary artery disease 
(CAD), such as hypertension and metabolic disorders, and more recently, with diabetes mellitus 
(12-13). A number of cohort studies and a subsequent meta-analysis, in fact, have assessed the 
association  of SUA levels with the incidence of IFG and T2DM, suggesting hyperuricemia to be an 
early indicator of impaired glucose control, thus possibly allowing to identify those patients at 
higher cardiovascular risk (14-17). 
 
We previously found no association between SUA and the extent of CAD (18), although 
different findings could be expected in diabetic patients, where contrasting results have been 
reported so far. In fact, the National Health and Nutrition Examination Survey III Linked 
Mortality Study (NHANES III) showed that baseline serum SUA level significantly predicted all-
cause mortality only in patients with diabetes (19), while a recent longitudinal study including 1268 
diabetics reported no association between baseline SUA level and all-cause or cardiovascular 
mortality at an extended 10 years follow-up (20). 
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Therefore, aims of the current study were to evaluate whether: 1) diabetes or glycaemic 
control are independently associated with elevated SUA; 2) SUA is associated with the 
extent of CAD and platelet aggregation among diabetic patients. 
 
Methods 
 
 
Our population is represented by a consecutive cohort of patients undergoing coronary 
angiography at Azienda Ospedaliera-Universitaria, “Maggiore della Carità”,  Novara, Italy from 
March 2007 to October 2012. 
 
All demographic and clinical data were collected after obtaining written informed consent from 
the patient and included in a dedicated database, in adherence to rules for protection of human 
subjects. No exclusion criteria were applied. Hypertension was defined as systolic pressure > 
140 mm Hg and/or diastolic pressure > 90 mm Hg or if the individual was taking antihypertensive 
medications. The diagnosis of diabetes was based on previous history of diabetes treated with 
or without drugs, fasting glycaemia > 126 mg/dL, random glycaemia > 200 mg/dL or HbA1c > 
6.5%. Acute Coronary Syndrome was defined as an elevation of cardiac biomarkers beyond the 
upper limit of normal (ULN) (respectively 0,04 μg/l for Troponin I and 5,0 μg/l for CK-MB) due to 
angiographically documented critical coronary stenosis (>70%). 
 
Biochemical measurements 
 
 
Blood samples were drawn at admission in patients undergoing elective (following a fasting 
period of 12 h) or urgent coronary angiography. Glucose, creatinine, uric acid, blood cells count 
and lipid profile were determined by standard methods. Cardiac biomarkers (Troponin I and CK-
MB) were assessed by sandwich immunoassay with direct chemiluminescence (21). 
 
Coronary angiography 
 
 
Coronary angiography was routinely performed, preferring a radial approach, using 6-French 
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right and left heart catheters. Quantitative coronary angiography was performed by experienced 
interventional cardiologists by automatic edge-detection systems (Siemens Acom Quantcor QCA, 
Erlangen, Germany) as previously described (22). After the visual inspection of the coronary 
artery, the frame of optimal clarity was selected, showing lesion at maximal narrowing and arterial 
silhouette in sharpest focus. After the calibration of guiding catheter, analysed arterial segment 
with coronary lesion was defined by moving the cursor from the proximal to the distal part of 
coronary artery to ensure adequate determination of reference diameter. We measured minimal 
luminal diameter, reference diameter, percent diameter stenosis, and length of the lesion. 
 
Significant coronary artery disease was defined as at least 1 coronary stenosis more than 50%. 
Severe coronary disease was defined as three-vessel disease and/or left main disease. For 
patients who had previously undergone a percutaneous coronary intervention, even though no 
restenosis was observed, the treated vessel was counted as  significantly diseased. In previously 
bypassed patients, native arteries and grafts were taken into account in the evaluation of extension 
of artery disease (number of diseased vessels). 
 
Platelet aggregation 
 
 
Blood was withdrawn from patients in 0.32% sodium citrate and immediately processed. 
Platelet rich plasma (PRP) was prepared by centrifugation of blood at 200 x g for 15 minutes at 
room temperature. 0.5 ml of PRP were centrifuged at 1500 x g for 10 minutes to obtained platelet-
poor plasma (PPP). 
 
PRP (0.25 ml) were prewarmed at 37°C in a Chronolog aggregometer for 2 min, and then 
stimulated with 1 μg/ml collagen type I (Chronolog Corporation, Havertown, PA, USA). 
Aggregation was monitored continuously for at least 5 min. 
 
PRP (2.5 μl; 5 × 105 platelets/samples) stimulated or not with 10 μM U46619 (a stable 
synthetic analogue of the prostaglandin PGH2) were incubated with PE-CD62P (P-selectin) or an 
isotype match control for 20 min at room temperature in the dark. The reaction was 
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stopped by adding 1 ml of PBS. The cells were analyzed using a BD  Bioscience FACSCalibur flow 
cytometer by acquiring 10000 events of the gated platelet population. TxB2 was purified from 
thawed PPP samples by solid phase extraction on C-18 columns. 
 
The extracts were quantified with a TxB2 EIA kit (Cayman Chemicals, Ann Arbor, MI, USA) 
following the manufacturer’s instructions. 
 
Statistical analysis 
 
 
Continuous  data  were  expressed  as  mean  +  SD  and  categorical  data  as   percentage. 
 
Analysis of variance and chi-square test were used for continuous and categorical variables, 
respectively. Forward logistic multiple logistic regression analysis was performed to evaluate 
independent predictors of higher uric acid (above the third tertile). The relationship between uric 
acid and coronary artery disease was evaluated after correction for baseline confounding factors 
that were entered in the model in block. Linear regression analysis was used to evaluate the 
relationship between SUA and BMI, TxB2, and platelet aggregation. Results were considered 
statistically significant at two-sided p< 0.05. Statistical analysis was performed using the SPSS 15.0 
statistical package. 
 
Results 
 
 
Among 3280 patients undergoing coronary angiography, we identified 1173 diabetic patients 
(35.7%). Main demographic and clinical characteristics in diabetics and non diabetics are 
presented in Table 1. Diabetes was related to age (p<0.001), hypercholesterolemia (p<0.001), 
hypertension (p<0.001), smoking (p=0.001), renal failure (p<0.001), previous MI (p<0.001) or 
coronary revascularization (p<0.001). Diabetic patients were more frequently on ACE-inhibitors 
(p<0.001), ARBs (p<0.001), b-blockers (p=0.001), calcium-antagonists (p<0.001), diuretics 
(p<0.001), statins (p<0.001), and ASA (p=0.004). Diabetic patients displayed   higher   glycemia   
(p<0.001)   and   HbA1c   (p<0.001),   higher   creatinine    and triglycerides (p<0.001), but lower 
total and HDL cholesterol (p<0.001) and haemoglobin (p<0.001). 
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Table 1. Clinical and demographical characteristics according to diabetes. 
 
 
Baseline Clinical Characteristics Non Diabetics 
(N=2159) 
Diabetics 
(N=1237) 
P Value 
Age (MeanrSd) 66.8r11.9 69r9.9 <0.001 
Male Sex (%) 69.1 69.8 0.63 
Body Mass Index ( MeanrSD) 26.7r4.2 28.3r5 <0.001 
Dyslipidemia ( %) 51.2 50 <0.001 
Renal Failure (%) 13.6 22.6 <0.001 
Smokers (%) 0.001 
Active Smokers 29.2 23.4  
Previous Smokers 18.5 18.3  
Hypertension (%) 65 79.8 <0.001 
History of MI (%) 22 28.2 <0.001 
Previous PCI (%) 20.5 26.4 <0.001 
Previous CABG (%) 9.3 16.2 <0.001 
Biochemistry  
Platelets Count (10^5/μlrSD) 216.2r64 215.4r68 0.73 
Hemoglobin ( g/dlrSD) 13.5r1.7 13.1r1.8 <0.001 
Creatinine (mg/dlrSD) 1.1r0.7 1.2r0.7 <0.001 
Glycaemia (mg/dlrSD) 108.5r20.2 163.1r60.6 <0.001 
Total Cholesterol (mg/dlrSD) 167.4r40.8 156r41.2 <0.001 
Triglycerides (mg/dlrSD) 129r73 147r109.5 <0.001 
HDL Cholesterol (mg/dlrSD) 41.9r12.3 38.6r12 <0.001 
Hba1c (%rSD) 5.6r0.7 7.2r1.6 <0.001 
Uric Acid (mg/dlrSD) 6.4r5.6 6.7r6.7 0.09 
Indication To Angiography 0.15 
Stable angina /Silent ischemia 22.1 24  
Acute Coronary Syndrome (%) 60.5 57  
Arrhythmias/Valvulopathy/LV Dysfunction (%) 17.4 19  
Therapy At Admission  
ACE Inhibitors (%) 35.4 42 <0.001 
ARB (%) 16.8 25.4 <0.001 
Beta Blockers (%) 47.4 53.6 0.001 
Calcium Antagonists (%) 17.9 23.4 <0.001 
Diuretics (%) 23.7 39 <0.001 
Statins (%) 44.1 53.9 <0.001 
ASA (%) 55.3 60.4 0.004 
Clopidogrel (%) 23.1 24.1 0.52 
 
ASA= acetylsalicylic acid, CABG= coronary artery bypass grafting; LV =left ventricle; MI= myocardial infarction; PCI= 
percutaneous coronary interventions; ACE= angiotensin converting enzyme; ARB= angiotensin receptor blocker 
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No significant difference in SUA levels was found between diabetic and non diabetic patients 
(p=0.09) (Table 1). 
 
A direct relationship was identified between SUA levels and Body Mass Index (BMI), r=0.06, 
p=0.002. At multivariate analysis, the following variables were identified as independent predictors 
of higher levels of uric acid (3rd tertile, ≥ 6.7 mg/dl or 0.39 mmol/l): age (OR [95%CI] = 1.02 
[1.01-1.03], p<0.001), BMI (OR [95%CI] = 1.03 [1.02-1.05], p<0.001); renal failure (OR [95%CI]= 
2.21 [1.79-2.3], p < 0.001), hypertension (OR [95%CI]= 1.4 [1.15-1.67], p = 0.001), smoking (OR 
[95%CI] = 1.22 [1.01- 1.35], p<0.001), use of diuretics (OR [95%CI] = 2.05 [1.73-2.44], p < 0.001), 
haemoglobin levels (OR [95%CI] = 1.1 [1.04-1.15], p <0.001) and higher triglycerides levels (OR 
[95%CI]= 1.003 [1.002-1.004], p<0.001), whereas an inverse relationship was found with statins 
(OR [95%CI]= 0.84 [0.72-0.99], p=0.04) and HDL cholesterol (OR [95%CI] = 0.98 [0.97-0.99], 
p<0.001). 
 
SUA and CAD 
 
 
Diabetic patients displayed a significantly higher prevalence and extent of CAD and more 
complex lesions at angiography, including calcified lesion, total  occlusions, in-stent restenosis 
(Table 2). 
Among 1173 diabetic patients, no relationship was found between SUA tertiles values (< 5.3 or 0.31 
mmol/l, ≥ 6.7 mg/dl or 0.39 mmol/l) and the extent of CAD (p=0.27), while  a significant association 
was found for severe (LM-trivessel) CAD (P=0.05) as displayed in Supplementary Figure 1 and 2 
respectively. 
After correction for baseline differences, uric acid confirmed no impact on the extent of CAD 
(adjusted OR [95%CI] = 0.93 [0.76-1.1], p = 0.48) or severe CAD (adjusted OR[95%CI]= 1.01 [0.86-
1.18], p = 0.94). 
No relationship was found between prevalence of CAD and SUA tertiles when dividing our 
population according to BMI above or under the median value (26.5) (low BMI: 81.3% vs 
80.6 vs 87, p adjusted=0.38; high BMI: 85.6% vs 79.5 vs 78.7, p adjusted=0.14) 
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Table 2. Angiographic characteristics (per lesion) according to diabetes. 
 
 
Variable Non Diabetics (N=2972) 
Diabetics 
(N=2256) 
 
P Value 
Coronary Artery Disease (%)§ 72.9 83.4 <0.001 
Left Main/Trivessel Disease (%)§ 24.1 35.2 <0.001 
Left Main Coronary Artery(%)§ 7.9 11.3 0.001 
Left Anterior Descending Coronary Artery (%)§ 49.9 59.8 <0.001 
Circumflex Coronary Artery (%)§ 37.1 48.1 <0.001 
Right  Coronary Artery (%)§ 40.8 52.9 <0.001 
Complex Type C Lesions (%) 33.4 37 0.007 
Lesion Length (mmrSD) 19.5r12.6 20r12.9 0.16 
Vessel Diameter (mmrSD) 3r0.8 2.9r0.7 <0.001 
Stenosis %(MeanrSD) 86r15.5 86.9r14.6 0.07 
Calcified Lesions(%) 22.1 28.7 <0.001 
Bifurcation (%) 20.7 20.4 0.82 
Intracoronary Thrombus (%) 6.3 4.3 0.36 
Chronic Occlusion (%) 16.8 20.3 0.001 
In-Stent Restenosis (%) 3.6 5 0.01 
TIMI Flow   0.006 
3 (%) 71.7 67.8  
2 (%) 4.7 4.6  
1 (%) 2.6 2.5  
0 (%) 21 25.1  
§ per patient definition 
 
Supplementary Figure 1. Bar graph showing the prevalence of coronary disease according to uric acid tertiles in 
diabetic patients. 
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Supplementary Figure 2. Bar graph showing the prevalence of severe (left main and/or trivessel) coronary disease 
according to uric acid tertiles in diabetic patients. 
 
 
SUA and platelet reactivity 
 
 
Platelet aggregation was assessed in 50 diabetic patients without history of cardiovascular 
disease, not receiving pharmacological therapy potentially affecting platelet aggregation. We firstly 
analyzed platelet aggregation by LTA. No significant relationship was found between SUA and 
platelet aggregation as evaluated by LTA when stimulated with 1 μg/ml collagen  (r=0.009, p = 
0.24; Supplementary Figure 3A). These data were confirmed by the absence of any relationship 
between SUA and the plasma TxB2 levels (r = 0.03, p = 0.14; Supplementary Figure 3B). Finally, 
SUA was not related to fold increase in the expression of P-Selectin (r = 
-0.21, p = 0.97; Supplementary Figure 3C) after stimulation with U46619. Similar results were 
achieved when dividing our patients according to BMI under or above the median value (26.5) 
(low BMI: r=0.19, p=0.45 for LTA; r=0.004, p=0.88 for TxB2; r=0.1, p=0.61 for P-selectin 
expression; High BMI: r=0.21, p=0.28 for LTA; r=0.39, p=0.06 for TxB2; r=0.12, p=0.63 for P-
selectin). 
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Supplementary Figure 3. Linear regression analysis showing the absence of relationship between uric acid and platelet 
aggregation as evaluated by LTA (after stimulation with 1 μg/ml collagen type I) (A), plasma TbX2   levels 
(B) and fold increase in P-Selectin after stimulation with U46619 (a stable synthetic analogue of the prostaglandin PGH2) 
(C) in additional 50 diabetic patients without history of coronary artery disease. 
 
 
 
 
Discussion 
 
 
The present study represents an attempt to define a role of SUA in coronary atherosclerosis in a 
large cohort of diabetic patients. Our main finding is that higher levels of uric acid are not related to 
diabetes mellitus or glycaemic control. Ageing, renal failure,  hypertension, smoking, BMI, use of 
diuretics and statins, haemoglobin, triglycerides and HDL levels resulted as independent predictors 
of high SUA. Moreover, in diabetic patients, hyperuricemia was not associated with the extent of 
CAD or platelet aggregation. 
Great efforts have been done in the last decades to improve antithrombotic and revascularization 
therapies, in order to treat and reduce cardiovascular mortality especially in the setting of ACS (23-
24), with unfortunately suboptimal results in some high-risk patients 
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(25-28). Therefore, large attention has been paid to the identification of new risk factors aiming to 
prevent CAD. 
Hyperuricemia as a potential contributor to cardiovascular risk, is still a debated matter. In fact, 
higher levels of SUA have been associated to higher mortality and increased rate of 
cardiovascular events; with an independent relationship between hyperuricemia and  gout with 
myocardial infarction (29), stroke (30) and higher overall mortality in CAD (31). 
Uric acid represents a metabolite of the degradation pathway of purines, with renal elimination. Its 
catabolism via the xanthine oxidase has been related  to oxidative damage and production of 
reactive oxygen species (ROS) (32), inducing endothelial dysfunction by reducing the 
bioavailability of nitric oxide. Moreover, uric acid has been reported to promote vascular smooth 
muscle proliferation and to up regulate the expression of platelet-derived growth factor (11) and 
monocyte chemoattractant protein-1 (33), and to induce cyclo- oxigenase-2; thus linking uric acid to 
inflammation and potentially to platelet hyperreactivity (34-36). However, despite several 
mechanisms have potentially explained the role of SUA on atherogenesis, its direct effects on CAD 
have never been confirmed (18). In addition, it has been proposed that uric acid confers protection 
against the development of atherosclerosis, in view of its antioxidant properties (37, 38). In 
particular, a recent study has demonstrated that intravenous administration of uric acid improves 
endothelial dysfunction in type  1 diabetic patients (39). 
Furthermore, other large studies, such as the Framingham Heart Study, (40) and more 
recently Panero et al. and Gurka et al. (41,42) concluded that uric acid was not a causal risk factor 
for cardiovascular events, but rather a coincidental phenomenon, due to its strict association 
with hypertension, metabolic disorders and lifestyle, reflecting consumption of meat and alcohol 
(43). 
In particular, great attention has been recently focused on the relationship between SUA and 
diabetes, as several studies and a subsequent meta-analysis suggested hyperuricemia to be strictly 
associated with the incidence of type 2 diabetes mellitus, with a 17% increment in the risk  of  
diabetes  per  1  mg/dl  increase  in  serum  uric  acid  level,  therefore  UA  possibly representing 
an early marker of future development of impaired glucose metabolism (17, 44,45). The  
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relationship between SUA and diabetes is, however, complex and has been potentially 
explained by insulin resistance (46). In, fact, the reduced effects of insulin might decrease SUA 
renal excretion or indirectly act on lipid profiles (47,48) and moreover, excessive intake of added 
sugars, especially fructose, has been demonstrated to increase oxidative metabolism and UA 
production, especially in patients with renal failure (49). 
Therefore, uricemia might play a more important role for cardiovascular risk in diabetic than in non 
diabetic patients. 
However, no study has ever evaluated directly the role of SUA on angiographically documented 
CAD in diabetic patients. In our study, patients with diabetes displayed a non significant trend in 
higher levels of uricemia. Furthermore, we demonstrated that neither the presence of diabetes nor 
the glycaemic control (as fasting glycemia or HbA1c) were independent predictors of higher SUA. 
On the contrary, ageing, BMI, smoking, haemoglobin, triglycerides and HDL levels, use of diuretics 
and statins and renal disease were independently related to hyperuricemia. 
Several explanations can be proposed to explain these findings. First, we confirmed the central 
role of renal function on SUA levels and the worsening of metabolic profile in elderly, as well 
described in literature. Moreover, we included in our population patients already meeting the 
diagnostic criteria for diabetes mellitus, therefore representing a higher-risk subset of patients than 
those with metabolic syndrome alone, who were included in previous studies relating SUA and new 
onset of diabetes. 
Confirming our previous findings (18), we observed that also among diabetics SUA was not 
independently associated with the extent of CAD, as the association of highest SUA with more 
severe CAD disappeared after correction for baseline differences. 
Similar conclusions were reached by Oikonen et al (50), evaluating the indicators of subclinical 
atherosclerosis, such as carotid intima-media thickness and brachial flow- mediated  dilatation, in  
1985  young  adults.  In  fact,  the  authors  found  that  SUA was significantly associated with BMI 
and established cardiovascular risk factors, thus not being an independent predictor of early 
atherosclerosis. 
Contrastingly, a relationship between hyperuricemia and coronary calcifications was found in  
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126 Ukraine patients with asymptomatic documented CAD (51), and by Rodriguez et al. 
evaluating 443 patients with type 1 diabetes and renal failure (52). However, coronary 
atherosclerosis was not evaluated by angiography and moreover, patients with renal impairment 
could have represented a population with further increased risk, displaying highest levels of SUA 
than patients included in our study. 
Present results potentially explain the previous lack of association between SUA and cardiovascular 
outcome reported by Ong et al (19) and the Casale Monferrato Study (20) and also by the 
National Health and Nutrition Examination Survey III Linked Mortality Study (NHANES III) (44), that 
however, showed a relationship between UA and all-cause mortality, but not with the occurrence of 
cardiovascular events. Similarly, Storhaug et al recently reported SUA to be associated with all-
cause mortality and with increased risk of stroke in men, even after adjustment for drug intake and 
traditional cardiovascular risk factors, however, no independent associations were observed with MI 
(53). In fact, in our diabetic patients elevated SUA levels did not increase platelet reactivity, that is 
held responsible for the majority of acute coronary events. 
 
 
Limitations 
 
First, pharmacological interferences as well as allopurinol administration may have played a role in 
modifying SUA levels. However, therapy at admission did not differ significantly within the SUA 
tertiles, with the only exception of diuretics. In fact, potential UA lowering effect has been described 
by hypoglicemic drugs, insulin and certain statins, as atorvastatin, however, the real size of this 
effect is still undefined. In addition, in few studies and the recent meta- analysis (54-57) evaluating 
the effects of UA lowering therapies on cardiovascular outcome, very weak benefits have been 
reported and therefore their use is, till now, very modest in this subset of asymptomatic patients. 
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Moreover, limits of our study are those of any observational study, therefore not providing 
information about long term effect of SUA on cardiovascular outcome. However, in recent large 
cohorts no difference in cardiovascular events has been detected at extended follow- up. 
Finally the use of intravascular imaging, such as IVUS technique, would have improved the 
definition of CAD, especially in patients with complex eccentric plaques and with negative 
remodelling, which has been more often demonstrated in older patients, as our patients with higher 
SUA (58). 
 
 
Conclusion 
 
Ageing, renal failure, hypertension, smoking, BMI, haemoglobin, triglycerides and  HDL levels, use 
of diuretics and statins, but not diabetes or glycemic control are independent predictors of 
hyperuricemia. In diabetic patients, higher SUA is not independently associated with the extent of 
CAD or platelet reactivity. 
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Abstract 
Background Advances in percutaneous coronary revascularization strategies and anti- thrombotic 
therapies have not filled the prognostic gap between diabetic and non diabetic patients after an 
acute cardiovascular event. 
In fact, diabetes mellitus and poor glycemic control represent well established pro- thrombotic 
conditions, that have been associated to a reduced effectiveness of antiplatelet therapies and an 
increased risk of high-residual platelet reactivity (HRPR) and recurrent ischemic events. New 
antiplatelet agents, as ticagrelor, have provided a more potent and predictable platelet inhibition, 
potentially offering larger benefits in those patients with enhanced thrombotic status. However, no 
study has so far investigated the relationship between diabetes mellitus and platelet reactivity in 
patients treated with ticagrelor for a recent acute coronary syndrome (ACS). 
 
Methods We included 224 post-ACS patients, treated with a dual antiplatelet therapy with ASA 
(100-160 mg) and ticagrelor (90 mg twice a day), that were scheduled for platelet reactivity 
assessment at 30-90 days post-discharge. Diabetic status was defined for an history of diabetes 
treated with or without drug therapies, fasting glucose >126 g/dl or HbA1c 
> 6.5% at the moment of admission. Aggregation was assessed by multiple-electrode 
aggregometry. HRPR during ticagrelor treatment was defined as ADP test results > 417 
AU*min. 
 
Results Among the 224 patients, 86 (38.4%) were diabetics. Diabetic status related to older age 
(P=0.05), higher BMI (P=0.009), renal failure (p=0.016), hypertension  (p=0.02), treatment with 
diuretics (p=0.02). higher levels of WBC, glycaemia, HbA1c, and lower levels of HDL-cholesterol 
(p<0.001, respectively). 
Platelet reactivity was higher in diabetics as compared to non diabetics (p=0.046 for ASPI test, 
p=0.013 for COL test, p=0.04 for TRAP test and p=0.002 for ADP test). 29 patients (12.9%) 
displayed HRPR with ticagrelor with an almost double rate in diabetics as compared to non-
diabetics (18.8% vs 9.4%, p=0.06; adjusted OR [95%CI]= 2.12[1.1-4.1], p=0.025). 
Direct linear relationship was observed between ADP-mediated platelet reactivity and glycosylated 
hemoglobin, as a parameter of chronic glycemic control, (r=0.15, p=0.029), but not with fasting 
glycemia (r=0.08, p=0.20). 
 
Conclusion Present study shows among post-ACS patients, that diabetic status is associated with 
a higher platelet reactivity despite dual antiplatelet therapy with ASA and ticagrelor, and 
especially in those patients with poor chronic glycemic control. In fact, diabetes emerged as 
independent predictor of HRPR  with ticagrelor. 
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Introduction 
 
 
Diabetes mellitus still represents one of the main determinants of cardiovascular risk, accounting for 
about one third of patients admitted for acute coronary syndromes (ACS) (1). Moreover, despite the 
introduction of new-generation drug eluted stents, new implantation techniques and 
pharmacological strategies (2–4), diabetes is still associated to an increased rate of thrombotic 
complications and worse prognosis after percutaneous coronary revascularization (PCI), that justify a 
more aggressive management (5–7). 
Enhanced platelet reactivity and reduced effectiveness of antiplatelet therapies play a central role in 
increasing the ischemic burden of diabetics, and especially among patients with inadequate 
glycemic control, where hyperglycemia, oxidative stress and enhanced inflammatory response can 
induce platelet activation. In fact, a higher rate of residual high-on treatment platelet reactivity 
(HRPR) has been shown in diabetics, as compared to non- diabetic patients, during clopidogrel 
treatment, thus negatively influencing cardiovascular outcomes (8,9). 
Newly developed antiplatelet agents, inhibiting platelet P2Y12 receptor, have only partially 
overcome the phenomenon of impaired effectiveness observed with clopidogrel, providing a more 
powerful and predictable antiplatelet effect. In particular, ticagrelor, a reversible, direct- acting 
P2Y12 blocker, has demonstrated in the PLATO-trial a reduction in major cardiovascular events 
among diabetics that was consistent with the results in the overall cohort of patients (10,11). 
However, a recent meta-analysis has suggested an association between diabetic status and 
platelet reactivity during ticagrelor maintenance therapy(12), although no study has so far 
addressed the relationship between diabetes mellitus, glucose control parameters and platelet 
reactivity in patients treated with ticagrelor. 
 
 
Methods 
 
We included patients admitted for acute coronary syndromes to the Division of Cardiology, 
“Maggiore  della  Carità”  Hospital,  Eastern  Piedmont  University  in  Novara,  Italy,    from 
September 2013 to October 2014. Invasive treatment with coronary angiography and eventual  
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coronary stenting was not a required inclusion criteria. All patients receiving at discharge dual 
antiplatelet therapy with ASA (100 to 160 mg daily) and ticagrelor (90 mg every 12 hours) were 
scheduled for chemistry and platelet function tests evaluation at 30-90 days from discharge. The 
study was approved by our local Ethical Committee and informed consent was obtained by all 
patients. 
Main demographic, clinical and angiographic data, together with the indication to dual antiplatelet 
therapy were recorded at discharge and included in a dedicated database, protected by password. 
Main cardiovascular risk factors were identified, hypertension was defined as systolic pressure > 
140 mm Hg and/or diastolic pressure was >90 mmHg or if the individual was taking 
antihypertensive medications. The diagnosis of diabetes was based on previous history of diabetes 
treated with or without drug therapies, fasting glucose >126 g/dl or HbA1c > 6.5% at the moment 
of admission (13). Compliance was assessed by medical interview. Exclusion criteria were 
patients’ refusal or if the patient had given up ticagrelor therapy. 
 
 
Biochemical measurements 
 
Blood samples were drawn in the early morning, following a fasting period of 12 h. Glucose, 
creatinine, glycosylated hemoglobin and lipid profile were determined as  previously described (14). 
Blood cells count was performed in a blood sample collected in tripotassium EDTA (7.2 mg) tubes. 
These blood samples were analyzed within 2 h of venipuncture by automatic blood cells counter 
(A Sysmex XE-2100) . 
 
 
Platelet aggregation 
 
Platelet aggregation was determined by Multiplate electrical impedance  aggregometry (MEA), 
within 1-2 hours from the morning dose of ticagrelor. The aggregation tests were performed from 
30 minutes to 2 hours from blood collection(15). Platelets aggregation was assessed after 
stimulation with arachidonic acid (0.5 mM) (ASPI test), collagen (3.2 μg/ml) (COL test), ADP (6.4 
μM) with prostaglandin E1 and thrombin receptor activating peptide, (TRAP-6; 30 μM). Results  
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were expressed as arbitrary Aggregation Units (AU) and plotted against time, defining platelet 
function as the area under curve (AUC or AU*min). HRPR for ticagrelor was defined for ADP test 
above 417 AU*min; (normal range: [417-1030])(16). The test was repeated in patients with HRPR to 
confirm the findings. 
 
 
Statistical analysis 
 
Statistical analysis was performed using SPSS 17.0 statistical package. Continuous data were 
expressed as mean + SD and categorical data as percentage. Analysis of variance and 
the chi-square test were used for continuous and categorical variables, respectively. 
 
Patients were grouped according to diabetic status. Linear regression  analysis was performed to 
compare glycemic control parameters and platelet reactivity at ADP test. Multiple logistic regression 
analysis was performed to evaluate the relationship between glycemic status and HRPR after 
correction for baseline differences, that were entered in the model in block. A p value < 0.05 was 
considered statistically significant. 
 
 
Results 
 
 
We included in our population of 224 patients. Among them 86 (38.4%) were diabetics and 138 
non diabetics. 
 
Diabetic status and platelet reactivity 
 
Table 1 shows main clinical and demographic features according to diabetic status. Diabetics were 
older (p=0.05), with a higher BMI (p=0.009), larger prevalence of renal  failure (p=0.016), 
hypertension (p=0.02) and were more frequently receiving a chronic therapy with diuretics (p=0.02). 
Diabetes mellitus directly related with White Blood Cells Count, glycaemia, HbA1c and HDL-
cholesterol (p<0.001, respectively). 
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Table 1. Clinical and demographic characteristics according to diabetic status 
 
Baseline Clinical Characteristics Diabetics Non Diabetics P Value 
Age (MeanrSD) 67.19 (r10.91) 64.25 (r11.5) 0.059 
Male Sex (%) 76.7 78.4 0.87 
BMI (MeanrSD) 28.1 (r5.1) 26.36 (r3.91) 0.009 
Hypercholesterolemia(%) 64.7 58 0.33 
Renal Failure (%) 24.4 11.5 0.016 
Smokers (%)   0.08 
Active Smokers 28.2 33.8  
Previous Smoker 17.6 24.5  
Hypertension (%) 82.4 67.6 0.02 
History of MI (%) 22.4 21.7 1 
Previous PCI (%) 30.6 25.2 0.44 
Previous CABG (%) 14.1 7.9 0.17 
Previous CVA (%) 8.2 4.2 0.25 
Indication to Angiography   0.93 
Unstable Angina (%) 35.3 32.1  
NSTEMI (%) 38.3 32.4  
STEMI (%) 26.4 35.5  
Multivessel CAD (%) 69.6 60.7 0.27 
Concomitant Medications  
ACE Inhibitors(%) 58.1 63.3 0.48 
ARBs (%) 22.1 12.2 0.06 
Beta Blockers (%) 86 90.6 0.29 
Nitrates (%) 45.3 38.1 0.33 
Statins (%) 86 90.6 0.29 
Calcium Antagonists (%) 26.7 16.5 0.09 
Diuretics (%) 36 21.6 0.02 
Biochemistry Parameters (MeanrSD)  
Platelets (10^3/μl) 238.91 (r77.26) 231.38 (r66.33) 0.44 
WBC (10^3/μl) 8.93 (r2.36) 7.54 (r2.01) <0.001 
HDL Cholesterol (mg/dl) 37.1 (r9.5) 44 (r12.8) <0.001 
LDL Cholesterol (mg/dl) 71.37 (r33.1) 75.72 (r27.18) 0.29 
Triglycerides (mg/dl) 134.87 (r81.74) 117.4 (r67.36) 0.085 
Glycaemia (mg/dl) 155.76 (r54.17) 101.38 (r13.48) <0.001 
Hba1c (%) 7.4 (r1.42) 5.74 (r0.5) <0.001 
Creatinine (mg/dl) 1.033 (r0.477) 0.981 (r0.572) 0.48 
C-Reactive Protein (mg/dl) 0.53 (r0.93) 0.44 (r0.82) 0.47 
Uric Acid (mg/dl) 5.78 (r1.73) 5.96 (r1.95) 0.48 
COL Test (AUC) 460.92 (r160.24) 412.04 (r128.36) 0.013 
ASPI Test (AUC) 369.16 (r190.7) 318.54 (r178.76) 0.046 
TRAP Test (AUC) 1183.16 (r289.15) 1099.73 (r296.86) 0.04 
ADP Test (Auc; MeanrSd) 315.55 (r159.21) 259.86 (r110.84) 0.002 
 
CAD = Coronary Artery Disease; MI = Myocardial Infarction; PCI = Percutaneous Coronary Interventions;   CABG 
= Coronary Artery Bypass Graft ;ACE = Angiotensin Converting Enzyme; ARB = Angiotensin Receptor Blockers; ASA = 
Acetylsalicylic Acid; LDL = Low-Density Lipoproteins; 
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Platelet reactivity was higher in diabetic as compared to non diabetic patients (p=0.046 for ASPI 
test, p=0.013 for COL test, p=0.04 for TRAP test and p=0.002 for ADP test, as in Table 1). 
A total 29 patients (12.9%) out of 224 displayed HRPR (ADP test > 417 AU*min) in treatment with 
ticagrelor, with an almost double rate of HRPR patients in presence of diabetes mellitus, (18.8% vs 
9.4%, p=0.06, Figure 1). 
In fact, at multivariate analysis, after correction for baseline differences (age, BMI, renal 
failure, hypertension, diuretics, White Blood Cells Count, glycaemia, HbA1c and HDL- cholesterol), 
diabetic status emerged as an predictor of HRPR with ticagrelor (OR[95%CI]= 2.12[1.1-4.1], 
p=0.025). 
 
 
Figure 1. Bar graphs showing the prevalence of high on treatment residual platelet reactivity (HRPR) with 
ticagrelor at ADP test according to diabetes mellitus diagnosis. 
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At linear regression analysis, as displayed in Figure 2A, a direct relationship was identified 
between platelet reactivity at ADP test and HbA1c (r=0.15, p=0.029), but not with fasting 
glycemia (r=0.08, p=0.20, Figure 2B). 
Figure 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Linear regressions showing the relationship between platelet reactivity at ADP test and 
glycosylated hemoglobin- HbA1c (figure A), and between platelet reactivity at ADP test and fasting 
glycemia (figure B). 
 
 
Discussion 
 
Present study represents the largest cohort of patients with recent Acute Coronary Syndromes 
treated with ticagrelor where the role of diabetes mellitus (DM) and glycemic control on platelet 
reactivity were assessed. 
Our main findings is that diabetes is independently associated with higher platelet reactivity. In 
addition, a significant linear association was observed between HPHR and Glycosylated 
hemoglobin but not with fasting glycaemia. 
Diabetes mellitus represents a major public heart concern, in particular for its progressively 
increasing prevalence and unfavorable cardiovascular prognosis. In fact, the improvements in  the  
management  of  ACS  and  in  revascularization  strategies  have  proven  largely unsatisfactory 
among diabetics, that still display a far higher risk of long-term mortality and acute ischemic  
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events(17–19). In particular, despite bypass surgery is deemed as the best  revascularization 
option in stable diabetics with multivessel coronary disease, a large quote of diabetic patients 
undergoes percutaneous procedures with stent implantation, especially in the context of acute 
myocardial, infarction, being exposed to a higher risk of periprocedural complications, stent 
thrombosis and repeated revascularization as compared to non diabetics(20–23). 
Platelet hyperreactivity can be held responsible for great part of the thrombotic risk in diabetics, 
thus explaining the great efforts accomplished to establish an optimal antiplatelet treatment among 
these patients. 
Indeed, diabetes has been clearly demonstrated as a risk factor for high- residual platelet 
reactivity (HRPR) despite dual antiplatelet therapy in the era of clopidogrel. 
In the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial, including patients 
with either unstable angina or recent MI, the benefits of dual antiplatelet therapy with clopidogrel vs 
aspirin alone were smaller in the subset of the 2840 patients with DM. (24)  More recently, Bae et 
al.(25) in a large real life cohort of patients reported that diabetes was an independent determinant 
of having a platelet aggregation value above the therapeutic threshold,  (OR = 1.75; P <0.0001) 
and high-platelet reactivity has been demonstrated by Angiolillo et al. as predicting the risk of 
major adverse events at long-term outcome in 173 diabetic patients undergoing elective PCI (26). 
However, a different scenario could be hypothesized with newly developed antiplatelet agents such 
as prasugrel and ticagrelor, providing a more potent and predictable antiplatelet effect. 
In the TRITON-TIMI 38 substudy addressing diabetic patients, the net clinical benefit with 
prasugrel was greater for subjects with DM (14.6% versus 19.2%; HR, 0.74; P<0.001) than for 
subjects without DM (11.5% versus 12.3%; HR, 0.92; P=0.16, P interaction=0.05)(1). 
On the contrary, in the PLATO(10), the clinical benefits of ticagrelor did not differ according to 
diabetic status, and a recent meta-analysis by Alexopulos et al. including the individual data of 
445 patients treated with ticagrelor maintenance dose, stated that diabetes and age >70 years 
were inversely associated to the higher levels of platelet inhibition(12). Contrastingly  
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Laine et colleagues reported in 100 diabetic post-ACS patients that ticagrelor achieved a  
significantly lower platelet reactivity as compared to prasugrel loading dose, and the authors 
suggested that the potent antiplatelet effect of this drug could potentially overcome the higher 
platelet reactivity of diabetics (27). 
Therefore, in presence of small studies and contrasting data, uncertainty still exists on the 
impact of DM and glycemic control on platelet function during ticagrelor treatment. 
In our study we included one of the largest cohorts of post-ACS patients treated with ticagrelor. 
Diabetic status was associate to higher platelet aggregation, with an  almost double rate of HRPR 
among diabetics. DM also related with older age and metabolic disorders, that are known per se 
to increase thrombogenicity. However, after correction for all baseline confounders, we confirmed 
a significant association between HRPR with ticagrelor and diabetes mellitus. 
Moreover, a positive correlation was observed between platelet function and glycosylated 
hemoglobin, among glucose control parameters, but not with fasting glycemia. 
Similar findings had been previously reported by Singla et al.(28) in diabetic patients with 
HbA1c ≥ 7 g/dl and additionally by Vivas et al., that documented a significant reduction of 
aggregation in post-ACS patients receiving intensive glucose control treatment with insulin(29). 
Indeed, hyperglycemia can impact on platelet function both directly and by modulating the 
release of pro-oxydant and inflammatory substances, thus inducing P-selectin  expression and 
glycated platelet surface proteins, with consequent amplification of platelet adhesion(30). However, 
all previous studies on glycemic parameters were  conducted  with clopidogrel, while in our 
population we firstly identified analogous results during ticagrelor treatment. 
Indeed, in the PLATelet inhibition and patient Outcomes (PLATO) substudy focusing on thee 1036 
diabetic patients, ticagrelor reduced the primary endpoint, all-cause mortality, and stent thrombosis 
in patients with or without HbA1c above the median(11). 
Present findings, on the contrary, shed new light on the still unsolved problem  of high residual 
platelet reactivity among diabetics, even despite the use of potent agents as ticagrelor. Thus, 
careful monitoring of these subgroups of patients at elevated cardiovascular risk could be  
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suggested during maintenance therapy, as tailoring antiplatelet therapy has been proven to 
significantly reduce cardiovascular events over time in the MADONNA trial only when HRPR was 
defined according to Multiple Electrode Analyzer (MEA), as in present study (31). Future large 
randomized trials are certainly needed to confirm whether a tailored approach can improve 
outcome among diabetic patients in the era of new ADP antagonists. 
 
 
Limitations 
 
A first limitation can be considered the relatively small sample of our patients, although including a 
large percentage of diabetic patients. Indeed, we did not perform glucose tolerance test to our 
non-diabetic population, thus potentially leading to the exclusion of a certain quote of patients 
with impaired glycemic metabolism. Moreover, we did not consider the potential influence of 
hypoglycemic therapies, and in particular of more recent oral drugs, whose anti-inflammatory and 
anti-thrombotic effects could have modulated platelet reactivity (32). 
In addition, our results and patients with HRPR were not confirmed by the use of light transmission 
aggregometry, that still represents the gold standard for platelet aggregation. However, a good 
correlation between ADP-mediated IPA and ADP-LTA has already been reported (33). Finally, we 
did not perform a systematic follow-up of our patients  and therefore, we cannot definitely evaluate 
the impact of ticagrelor non-responsiveness on clinical outcome. 
 
 
Conclusion 
 
Present study shows that diabetes mellitus is as independent predictor of high-residual platelet 
reactivity in post-ACS patients treated with ticagrelor. In addition, a linear association was 
observed between HRPR and glycosylated hemoglobin levels, a parameter of chronic glycemic 
control, but not with fasting glycaemia. 
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Abstract 
Bivalirudin has gained ground against unfractionated heparin (UFH) in percutaneous coronary 
interventions (PCI), due to a reported better safety profile. However, whether bivalirudin may 
provide also advantages in clinical outcome beyond the known benefits in major bleedings, is still a 
debated matter and was, therefore, the aim of present meta-analysis of randomized trials, 
evaluating efficacy and safety of bivalirudin as compared with UFH in PCI. 
 
Methods and study outcomes. Literature archives (Pubmed, EMBASE, Cochrane) and main 
scientific sessions were scanned. Primary endpoint was overall mortality. Secondary endpoints 
were: 1) mortality within 30-days; 2) overall and within 30-days non fatal myocardial infarction; 3) 
overall and within 30-days stent thrombosis. Safety endpoint were major bleedings (per protocol 
definition or TIMI classification). A prespecified analysis was conducted according to clinical 
presentation (Elective, ACS, STEMI). 
 
Results. A total of 22 randomized clinical were finally included, involving 40156 patients 
randomized to bivalirudin (52.9%) or to UFH (47.1%). Death occurred in 1100 (2.8%) of patients, 
with no difference between bivalirudin and UFH (2.7% vs 2.8% OR[95%C]=0.94[0.83,-.06], p=0.32, 
phet=0.48). The results did not change according to clinical presentation. By meta-regression 
analysis, the effects on mortality were not related to patients risk profile (r=-0.38(-0.89-0.14), 
p=0.15) or the reduction in bleeding complications (r=-0.008(-0.86-0.85), p=0.98). A significant 
increase in short-term stent thrombosis was observed with bivalirudin (OR [95%CI]=1.42 [1.10- 
1.83], p=0.006). However, Bivalirudin significantly reduced bleedings according to both study 
protocol definition (OR [95%CI]=0.63 [0.57-0.69], p<0.00001; phet=0.0003) or TIMI major criteria 
(OR [95%CI]=0.65 [0.53-0.79], p<0.0001, phet=0.95). 
 
Conclusions. In present meta-analysis, among patients undergoing PCI, bivalirudin, as compared 
with UFH, is associated with a significant reduction in major bleeding complications that, however, 
does not translate into mortality benefits. Furthermore, bivalirudin is associated with higher rate of 
30-days stent thrombosis and recurrent MI among STEMI patients. 
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Background 
 
 
Large interests have been focused in the last decade on the improvement in antithrombotic 
therapies in patients with acute coronary syndromes, especially for those with STEMI undergoing 
primary angioplasty (1-6). 
 
Bivalirudin has been addressed in the last 20 years as an alternative strategy for anticoagulation in 
patients undergoing percutaneous coronary interventions (PCI). Bivalirudin, in fact, due to its 
pharmacological properties, should offer several advantages, as compared with the traditional 
heparin (7). First, bivalirudin is a direct thrombin inhibitor and can, therefore, block selectively also 
clot-bound thrombin, potentially achieving a more potent and more predictable anticoagulant 
response than unfractionated heparin (UFH) (8-11). Moreover bivalirudin can also display an 
antiplatelet effect, which could contribute to further benefits for patients undergoing PCI (11). 
 
In addition, a great attention has been raised on the lower rate of bleeding complications with 
bivalirudin. In fact major bleedings in the setting of PCI have been associated with increased major 
adverse cardiac events, longer in-hospital stay and higher mortality, despite the use of radial 
approach have significantly reduced this kind of complications (12-15). 
 
Although several studies have attempted to provide an evidence for the advantages of bivalirudin 
in higher risk patients such as in the setting of ACS, its clinical benefits are still controversial (16), 
as the benefits of a strategy combining heparin with the potent GPIIbIIIa inhibitors are more 
consolidated in order to overcome the delayed onset of action of oral antiplatelet agents, especially 
in STEMI patients (17-20). 
 
In addition, despite the reduction in bleedings with bivalirudin, it is still a matter of debate whether 
these advantages can translate into benefits in ischemic events or mortality (21-22). 
 
Therefore, aim of current study was to perform a comprehensive meta-analysis of randomized 
trials evaluating safety and efficacy of bivalirudin as compared with UFH, with or without GP IIb-IIIa 
inhibitors, in patients undergoing PCI. 
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Methods 
 
 
Eligibility and search strategy. The literature was scanned by formal searches of electronic 
databases (MEDLINE, Cochrane and EMBASE) for clinical studies and furthermore the scientific 
session abstracts, searched on the TCT (www.tctmd.com), EuroPCR (www.europcr.com), ACC 
(www.acc.org), AHA (www.aha.org), and ESC (www.escardio.org) websites, for oral presentations 
and/or expert slide presentations from January 1990 to September 2014. The following key words 
were used: randomized trial, bivalirudin, hirulog, anticoagulation, unfractionated heparin, acute 
coronary syndrome, myocardial infarction, reperfusion, STEMI, primary angioplasty, coronary 
angioplasty, stent. No language restrictions were enforced. 
 
Data extraction and validity assessment. 
 
 
Data were independently abstracted by two investigators. In case of incomplete or unclear data, 
authors, where possible, were contacted. Disagreements were resolved by consensus. Data were 
managed according to the intention-to-treat principle. 
 
Outcome measures. 
 
 
Primary efficacy endpoint was overall mortality, including the longest available follow-up. 
Secondary efficacy endpoints were: 1) Mortality within 30 days; 2) Overall non fatal myocardial 
infarction; 3) Non fatal myocardial infarction within 30 days; 4) Overall stent thrombosis 
(definite/probable); 5) Stent thrombosis (definite/probable) within 30 days. Safety endpoints   were: 
1) Major bleedings (according to per protocol definition) and 2) Major bleedings according to TIMI 
Major definition within 30 days. 
 
Data analysis 
 
 
Statistical analysis was performed using the Review Manager 4.27 freeware package, SPSS   17.0 
statistical package. Odds ratio (OR) and 95% confidence intervals (95% CI) were used as 
summary statistics.  The pooled  odds  ratio  was  calculated  by using  a  fixed  effect  model.  The 
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Breslow-Day test was used to examine the statistical evidence of heterogeneity across the studies 
(p < 0.1). The study quality was evaluated by the same two investigators according to a score, that, 
as previously described (23), was expressed on a ordinal scale, allocating 1 point for the presence 
of each of the following: 1) statement of objectives; 2) explicit inclusion and exclusion criteria; 3) 
description of intervention; 4) objective means of follow-up; 5) availability of data on endpoint 
events; 6) power analysis; 7) description of statistical methods; 8) multicenter design; 9) discussion 
of withdrawals; 10) details on medical therapy. A meta-regression analysis was carried out to 
evaluate the relationship between benefits in mortality from bivalirudin vs UFH, patients’ risk profile 
(as Log of the Odds for mortality in the control group) and reduction in bleeding complications (as 
Log of the Odds Ratio for bleedings - as per protocol definition- in bivalirudin vs control group). The 
study was performed in compliance with the Quality of Reporting of Meta-Analyses (PRISMA) 
guidelines (24). 
 
 
 
Results 
 
Eligible studies. A total of 22 randomized clinical trials (25-46) were finally included, for a total 
population of 40156 patients (Figure 1). Among them, 20870 patients (52.9%), were randomized to 
bivalirudin, while 19286 patients (47.1%) to UFH with or without planned GPIIb/IIIa inhibitors. 
Preprocedural fondaparinux was administered in 100% of patients in one trial (38). Detailed 
characteristics of included trials are shown in Table 1. As displayed in Table 2, mean age was 
63.7.1±4.4 years, with 25% of diabetics and 22.9% with renal failure. Use of GPIIbIIIa inhibitors 
was 20.8% in the bivalirudin group (excluded in 4 trials (28, 33, 34, 46)) and 53% in the UFH group 
(planned 100% in 9 trials (25, 29, 31, 33,34, 36, 43, 45, 46)). Five trials were conducted on  STEMI 
 
patients (30,31,37,39, 41), while 7 trials focused on patients with ACS (UA/NSTEMI) (25, 28, 33, 
 
38, 44, 45, 46). Follow-up data were collected within 30 days in 14 trials (26,27,29,30,34, 35, 37, 
 
38, 39, 42, 43, 44, 45, 46), between 6 and 12 months in 7 trials (25,28,32,33,36,40, 41), and at 3 
 
years in 1 trial (31). 
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Table 1. Characteristics of included studies 
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Table 2. Clinical features of patients in included studies 
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Figure 1 
 
543 potentially 
relevant citations 
identified 
 
 
 
110 citations excluded as not 
relevant to the meta-analysis 
 
433 studies comparing 
bivalirudin with heparin in 
patients undergoing PCI 
 
 
 
411 studies excluded as: 
-duplicate studies; 
-no original data; 
-no data on mortality or clinical 
outcome. 
 
 
 
 
 
Figure 1. Flow diagram of the systematic overview process. 
 
 
 
 
Clinical outcome 
 
Primary endpoint. Data on overall mortality were available in 39676 patients (98.8%). Death 
occurred in 1100 (2.8%) of patients. As shown in Figure 2, no difference in mortality was observed 
between bivalirudin and UFH (2.7%, (567/20664) vs 2.8% (533/19012), OR [95%C]= 0.94 [0.86- 
1.06], p=0.32; phet=0.48). Similar results were obtained for elective patients (1.6% (121/7287) vs 
1.9% (142/7325), OR [95%C]= 0.85 [0.67-1.09], p=0.85; phet=0.41), in patients with ACS (2.8%, 
(242/8567) vs 2.3% (140/6126), OR [95%C]= 1.11 [0.89,1.37], p=0.35; phet=0.55) and in STEMI 
(4.2%  (204/4810)  vs 4.5%  (251/5561), OR [95%C]=  0.88 [0.72-1.06],   p=0.17;  phet=0.49,  p int 
=0.18). By meta-regression analysis no significant relationship was observed between benefits in 
mortality with bivalirudin as compared to UFH, and patients risk profile or the reduction in bleeding 
complications (r=-0.38 [-0.89-0.14], p=0.15) and (r=-0.008 [-0.86-0.85], p=0.98). (Figure 3, upper 
and lower graphs, respectively). 
22 randomized trials 
included in final 
meta-analysis 
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Figure 2 Bivalirudin versus UFH on overall mortality (including the longest follow-up available) with odds ratios and 95% 
confidence intervals (CI). The size of the data markers (squares) is approximately proportional to the statistical weight of 
each trial. 
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Study 
 
 
Secondary endpoints 
Death within 30 days 
Data on mortality within 30 days were available in 21 trials, for a total of 39855 patients (99.2%). 
As depicted in Figure 4, no difference in mortality was observed between bivalirudin and UFH (1.15 
%,  (239/20738)  vs  1.23%  (237/19117),  OR  [95%C]=  0.95  [0.79-1.15],  p=0.61; phet=0.45).No 
 
benefit with bivalirudin was observed for elective patients (0.3% (22/7279) vs 0.4% (32/7317), OR 
[95%C]= 0.70 [0.41-1.19], p=0.19; phet=0.32), patients with ACS (0.9%, (82/8649) vs 0.7% 
(41/6239), OR [95%C]= 1.28 [0.88-1.87], p=0.24; phet=0.75) and in STEMI patients (2.8 %, 
(135/4810) vs 2.9% (164/5561), OR [95%C]= 0.90 [0.71-1.14], p=0.40; phet=0.28, p int =0.14). 
 
Figure 4 Short-term Mortality 
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Figure 4 Bivalirudin versus UFH on mortality within 30 days, with odds ratios and 95% confidence intervals 
(CI). The size of the data markers (squares) is approximately proportional to the statistical weight of each 
trial. 
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Non fatal myocardial infarction (MI) 
 
Data on overall myocardial infarction were reported in 39576 patients (98.5%). A recurrent MI 
occurred in 2449 (6.2%) of patients. As depicted in figure 5, no difference was observed between 
bivalirudin and heparin (6.6%, (1352/20614) vs 5.8% (1097/18962), OR [95%C] = 1.04 [0.95-1.13], 
p=0.38; phet=0.05). Similar results were obtained for elective (6.3%, (459/7287) vs 5.9% 
(430/7325), OR [95%C]= 1.08 [0.94-1.23], p=0.29; phet=0.42), ACS (8.5% (728/8517) vs 7.9% 
(477/6076), OR [95%C]= 1.07 [0.95-1.21], p=0.27; phet=0.37) and in STEMI patients (3.4% 
(165/4810) vs 3.8% (190/5561), OR [95%C]= 0.86 [0.70-1.27], p=0.18; phet=0.004; p int=0.19). 
Data on MI at 30 days were available in 21 included trials (98.8% of patients). A total of 1863 
patients (4.7%) experienced an event. As depicted in Figure 6, bivalirudin did not significantly 
impact on the recurrence of MI at 30 days (5% (1035/20677) vs 4.3% (828/19057), OR [95%CI]= 
1.09 [0.99-1.19], p=0.09; phet= 0.21). Similar results were obtained for elective (5.6% (409/7217) 
vs 5.2 % (382/7258), OR [95%C]= 1.08 [0.93-1.25], p=0.30; phet=0.51), ACS patients (6.3% 
(539/8599) vs 6.1% (377/6189), OR [95%C]= 1.04 [0.90-1.20], p=0.63; phet=0.29), while a 
significant increase in recurrent MI was observed with Bivalirudin in patients with STEMI (1.8% 
(87/4810) vs 1.2% (69/5561), OR [95%C]=1.40 [1.01-1.95], p=0.04; phet=0.12; p int= 0.26). 
 
 
Stent thrombosis 
 
Data on stent thrombosis were available in 12 studies. Stent thrombosis (definite or probable 
according to the Academic Research Consortium definition) occurred in 297 (1.5%) of patients. 
As depicted in Figure 7, bivalirudin did not significantly impact on stent thrombosis (1.6% 
(152/9216)  vs  1.4%  (145/9965);  OR  [95%CI]=  1.13    [0.90-1.43],  p=0.30;  phet=  0.07). Similar 
results were obtained for elective patients (0.6% (21/3548) vs 0.5 % (19/3545), OR [95%C]= 1.10 
[0.60-2.04], p=0.76; phet=0.87), those with ACS (0.9% (8/860) vs 1.2% (11/861), OR [95%C]= 0.73 
[0.29-1.81],  p=0.49),  or STEMI  (2.5% (123/4810)  vs  2.1%  (115/5561), OR [95%C]=1.18  [0.91- 
1.53], p=0.22; phet=0.006; p int= 0.60). 
 
Data on stent thrombosis at short-term follow-up were available in 26498 patients (66%), with 669 
events occurring within 30 days (2.5%). 
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Figure 5 Bivalirudin versus UFH on overall myocardial infarction (including the longest follow-up available), with odds 
ratios and 95% confidence intervals (CI). The size of the data markers (squares) is approximately proportional to the 
statistical weight of each trial. 
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Figure 6 Bivalirudin versus UFH on myocardial infarction occurring within 30 days, with odds ratios and 95% 
confidence intervals (CI). The size of the data markers (squares) is approximately proportional to the 
statistical weight of each trial. 
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Figure 7 Bivalirudin versus UFH on overall definite/probable stent thrombosis (including the longest follow-up available), 
with odds ratios and 95% confidence intervals (CI). The size of the data markers (squares) is approximately proportional 
to the statistical weight of each trial. 
 
 
 
 
As depicted in Figure 8, bivalirudin significantly increased the risk of stent thrombosis (2.6% 
(372/14214)  vs  2.4%  (297/12284);  OR  [95%CI]=  1.42     [1.10-1.83],  p=0.006;  phet=      0.26). 
Significant results were observed in STEMI (1.9% (90/4810) vs 1% (60/5561), OR [95%C]=1.64 
[1.17-2.29], p=0.004; phet=0.05), but not in elective patients (0.4% (5/1259) vs 0.2% (3/1264), OR 
[95%C]= 1.58 [0.41-6.07], p=0.50; phet=0.81), or those with ACS (3.4% (277/8147) vs 4.3% 
(234/5461), OR [95%C]= 1.15 [0.77-1.71], p=0.50; phet=0.93; p int= 0.40). 
 
 
Safety endpoints 
 
Bleedings, as per protocol definition, were reported within the first 30 days from randomization in 
39400 patients (98.1%). A major bleeding occurred in 1694 patients (4.2%), with a significant 
reduction of events in patients treated with bivalirudin respect to UFH (3.5%, (739/20859) vs 4.9% 
(955/19271); OR [95%CI]= 0.62 [0.56-0.69], p<0.00001;  phet=0.0003), (Figure 9). 
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Figure 8 Bivalirudin versus UFH on definite/probable stent thrombosis occurring within 30 days, with odds ratios and 
95% confidence intervals (CI). The size of the data markers (squares) is approximately proportional to the statistical 
weight of each trial. 
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Figure 9 Bivalirudin versus UFH on major bleedings according to protocol definition- (within 30 days), with odds ratios 
and 95% confidence intervals (CI). The size of the data markers (squares) is approximately proportional to the statistical 
weight of each trial. 
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Similar results were obtained in elective patients (1.7%, (121/7287) vs 2.4% (173/7325), OR 
[95%C]= 0.69 [0.54-0.87], p=0.002; phet=0.68), in those with ACS (4.5% (394/8762) vs 6.8% 
(433/6385), OR [95%C]= 0.59 [0.51-0.68], p<0.00001; phet=0.0004) or STEMI (4.7% (224/4810) 
vs 6.3% (349/5561), OR [95%C]= 0.64 [0.54-0.77], p<0.00001; phet=0.002; p int = 0.48). 
Similar data were obtained when considering bleeding according to TIMI Major  Bleedings 
definition, that was reported in 22898 patients (58.1%). In fact, a major bleeding occurred in 428 
patients (2%), with a significantly lower rate of events in the overall bivalirudin treated arm (1.5%, 
(194/12620) vs 2.3% (234/10278), OR [95%CI]= 0.65 [0.53-0.79], p<0.0001;  phet= 0.95),   (Figure 
10), that was similarly observed in elective patients (0.5% (15/2905) vs 1% (29/2903), OR 
[95%CI]= 0.51 [0.28-0.96], p=0.04; phet= 0.96), ACS (1.7% (103/6555) vs 1.9% (83/4187), OR 
[95%C]= 0.72 [0.54,0.97], p=0.03 phet=0.66), or STEMI (2.4% (76/3160) vs 3.8 % (122/3188), OR 
[95%C]= 0.62 [0.46-0.82], p=0.001; phet=0.76; p int= 0.56). 
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Figure 10 Bivalirudin versus heparin in major bleedings according to TIMI definition (within 30 days), with odds ratios 
and 95% confidence intervals (CI). The size of the data markers (squares) is approximately proportional to the statistical 
weight of each trial. 
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Discussion 
 
 
This is the most comprehensive meta-analysis evaluating the effectiveness and safety of 
bivalirudin, as compared with UFH, with long-term follow-up data in patients undergoing coronary 
angioplasty. Our main finding is that bivalirudin is associated with a significant reduction in major 
bleeding complications that, however, did not translate into beneficial effects mortality. Importantly, 
these results were confirmed in the setting of STEMI, where bivalirudin was associated with a 
higher risk of recurrent MI and stent thrombosis within 30 days. 
Coronary artery disease still represents the leading cause of mortality in developed countries. The 
larger availability of reperfusion therapies, the improvement of antithrombotic therapies and 
mechanical devices have contributed to the significant reduction in mortality observed in the last 
decade (47-51). However, the outcome is still unsatisfactory in high-risk patients (52-56), that 
therefore justifies the need for further improvements. 
 
Previous studies have shown that bleeding complications are associated with higher mortality rates 
among patients undergoing coronary angioplasty (12, 57, 58). 
 
Bivalirudin has emerged in the last years as an anticoagulation strategy alternative to UFH during 
PCI, providing significant benefits in the reduction of bleeding events (59). However, its 
effectiveness in the prevention of short and long-term thrombotic complications is still a matter of 
debate. 
 
Being a direct thrombin- inhibitor, bivalirudin has been suggested to display more favorable 
pharmacological properties as compared to UFH (59), including a more stable activity, as it does 
not bind to plasma proteins, it is not inactivated by heparinases and acts also on clot-binding 
thrombin (48). In addition, bivalirudin displays a short half life, with a clearance only partially (20%) 
mediated by the kidney, an inhibitory effect on monocytes and platelets (11), and a safer profile in 
elderly patients or in presence of renal failure. 
 
However, the first randomized trial with bivalirudin, the Hirulog Angioplasty Study (HAS) trial (28) 
including   4098   patients   with   unstable   or   post-infarction   angina   undergoing    angioplasty, 
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demonstrated only some benefits in terms of major bleeding complications, with no benefits in 
terms of death and myocardial infarction. Similar results were observed in the large REPLACE-2 
(36). In the ISAR-REACT-3 (32), including elective patients or unstable patients with negative 
troponin, despite the large amount of UFH (140 IU/Kg), only a weak reduction in terms of TIMI 
major bleedings was observed with bivalirudin. 
 
However, these trials did not consider patients with ACS, where the balance between bleedings 
and ischemic events may play a more relevant role. 
 
In the ACUITY trial, among patients undergoing angioplasty (those included in the meta-analysis) 
(25), despite the significant reduction in major bleeding complications with bivalirudin, no benefits 
were observed in death and myocardial infarction. 
Similar benefits in bleedings were reported in the HORIZON-AMI trial and EUROMAX trial (30, 31) 
among patients undergoing primary angioplasty for STEMI. However, in both studies, bivalirudin 
treated patients displayed a higher rate of early stent thrombosis, with contrasting findings in terms 
of mortality, that was favorably lower with bivalirudin only in the HORIZON-AMI. The higher risk of 
stent thrombosis in STEMI patients has been confirmed in the HEAT PPCI trial that did not find any 
benefit in mortality (39). Absence of benefits in ischemic complications and mortality in the setting of 
STEMI, despite the benefits in major bleedings, has additionally been observed in the BRIGHT trial 
(41). 
Although bleeding reduction may be a mechanism through which bivalirudin may reduce mortality 
compared with a UFH with or without GP IIb-IIIa inhibitors, a post hoc analysis of the HORIZONS- 
AMI trial (59) suggested that bivalirudin reduced mortality in both patients with and without major 
bleedings, an observation that was similarly seen in a large registry (60). Previous reports 
suggested an alternative explanation for the mortality reduction by bivalirudin, more effectively 
inhibiting thrombin as compared with UFH and then potentially playing a critical role in the 
modulation of coagulation, platelet activation, and inflammation and potentially exerting effects 
beyond bleeding (61,62). However, this hypothesis clearly contrasts with the observed higher risk of 
stent thrombosis in this study. 
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Present study represents the most comprehensive meta-analysis on Bivalirudin in patients 
undergoing coronary angioplasty, including 22 randomized trials with 40156 patients. We showed 
that, despite the benefits in major bleedings, bivalirudin was not associated with a significant 
reduction in mortality as compared with UFH. These results were independent from the type of 
presentation (elective, ACS or STEMI). We did not observe any relationship between reduction in 
mortality and benefits in bleeding complications or risk profile. In addition, in our meta-analysis, 
bivalirudin was associated to an increased risk of early (within 30 days) stent thrombosis, 
especially among STEMI patients, where a significantly higher rate of reinfarction was also 
observed. 
Recent experiences showed the safety and beneficial effects in terms of bleeding complications 
from routine administration of postprocedural protamine, even in the setting of primary angioplasty 
(63, 64). Therefore, routine intravenous UFH should still remain the antithrombotic therapy of 
choice, due to its lower costs and more consolidated experience, especially in the setting of 
STEMI. The use of Gp IIb-IIIa inhibitors should be restricted to those patients at higher risk of 
thrombotic complications and impaired reperfusion, especially in the setting of STEMI (5), whereas 
bivalirudin may be considered only for those sicker patients at higher of bleeding complications. 
 
 
 
Limitations 
 
 
First limitation to our study can be considered the lack of an extended follow-up in some trials. 
However, bivalirudin is an endovenous drug with very fast onset of action and short half-life, thus 
displaying its effects only in the periprocedural period. In fact, even in the trials with longer follow- 
up, the differences in cardiovascular endpoints were achieved within the first month from 
randomization. Moreover, no heterogeneity was found among studies for the majority of our 
endpoints. One trial included mostly STEMI patients (87.7% vs 12.3% NSTEMI patients) (41) and 
therefore was pooled with trials on STEMI. 
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Another limitation can be considered the use of differential dosages of heparin in the control group, 
with two trials even allowing enoxaparin (30,46). However, in the majority of the included studies 
UFH was administered at similar dosages, ranging from 60 to 75 U/Kg. 
 
Finally, the lack of individual patients’ data did not allow a subgroup analysis, and therefore we 
could not consider the role of GPIIbIIIa inhibitors, whose differential use in patients treated with 
bivalirudin and heparin has recently been reported as a major determinant for the bleedings 
reduction with bivalirudin (65). Moreover, the role of radial approach, which have been 
demonstrated to provide a significant reduction in site access hemorrhagic complications, could 
have decreased the benefits of bivalirudin (66). 
 
Conclusions. 
 
 
This meta-analysis shows that in patients undergoing PCI, bivalirudin, as compared with UFH, is 
associated with a significant reduction in major bleeding complications that, however, does not 
translate into benefits in survival, independently from the type of presentation. In addition, 
Bivalirudin is associated with higher rates of 30-day stent thrombosis and recurrent MI among 
STEMI patients. 
Platelets in CAD- Part 4 
149 
 
 
 
 
References 
 
1.De Luca G, Bellandi F, Huber K, Noc M, Petronio AS, Arntz HR, Maioli M, Gabriel HM, Zorman S, De Carlo M, Rakowski T, 
Gyongyosi M, Dudek D. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty-abciximab long- term results (EGYPT-
ALT) cooperation: individual patient's data meta-analysis. J Thromb Haemost. 2011;9(12):2361-70. 
2.De Luca G, Marino P. Adjunctive benefits from low-molecular-weight heparins as compared to unfractionated heparin 
among patients with ST-segment elevation myocardial infarction treated with thrombolysis. A meta- analysis of the 
randomized trials. Am Heart J 2007; 154: 1085.e1-6. 
3.De Luca G, Navarese EP, Cassetti E, Verdoia M, Suryapranata H. Meta-analysis of randomized trials of glycoprotein 
IIb/IIIa inhibitors in high-risk acute coronary syndromes patients undergoing invasive strategy. Am J Cardiol. 2011; 107: 198-
203. 
4.De Luca G, Verdoia M, Suryapranata H. Benefits from intracoronary as compared to intravenous abciximab administration 
for STEMI patients undergoing primary angioplasty: a meta-analysis of 8 randomized trials. Atherosclerosis. 2012; 
222: 426-33. 
5.De Luca G, Smit JJ, Ernst N, Suryapranata H, Ottervanger JP, Hoorntje JC, Dambrink JH, Gosslink AT, de Boer MJ, van 't 
Hof AW. Impact of adjunctive tirofiban administration on myocardial perfusion and mortality in patients undergoing primary 
angioplasty for ST-segment elevation myocardial infarction. Thromb Haemost 2005; 93: 820-3. 
6.De Luca G, Suryapranata H, Marino P. Reperfusion strategies in acute ST-elevation myocardial infarction: an overview of 
current status. Prog Cardiovasc Dis 2008; 50: 352-82. 
7.Warkentin TE, Greinacher A, Koster A. Bivalirudin. Thromb Haemost 2008; 99: 830–839 
8.Gladwell TD. Bivalirudin: a direct thrombin inhibitor. Clin Ther. 2002;24(1):38-58 
9.Heras M, Chesebro JH, Penny WS, et al. Effects of thrombin inhibition on development of acute plateletthrombus deposition 
during angioplasty in pigs. Circulation 1989; 79; 657–665 
10. Badimon L, Badimon J, Lassila R, et al. Thrombin regulation of platelet interaction with damaged vessel wall and 
isolated collagen type I at arterial flow conditions in a porcine model: effects of hirudins, heparin, and calcium chelation. 
Blood 1991; 78: 423–434 
11. Busch G, Steppich B, Sibbing D, et al. Bivalirudin reduces platelet and monocyte activation after elective 
percutaneous coronary intervention. Thromb Haemost 2009; 101: 340–344 
12. Sergie Z, Mehran R, Stone GW. What is the optimal antithrombotic strategy in primary percutaneous coronary intervention? 
Curr Opin Cardiol. 2012;27(4):361-7 
13. Manoukian SV, Feit F, Mehran R, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients 
with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol 2007; 49: 1362– 1368 
14. De Servi S, Mariani G, Mariani M, D'Urbano M. How to reduce mortality in ST-elevation myocardial infarction patients 
treated with primary percutaneous coronary interventions: cut the bleeding. Curr Med Res Opin. 2013;29(3):189-94. 
15. De Luca G, Schaffer A, Wirianta J, Suryapranata H. Comprehensive meta-analysis of radial vs femoral approach in primary 
angioplasty for STEMI. Int J Cardiol 2013; 168: 2070-81. 
16. De Servi S, Mariani G, Mariani M, D'Urbano M. The bivalirudin paradox: high evidence, low use. J Cardiovasc Med 
(Hagerstown). 2013;14(5):334-41 
17. De Luca G, Suryapranata H, Stone GW, Antoniucci D, Tcheng JE, Neumann FJ, Van de Werf F, Antman EM, Topol EJ. 
Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial  infarction: a meta-analysis of 
randomized trials. JAMA 2005; 293: 1759-6. 
18. De Luca G, Navarese E, Marino P. Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST- segment 
elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials. Eur Heart 
J 2009; 30: 2705-13. 
19. Montalescot G, Antoniucci D, Kastrati A, Neumann FJ, Borentain M, Migliorini A, Boutron C, Collet JP, Vicaut E. Abciximab 
in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' 
data with long-term follow-up. Eur Heart J 2007; 28: 443-9 
20. Heestermans AA, van Werkum JW, Taubert D, Seesing TH, von Beckerath N, Hackeng CM, Schömig E, Verheugt FW, ten 
Berg JM. Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. Thromb Res. 
2008;122(6):776-81 
21. Shelton R, Eftychiou C, Somers K, Liu A, Burton-Wood N, Anderson M, Makri L, Blaxill J, McLenachan J, Wheatcroft 
S, Greenwood J, Blackman D. Bivalirudin in patients undergoing primary percutaneous coronary intervention for acute ST-
elevation myocardial infarction: outcomes in a large real-world population. EuroIntervention 2013; 9: 118-2. 
22. De Luca G, Cassetti E, Verdoia M, Marino P. Bivalirudin as compared to unfractionated heparin among patients undergoing 
coronary angioplasty: A meta-analyis of randomised trials. Thromb Haemost. 2009;102(3):428-36 
Platelets in CAD- Part 4 
150 
 
 
 
 
23. Biondi-Zoccai GG, Abbate A, Agostoni P, Parisi Q, Turri M, Anselmi M, Vassanelli C, Zardini P, Biasucci LM. Stenting 
versus surgical bypass grafting for coronary artery disease: systematic overview and meta-analysis of randomized trials. Ital 
Heart J 2003; 4: 271-80. 
24. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The 
PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: 
explanation and elaboration. Ann Intern Med 2009; 151: W65-94 
25. Stone GW, White HD, Ohman EM, et al. Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial 
investigators. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a 
subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet. 2007; 
369: 907–919. 
26. Patti G, Pasceri V, D'Antonio L, D'Ambrosio A, Macrì M, Dicuonzo G, Colonna G,Montinaro A, Di Sciascio G. Comparison 
of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary 
intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs 
Heparin study). Am J Cardiol. 2012 Aug 15;110(4):478-84 
27. Parodi G, Migliorini A, Valenti R, Bellandi B, Signorini U, Moschi G, Buonamici P, Cerisano G, Antoniucci D. Comparison of 
bivalirudin and unfractionated heparin plus protamine in patients with coronary heart disease undergoing percutaneous 
coronary intervention (from the Antithrombotic Regimens aNd Outcome [ARNO] trial). Am J Cardiol. 2010 Apr 
15;105(8):1053-9 
28. Bittl JA, Chaitman BR, Feit F, et al. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction 
angina: Final report reanalysis of the Hirulog Angioplasty Study. Am Heart J 2001; 142: 952–959. 
29. Lincoff AM, Kleiman NS, Kottke-Marchant K, et al. Bivalirudin with planned or provisional abciximab versus low- dose 
heparin and abciximab during Percutaneous coronary revascularization: results of the Comparison of Abciximab 
Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J 2002; 143: 847–853. 
30. Steg PG, van 't Hof A, Hamm CW, Clemmensen P, Lapostolle F, Coste P, Berg JT, Van Grunsven P, Eggink GJ, Nibbe L, 
Zeymer U, Orto MC, Nef H, Steinmetz J, Soulat L, Huber K, Deliargyris EN, Bernstein D, Schuette D, Prats J, Clayton T, 
Pocock S, Hamon M, Goldstein P; the EUROMAX Investigators. Bivalirudin Started during Emergency Transport for 
Primary PCI. N Engl J Med. 2013 Oct 30 [Epub ahead of print]. 
31. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock 
SJ, Dangas G, Wong SC, Fahy M, Parise H, Mehran R; HORIZONS-AMI Trial  Investigators. Heparin plus a glycoprotein 
IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial 
infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet. 2011; 
25;377(9784):2193-204 
32. Shulz S, Mehilli J, Ndrepepa G et al, Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in 
patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial. European Heart Journal (2010) 
31, 582–587 
33. Shulz S, Kastrati A, Ferenc M et al. One-year outcomes with abciximab and unfractionated heparin versus bivalirudin 
during percutaneous coronary interventions in patients with non-ST-segment elevation myocardial infarction: updated 
results from the ISAR-REACT 4 trial. EuroIntervention 2013;9:430-436 
34. Tavano D, Visconti G, D’Andrea D et al. Comparison of  Bivalirudin  Monotherapy  Versus Unfractionated Heparin Plus 
Tirofiban in Patients With Diabetes Mellitus Undergoing Elective Percutaneous Coronary Intervention. Am J Cardiol 
2009;104:1222–1228 
35. Lincoff AM, Bittl JA, Kleiman NS, et al. REPLACE-1 Investigators. Comparison of bivalirudin versus heparin during 
percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events 
[REPLACE]-1 trial). Am J Cardiol 2004; 93: 1092–1096 
36. Lincoff AM, Bittl JA, Harrington RA, et al. REPLACE- 2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa 
blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during Percutaneous coronary intervention: 
REPLACE-2 randomized trial. JAMA 2003; 289: 853–863 
37. Schulz S, Richardt G, Laugwitz KL, Mehran R, Gershlick AH, Morath T, Mayer K, Neudecker J, Tölg R, Ibrahim T, 
Hauschke D, Braun D, Schunkert H, Kastrati A, Mehilli J; for the Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4 
Investigators. Comparison of Prasugrel and Bivalirudin vs Clopidogrel and Heparin in Patients With ST-Segment Elevation 
Myocardial Infarction: Design and Rationaleof the Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4 Trial. Clin 
Cardiol. 2014 Mar 14. doi: 10.1002/clc.22268. [Epub ahead of print] 
38. Waksman R, Bertrand O, Driesman M, Gruberg L, Rossi J, Mehta S, Swymelar S, Dvir D, Xue Z, Torguson R. Bivalirudin 
versus unfractionated heparin during percutaneous coronary intervention in patients with non-ST- segment elevation acute 
coronary syndrome initially treated with fondaparinux: results from an international, multicenter, randomized pilot study 
(SWITCH III). J Interv Cardiol. 2013;26(2):107-13 
39. Stables R, Shahzad A. HEAT PPCI Investigators. How Effective are Antithrombotic Therapies in  PPCI.  American College 
of Cardiology, 2014.    
Platelets in CAD- Part 4 
151 
 
 
 
 
http://www.cardiosource.org/~/media/Files/Science%20and%20Quality/Clinical%20Trials/ACC%2014%20Slides/HEAT%20PP
CI%20ACC14%20Presentation%20Slides.ashx   
 
40. Briguori C, NAPLES III investigators. Randomised Comparison of Bivalirudin versus Unfractionated Heparin in Patients at 
High Risk of Bleeding Undergoing Elective Coronary Stenting thought the Femoral Approach. AmericanCollegeof
Cardiology,2014. 
http://anticoagulation.cardiosource.org/~/media/Files/Science%20and%20Quality/Clinical%20Trials/ACC%2014 
%20Slides/NAPLES%20III%20ACC14%20Presentation%20Slides.ashx. 
41. Yaling H. Bivalirudin versus Heparin and Heparin plus Tirofiban in Patients with AMI Undergoing PCI. Thirty-Day andOne-
YearOutcomesoftheBRIGHTTrial.TCT,2014. 
http://www.cardiosource.org/News- Media/Publications/Cardiology-Magazine/2014/09/BRIGHT-Bivalirudin-Monotherapy-vs-
Heparin-Monotherapy- vs-Heparin-Plus-Tirofiban-in-AMI-Patients.aspx 
42. Xiang Xiang DC, Gu XL, Song YM, Huang WJ, Tang LQ, Yin YH, Geng SH, Zhou H, Fan WM, Hu R, Pan CM, Zhang Y, 
Xiao FY, Wan HB, Liu ZZ. Evaluation on the efficacy and safety of domestic bivalirudin during percutaneous coronary 
intervention. Chin Med J (Engl). 2013;126(16):3064-8 
43. Dhespande Deshpande NV, Pratiti R, Admane P, Mukherjee D, Mardikar HM. Safety and efficacy of bivalirudin with 
glycoprotein IIb/IIIa for high-risk percutaneous coronary intervention. Indian Heart J. 2012;64(5):444-8 
44. Feldman A, Suleiman K, Bushari L, Rozner E, Freedberg NA et al. Bivalirudin Vs Unfractionated Heparin during 
Percutaneous Coronary Intervention in High Risk Patients for Bleeding. AntiCoagulant Regimen In high risk PAtients for 
Bleeding - ACRIPAB Trial. ESC; 2012. http://congress365.escardio.org/Interventional-Cardiology-&- 
Surgery?vgnextkeyword=&Years=C365YEAR2012&ordering=slides%2Cyeardesc%2Ctitle&vgnextsearchresults 
pageno=2#.VBs9JPl_uSo 
45. Moliterno DJ; TENACITY Steering Committee and Investigators. A randomized two-by-two comparison of high- dose bolus 
tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization 
and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin 
(TENACITY) study trial. Catheter Cardiovasc Interv. 2011;77(7):1001-9 
46. Gibson Gibson CM, Morrow DA, Murphy SA, Palabrica TM, Jennings LK, Stone PH, Lui HH, Bulle T, Lakkis N, Kovach R, 
Cohen DJ, Fish P, McCabe CH, Braunwald E; TIMI Study Group. A randomized trial to evaluate the relative protection 
against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet 
and antithrombotic agents: the PROTECT-TIMI-30 trial. J Am Coll Cardiol. 2006;47(12):2364-7 
47. Navarese EP, De Luca G, Castriota F, Kozinski M, Gurbel PA, Gibson CM, Andreotti F, Buffon A, Siller-Matula JM, 
Sukiennik A, De Servi S, Kubica J. Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous 
coronary intervention for ST-elevation myocardial infarction: a meta-analysis. J Thromb Haemost 2011; 9: 1902-15. 
48. De Luca G, Marino P. Advances in antithrombotic therapy as adjunct to reperfusion therapies for ST-segment elevation 
myocardial infarction. Thromb Haemost 2008; 100: 184-95. 
49. Navarese EP, Kubica J, Castriota F, Gibson CM, De Luca G, Buffon A, Bolognese L, Margheri M, Andreotti F, Di Mario C, 
De Servi S. Safety and efficacy of biodegradable vs. durable polymer drug-eluting stents: evidence from a meta-analysis of 
randomised trials. EuroIntervention 2011; 7: 985-94. 
50. Capozzolo C, Piscione F, De Luca G, Cioppa A, Mazzarotto P, Leosco D, Golino P, Indolfi C, Chiariello M. Direct coronary 
stenting: effect on coronary blood flow, immediate and late clinical results.Catheter Cardiovasc Interv 2001; 53: 464-73. 
51. Di Lorenzo E, De Luca G, Sauro R, Varricchio A, Capasso M, Lanzillo T, Manganelli F, Mariello C, Siano F, Pagliuca MR, 
Stanco G, Rosato G. The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) 
Randomized Trial. JACC Cardiovasc Interv 2009;2: 515-23. 
52. De Luca G, Ernst N, van 't Hof AW, Ottervanger JP, Hoorntje JC, Gosselink AT, Dambrink JH, de Boer MJ, Suryapranata 
H. Predictors and clinical implications of early reinfarction after primary angioplasty for ST- segment elevation myocardial 
infarction. Am Heart J. 2006; 151: 1256-9. 
53. De Luca G, Małek LA, Maciejewski P, Wasek W, Niewada M, Kamiński B, Drzewiecki J, Kośmider M, Kubica J, Ruzyłło W, 
Peruga JZ, Dudek D, Opolski G, Dobrzycki S, Gil RJ, Witkowski A; STEMI 2003 Registry Collaborators. Impact of diabetes 
on survival in patients with ST-segment elevation myocardial infarction treated by primary angioplasty: insights from the 
POLISH STEMI registry. Atherosclerosis 2010; 210: 516-20. 
54. De Luca G, Gibson CM, Bellandi F, Noc M, Dudek D, Zeymer U, Arntz HR, Cutlip D, Maioli M, Zorman S, Mesquita Gabriel 
H, Emre A, Rakowski T, Gyongyosi M, Huber K, Van't Hof AW. Diabetes mellitus is associated with distal embolization, 
impaired myocardial perfusion, and higher mortality in patients with ST-segment elevation myocardial infarction treated with 
primary angioplasty and glycoprotein IIb-IIIa inhibitors. Atherosclerosis 2009; 207: 181-5. 
55. De Luca G, Maas AC, Suryapranata H, Ottervanger JP, Hoorntje JC, Gosselink AT, Dambrink JH, de Boer MJ, van 't Hof 
AW. Prognostic significance of residual cumulative ST-segment deviation after mechanical reperfusion in patients with ST-
segment elevation myocardial infarction. Am Heart J 2005; 150: 1248-54. 
Platelets in CAD- Part 4 
152 
 
 
 
 
56. De Luca G, Ernst N, Suryapranata H, Ottervanger JP, Hoorntje JC, Gosselink AT, Dambrink JH, de Boer MJ, van 't Hof 
AW. Relation of interhospital delay and mortality in patients with ST-segment elevation myocardial infarction transferred 
for primary coronary angioplasty. Am J Cardiol 2005; 95: 1361-3. 
57. Eikelboom JW, Mehta SR, Anand SS, et al. Adverse impact of bleeding on prognosis in patients with acute coronary 
syndromes. Circulation 2006; 114: 774–82. 
58. Mehran R, Pocock SJ, Nikolsky E, et al. A risk score to predict bleeding in patients with acute coronary syndromes. J Am 
Coll Cardiol 2010; 55: 2556–66. 
59. Stone GW, Clayton T, Deliargyris EN, Prats J, Mehran R, Pocock SJ. Reduction in cardiac mortality with bivalirudin 
in patients with and without major bleeding: The HORIZONS-AMI trial (Harmonizing Outcomes with Revascularization and 
Stents in Acute Myocardial Infarction). J Am Coll Cardiol. 2014; 63: 15-20. 
60. Garratt KN, Cohen HA, Fan W. Mortality Reductions Linked to Bivalirudin Use in Unselected Angioplasty Patients With and 
Without Bleeding Complications. J Am Coll Cardiol. 2010;56(Suppl 13):B28. 
61. Palmerini T, Brener SJ, Mehran R, Dangas G, Genereux P, Riva DD, Mariani A, Xu K, Stone GW. Leukocyte count is a 
modulating factor for the mortality benefit of bivalirudin in ST-segment-elevation acute myocardial infarction: the 
HORIZONS-AMI trial. Circ Cardiovasc Interv. 2013; 6: 518-26. 
62. Simpson EL, Fitzgerald P, Evans P, Tappenden P, Kalita N, Reckless JP, Bakhai A. Bivalirudin for the treatment of ST-
segment elevation myocardial infarction: a NICE single technology appraisal. Pharmacoeconomics. 2013; 31: 269-75 
63. Parodi G, De Luca G, Moschi G, Bellandi B, Valenti R, Migliorini A, Carrabba N, Antoniucci D. Safety of immediate 
reversal of anticoagulation by protamine to reduce bleeding complications after infarct artery stenting for acute myocardial 
infarction and adjunctive abciximab therapy. J Thromb Thrombolysis 2010; 30: 446-51. 
64. De Luca G, Parodi G, Antoniucci D. Safety and benefits of protamine administration to revert anticoagulation soon after 
coronary angioplasty. A meta-analysis. J Thromb Thrombolysis 2010; 30: 452-8 
65. Cavender MA, Sabatine MS. Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-
analysis of randomised controlled trials. Lancet. 2014;384(9943):599-606 
66. MacHaalany J, Abdelaal E, Bataille Y, Plourde G, Duranleau-Gagnon P, Larose É, Déry JP, Barbeau G, Rinfret S, Rodés-
Cabau J, De Larochellière R, Roy L, Costerousse O, Bertrand OF. Benefit of bivalirudin versus heparin after 
transradial and transfemoral percutaneous coronary intervention. Am J Cardiol 2012; 110: 1742-8. 
Platelets in CAD- Part 4 
153 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 9 
 
 
Benefits from new ADP-antagonists as compared to 
clopidogrel in patients with stable angina or acute coronary 
syndrome: a meta-analysis of randomized trials 
 
 
Monica Verdoia, Alon Schaffer, Lucia Barbieri, Ettore Cassetti, Raffaele Piccolo, Gennaro Galasso, 
Paolo Marino, Fabiola Sinigaglia, Giuseppe De Luca, 
on behalf of the Novara Atherosclerosis Study Group (NAS) 
 
 
 
Division of Cardiology (MV,LB, AS, EC, PM, GDL), Azienda Ospedaliera-Universitaria “Maggiore della 
Carità”, Eastern Piedmont University, Novara, Italy, Department of Translational Medicine and Centro di 
iotecnologie per la Ricerca Medica Applicata (BRMA), Eastern Piedmont University, Novara, Italy (FS); 
Department of Advanced  Biomedical Sciences, University of Naples Federico II, Naples, Italy (RP, GG) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
J Cardiovasc Pharmacol. 2014;63:339-50 
Platelets in CAD- Part 4 
154 
 
 
 
 
Abstract 
 
Aims. New P2Y12 receptor inhibitors has provided new and more potent antiplatelet strategies, 
although raising several concerns on possible increase of bleedings. Aim of current meta-analysis 
was to evaluate efficacy and safety of new ADP antagonists as compared to clopidogrel in elective 
or ACS  patients managed invasively. 
 
Methods and results. Literature archives (Pubmed, EMBASE, Cochrane) and main scientific 
sessions abstracts were scanned for randomized trials comparing new ADP –antagonists with 
clopidogrel in patients with ACS or stable angina. Primary endpoint was mortality. Secondary 
endpoints were: 1) non fatal myocardial infarction (MI); 2) recurrent ischemia symptoms or 
ischemia driven revascularization (RI/IDR) ; 3) stent thrombosis (ST); 4) safety endopoints, defined 
as for TIMI Major Bleeding criteria. A total of 8 randomized clinical trials were finally included, for a 
total population of 67851 patients. Mean follow-up was 7.6 months, ranging from 48 hours to 30 
months. New ADP-antagonists significantly reduced mortality (3.1% vs 3.6%, OR [95%CI] = 0.86 
[0.79,0.94], p=0.0008, phet=0.18), with greater impact of oral drugs. Similar benefits were found for 
MI (6,1% vs 7%; OR [95%CI] (Random-effect model) = 0.88 [0.79, 0.98] p= 0.01, phet= 0.02), 
recurrent ischemia (2.7% vs 3.1%; OR [95%CI]= 0.85 [0.77,0.93], p=0.0005, phet= 0.09) or stent 
thrombosis (1.1% vs 1.7%; OR [95%CI]= 0.60 [0.51-0.71], p<0.00001, phet= 0.13). By meta- 
regression analysis no relationship was observed between benefits in mortality, new MI, recurrent 
ischemia and stent thrombosis with new ADP-antagonists and patients’ risk profile (beta [95% CI] = 
- 0.01 [-0.30 – 0.27], p = 0.94; beta [95% CI] = - 0.05 [-1.49 – 1.43], p = 0.96); beta [95% CI] = 0.19 
[-0.18 –0.57], p = 0.31 and beta [95% CI] = -0.08 [-0.86 – 0.70], p = 0.84, respectively). 
 
Conclusions. Present meta-analysis shows that the new ADP-antagonists prasugrel, ticagrelor 
and cangrelor are associated to significant reduction of mortality, reinfarction, recurrent ischemia 
and stent thrombosis respect to clopidogrel alone, without significant increase in bleeding 
complications. 
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Background 
 
 
Optimal antithrombotic therapy represents the cornerstone for treatment of acute coronary 
syndromes (ACS) and of patients undergoing PCI .1-4 In fact, technological improvements and the 
introduction of DES allows nowadays percutaneous treatment of more complex lesions, with 
therefore increased thrombotic risk. 5, 6 ADP-antagonists represent a major pillar. However, 
clopidogrel, the most diffuse thienopyridine, has demonstrated inadequate platelet inhibition in 15 
to 48% of patients, even with 600mg loading bolus and dose adjustments. 
 
In fact, clopidogrel displays a complex metabolic pathway, explaining the delayed onset of action 
and the increased risk of stent thrombosis and recurrent cardiovascular events in poor responders, 
with negative impact on survival. 7-11 
 
Therefore, great attention has been focused in the last few years on the development of new 
P2Y12 antagonists, such as prasugrel and ticagrelor, and more recently the intravenous cangrelor. 
Still controversial remains the exact balance between benefits in ischemic complications vs the risk 
of bleeding complications with new ADP antagonist, that therefore is the aim of present meta- 
analysis. 
 
Methods 
 
Eligibility and search strategy. The literature was scanned by formal searches of electronic 
databases (MEDLINE, Cochrane and EMBASE) for clinical studies and furthermore the scientific 
session abstracts, searched on the TCT (www.tctmd.com), EuroPCR (www.europcr.com), ACC 
(www.acc.org), AHA (www.aha.org), and ESC (www.escardio.org) websites, for oral presentations 
and/or expert slide presentations from January 2000 to April 2013. The following key sentence 
was used: “[ADP antagonists], or [prasugrel] or[ ticagrelor] or [cangrelor] and [randomized trial]”. 
 
Data extraction and validity assessment. Data were independently abstracted by two 
investigators. In case of incomplete or unclear data, authors, where possible, were contacted. 
Disagreements were resolved by consensus. Data were managed according to the intention-to- 
treat principle. 
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Purpose and outcome measures. Primary endpoint was mortality. Secondary endpoints were: 1) 
non fatal myocardial infarction (MI); 2) recurrent ischemia symptoms or ischemia driven 
revascularization (RI/IDR) ; 3) stent thrombosis (ST); 4) safety endopoints, defined as for TIMI 
Major Bleeding criteria. 
 
Data analysis 
 
 
Statistical analysis was performed using the Review Manager 4.27 freeware package, SPSS 11.5 
statistical package. Odds ratio (OR) and 95% confidence intervals (95% CI) were used as 
summary statistics. The pooled odds ratio was calculated by using a fixed (The DerSimonian and 
Laird method) or random (Peto) effect model (the last in case of significant heterogeneity). The 
Breslow-Day test was used to examine the statistical evidence of heterogeneity across the studies 
(p < 0.1). The study quality was evaluated by the same two investigators according to a score, that, 
as previously described, 12 was expressed on a ordinal scale, allocating 1 point for the presence of 
each of the following: 1) statement of objectives; 2) explicit inclusion and exclusion criteria; 3) 
description of intervention; 4) objective means of follow-up; 5) availability of data on endpoint 
events; 6) power analysis; 7) description of statistical methods; 9) discussion of withdrawals; 10) 
details on medical therapy. A meta-regression analysis (fixed or random-effect model according to 
evidence of heterogeneity) was carried out to evaluate the effects on risk (as Log Odds Ratio) of 
death, non fatal MI, stent thrombosis and need for coronary revascularization in treated arm plotted 
against the patients’risk profile, that was defined as the event rate in control population (expressed 
as log Odds for the event in control arm). The study was performed in compliance with the Quality 
of Reporting of Meta-Analyses (PRISMA) guidelines.13 
 
 
Results 
Eligible studies 
 
A total of 8 randomized clinical trials 14-21 were finally included, for a total population of 67851 
patients  (Figure  1).  Of  these  patients,  33939  (50%)  received  new  ADP-antagonists,    (either 
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prasugrel, ticagrelor or cangrelor), while 33912 (50%) received clopidogrel only. Mean follow-up 
was 7.6 months, with a minimum of 2 days 20 and maximum of 30 months 17. Study characteristics 
of included trials are shown in Table 1. 
 
Enrolled patients, as displayed in Table 2, were almost 70% of males, with a mean age of 62.4 
years and 28.2% of diabetics. Indication for dual antiplatelet treatment was mainly ACS, with four 
studies allowing inclusion of elective patients. 18-21 Coronary angioplasty was performed in 86% of 
patients (100% in 4 studies) 18-21 while in one study indication to PCI represented an exclusion 
criteria. 16 STEMI patients were allowed in 4 studies. 14, 15, 18, 20 
 
Figure 1 
 
 
10306 potentially relevant 
citations identified 
 
9261 citations excluded as 
not relevant to the 
meta-analysis 
 
1045 studies reporting cardiovascular 
outcome with new ADP-antagonists 
 
 
1037 studies excluded as: 
-duplicate studies; 
-no original data/ meta-analysis; 
-no comparation with traditional 
antiplatelet agents (clopidogrel). 
 
 
 
 
 
 
 
 
 
Figure 1. Flow diagram of the systematic overview process. 
8 randomized trials 
included in final 
meta-analysis 
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Table 1. Characteristics and quality score of included studies 
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Clinical outcome 
 
Primary endpoint. Follow-up data ranged from 48 h 20 to 30 months. 17 Trials with endovenous 
administration of cangrelor had a shorter follow up (48 hours to 1 month), while trials with oral 
P2Y12 antagonists follow-up was up to 30 months, except than in two trials 16,21. Data on mortality 
were available in 67851 patients (100%). Death occurred in 2301 (3.4%) of patients. 
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Table 2. Population and treatment arms in included studies 
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As shown in Figure 2, new ADP-antagonists significantly reduced mortality (3.1% (1073/33939) vs 
3.6% (1228/33912), OR [95%C]= 0.86 [0.79,0.94], p=0.0008, phet=0.18), with greater impact of oral 
drugs (4.6% (979/21343) vs 5.2% (1116/21330), OR [95%C]= 0.87 [0.79,0.95], p=0.002, phet=0.13), 
while no benefits were observed with cangrelor (0.8% (94/12596) vs 0.9% (112/12582), OR 
[95%C]= 0.73 [0.47,1.12], p=0.15, phet=0.25, p interaction=0.43). 
By meta-regression analysis no relationship was observed between benefits in mortality with new 
ADP-antagonists and patients’ risk profile (beta [95% CI] = - 0.01 [-0.30 – 0.27], p = 0.94) (Figure 
3A; Table 3). 
 
 
Figure 2 New versus traditional antiplatelet agents in mortality, with odds ratios and 95% confidence intervals (CI). The 
size of the data markers (squares) is approximately proportional to the statistical weight of each trial. 
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Figure 3 Fixed-effect meta-regression analyses for the risk (OR) of mortality (A), non fatal MI (B), recurrent 
ischemia/ischemia driven revascularization (C) and stent thrombosis (D) between new and traditional antiplatelet agents 
and risk profile. The size of the circle corresponds to its statistical weight. 
 
 
 
Secondary endpoints 
 
 
Non fatal myocardial infarction (MI). 
 
 
Data on MI were available in all included trials (100% of patients). A total of 4454 patients (6.6%) 
experienced an event. As depicted in Figure 4, new P2Y12 inhibitors significantly reduced the 
recurrence of MI (6.1% (2080/33939) vs 7% (2374/33912); OR [95%CI] (Random-effect model)   = 
0.88 [0.79, 0.98] p= 0.01, phet= 0.02). Significant impact, in fact, was observed with oral antiplatelet 
agents (6.4% (1365/21343) vs 7.6% (1624/21330); OR [95%CI] (Random-effect model) = 0.83 
[0.75, 0.93], p = 0.001, phet= 0.18), but not with cangrelor (5.7% (715/12596) vs 5.9% (750/1258); 
OR [95%CI] (Random-effect model) = 0.94 [0.78, 1.13], p = 0.5, phet= 0.05, p interaction = 0.05). By 
meta-regression analysis (random effect model), we did not find any relationship between  benefits 
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in recurrent MI and patient’s risk profile (beta [95% CI] = - 0.05 [-1.49 – 1.43], p = 0.96) (Figure 3B; 
Table 3). 
 
 
 
Figure 4 New versus traditional antiplatelet agents in non fatal MI, with odds ratios and 95% confidence intervals (CI). 
The size of the data markers (squares) is approximately proportional to the statistical weight of each trial. 
 
 
 
Recurrent ischemia or ischemia driven revascularization. 
 
 
Data on recurrent ischemia symptoms either requiring or not coronary revascularization, were 
reported in 4 studies, 14,16,17,21 (42.8% of patients). The other 4 trials (38786 patients, 57.2%) 
reported data on coronary revascularization for symptoms or inducible ischemia. The composite 
endpoint RI/IDR occurred in 1982 (2.9%) of patients. As depicted in Figure 5, new ADP- 
antagonists significantly reduced the recurrence of ischemia or coronary revascularization (2.7% 
(917/33939) vs 3.1% (1065/33912); OR [95%CI]= 0.85 [0.77,0.93], p=0.005, phet= 0.09). Benefits 
were significant with both oral inhibitors (3.7% (790/21343) vs 4.3% (909/1330); OR [95%CI]= 0.86 
[0.78,0.95], p=0.003, phet= 0.03) and cangrelor (1% (127/12596) vs 1.3% (156/1258); OR [95%CI]= 
1.71 [0.52-0.97], p=0.03, phet= 0.98, p interaction=0.26). By meta-regression analysis no significant 
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relationship was observed between benefits in of RI/IDR and to patient’s risk profile (beta [95% CI] 
 
= 0.19 [-0.18 –0.57], p = 0.31) (Figure 3C; Table 3). 
 
 
 
 
Figure 5 New versus traditional antiplatelet agents in recurrent ischemia/ischemia driven revascularization, with odds 
ratios and 95% confidence intervals (CI). The size of the data markers (squares) is approximately proportional to the 
statistical weight of each trial. 
 
 
Stent thrombosis. 
 
Data on stent thrombosis were available in 6 trials (50529 patients, 74.4%). 14, 15, 18-21 Definite or 
probable ST occurred in 714 patients (1.4%). New P2Y12 inhibitors significantly reduced ST (1.1% 
(275/25249) vs 1.7% (439/2280); OR [95%CI]= 0.60 [0.51,0.71], p<0.00001, phet= 0.13), (Figure 6). 
Benefits were observed with both oral antiplatelet agents (1.5% (187/12653) vs 2.4% (306/12698); 
OR [95%CI]= 0.61 [0.50,0.73], p<0.00001, phet= 0.04) and cangrelor (0.7%(88/12596) vs 1.1% 
(133/12582); OR [95%CI]= 0.59 [0.43,0.80], p=0.0009, phet= 0.37, p interaction=0.86). By meta- 
regression  analysis,  no  relationship  was  observed  between  benefits  in  ST  with  new     ADP- 
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antagonists and patients’ risk profile (beta [95% CI] = -0.08 [-0.86 – 0.70], p = 0.84) (Figure 3D; 
Table 3). 
 
 
 
Figure 6 New versus traditional antiplatelet agents in stent thrombosis, with odds ratios and 95% confidence intervals 
(CI). The size of the data markers (squares) is approximately proportional to the statistical weight of each trial. 
 
Safety endpoints. 
 
 
Bleedings, as defined for TIMI major bleedings criteria, were reported in 67426 patients (99.4%). 
For all 3 trials with cangrelor, 18-20 complications were reported at 48 hours. A major bleeding 
occurred in 1769 (2.6%) patients, with no difference between new agents and clopidogrel 
(2.7%(916/33738)  vs  2.5%  (853/33688);  OR  [95%CI]=  1.07  [0.97,1.18],  p=0.15;    phet=  0.48), 
(Figure 7). Similar rate of bleedings occurred with both oral drugs (4.1% (862/20839) vs 3.8% 
(799/20819); OR [95%CI] = 1.08 [0.98,1.19], p=0.14, phet= 0.42), and cangrelor (0.2%(28/12565) 
vs 0.2% (28/12542); OR [95%CI]= 1 [0.59,0.69], p=0.99, phet= 0.27, p interaction=0.78). By meta- 
regression analysis, we observed no relationship between the risk of bleedings with new ADP- 
antagonists and patients’ risk profile (beta [95% CI] = -0.16 [-0.42 – 0.09], p = 0.21) (Figure8; Table 
3). 
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Figure 7 New versus traditional antiplatelet agents in TIMI major bleedings, with odds ratios and 95% confidence 
intervals (CI). The size of the data markers (squares) is approximately proportional to the statistical weight of each trial. 
 
 
 
Figure 8 Fixed-effect meta-regression analyses for the risk (OR) of TIMI major bleedings between new and traditional 
antiplatelet agents and risk profile. The size of the circle corresponds to its statistical weight. 
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Table 3. Meta-regression analysis for death, non fatal MI, coronary revascularization and 
stent thrombosis. 
 
 
Mortality  
Plotted Variable 
 
 
 
Beta 
 
 
 
95% CI 
 
 
 
p value 
 
Log ODDS Death Control -0.01 -0.29 ,0.27 0.94 
Diabetics rate (%) 0.007 -0.006,0.02 0.31 
STEMI rate (%) -0.009 -0.02,0.004 0.18 
PCI rate (%) 0.004 -0.006,0.01 0.15 
Non fatal myocardial infarction    
Plotted Variable Beta 95% CI p value 
Log ODDS MI Control -0.05 -1.49, 1.43 0.96 
Diabetics rate (%) 2 -0.003, 0.04 0.09 
STEMI rate (%) 0.28 -0.01, 0.014 0.79 
PCI rate (%) -1.01 -0.045, 0.028 0.42 
Recurrent ischemia or ischemia-driven revascularization 
Plotted Variable Beta 95% CI p value 
Log ODDS IDR Control 0.19 -0.18, 0.57 0.31 
Diabetics rate (%) 0.01 -0.007 , 0.03 0.23 
STEMI rate (%) 0.009 -0.003 , 0.02 0.13 
PCI rate (%) -0.007 -0.01, -0.001 0.12 
Stent thrombosis    
Plotted Variable Beta 95% CI p value 
Log ODDS ST Control -0.08 -0.87 , 0.71 0.84 
Diabetics rate (%) 0.03 -0.02, 0.18 0.28 
STEMI rate (%) 0.04 -0.01,0.02 0.64 
PCI rate (%) -0.007 -0.015 , 0.0009 0.08 
 
 
 
Discussion 
 
 
Present meta-analysis represents the largest attempt to compare the new P2Y12 antagonists with 
clopidogrel for the prevention of cardiovascular events and bleeding complications in patients with 
coronary artery disease undergoing invasive. In 8 trials administering prasugrel, ticagrelor and 
cangrelor in patients either with ACS or undergoing PCI, we demonstrated significant benefits with 
new antiplatelet agents in terms of mortality, recurrence of non fatal MI, ischemia or stent 
thrombosis as compared to clopidogrel, without significant increase in major bleedings. 
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Platelet inhibitors represent a main pharmacological pillar in the prevention and treatment of 
myocardial infarction. 1-4, 22 Furthermore, improvement in stent technology has further  expanded the 
indication of PCI to a larger proportion of high-risk anatomical and clinical subsets, especially the 
acute setting, 23,24 although potentially increasing the risk of thrombotic complications. 24 Therefore, 
while prompt and strong platelet inhibition is required for these patients, traditional antiplatelet 
agents and especially clopidogrel have raised many concerns. In fact, large interindividual variability 
and delayed onset of action, due to a complex activating  metabolism, have been reported with 
clopidogrel, achieving adequate platelet inhibition at least 4 hours after administration and in 
about only 70% of patients. 25-29 The introduction of high-dose 600 mg clopidogrel bolus, after 
CURRENT OASIS 7 trial, 30 has only partially overcome such clopidogrel “resistance”, but 
increasing the risk of bleeding complications. 
 
Prasugrel is a third-generation thienopyridine with a rapid and effective metabolic activation has 
demonstrated in TRITON-TIMI 38 a significant reduction in stent thrombosis, so that the higher rate 
of major bleeding complications was largely counterbalanced by the benefits in terms of thrombotic 
complications 14. However, the subsequent TRILOGY ACS trial did not show significant benefits in 
ACS patients treated conservatively.17 
 
Ticagrelor is a reversible, non-thienopyridine, P2Y12 inhibitor, with a faster onset and offset of 
action and significantly higher inhibition of platelet aggregation as compared to 600 mg clopidogrel. 
15 The significant reduction in mortality observed in PLATO trial, not apparently depending from the 
degree of antiplatelet effect, that has been described similar to prasugrel, may suggest possible 
“pleiotropic effects” of ticagrelor. 31 
 
Present results confirm the greatest advantages with prasugrel and ticagrelor respect to 
clopidogrel in reduction of mortality, recurrence of MI or ischemia and stent thrombosis without 
significant increase in bleeding risk. 
 
Similar trend in benefits were found with cangrelor, the new endovenous ADP-antagonist, although 
reaching   statistical   significance   only   for   stent   thrombosis   and   repeated revascularization. 
Platelets in CAD- Part 4 
169 
 
 
 
 
Moreover, in the 3 CHAMPION trials, where all patients underwent PCI, cangrelor, as adjunct to 
clopidogrel, displayed a good safety profile, without significant increase in  periprocedural 
bleedings, even in association to GPIIbIIIa inhibitors. 
 
Future randomized trials are certainly needed to explore the use of cangrelor in addition to new 
oral ADP antagonist prasugrel and ticagrelor, especially in the setting of STEMI and as upstream 
strategy. 
 
Limitations 
 
 
Certain limitations should be addressed in present study, of which the most important relates to the 
synthesis of data from heterogeneous trials. However, significant heterogeneity among studies was 
observed only for recurrence of MI, mainly driven by the three smaller studies. In fact, although the 
study populations might seem relatively alike with regard to their high cardiovascular risk, the pro- 
thrombotic milieu and the status of platelets activation might be very different in patients undergoing 
elective PCI or primary PCI for STEMI, thus requiring different degrees of pharmacological inhibition 
to prevent thrombotic events. However, as individual patients data were not available, we were not 
able to definitely stratify patients according to their risk  profile. Moreover, the important differences 
in timing of follow-up might have certainly  influenced the power of some trials, especially those with 
cangrelor, in detecting cardiovascular endpoints. However, a clear trend for benefits with new ADP-
antagonists was found in almost all trials and for all our study endpoints and therefore, can be the 
probably ascribed to the more potent antiplatelet inhibition achieved with new molecules rather 
than a specific effect of a single drug. Finally, the application of new recently introduced definition 
of MI 32 would have improved the classification of this event and our final results. However, these 
data were available only from 1 trial, 33 and were not part of the primary study protocol. Therefore, 
they were not included in our analysis. 
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Conclusions 
 
Present meta-analysis shows that the new ADP-antagonists prasugrel, ticagrelor and cangrelor are 
associated to significant reduction of mortality, reinfarction, recurrent ischemia and stent thrombosis 
respect to clopidogrel alone, without significant increase in bleeding complications and therefore, 
their use should be strongly advised. 
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Abstract 
 
Despite new generation DES, the optimal duration of dual antiplatelet therapy (DAPT) still remains 
controversial. We performed a meta-analysis of randomized trials (RTs) evaluating the 
effectiveness and safety of shorter vs longer DAPT duration strategies in patients undergoing PCI 
with DES. Literature and main scientific sessions’ abstracts were searched. Primary endpoint was 
mortality. Secondary endpoints were: 1)cardiovascular mortality; 2)non fatal myocardial infarction; 
3)definite/probable stent thrombosis (ST); 4) major bleedings. 
We included 11 RTs, (n=32372 patients). Shorter DAPT duration reduced mortality 
(OR[95%CI]=0.85[0.71,1],p=0.05;phet=0.91). Similar results were  observed when  comparing 3-6 
vs 12 months DAPT, while a significant increase in recurrent ischemic events was found for 6-12 
months DAPT vs extended treatment (myocardial infarction: OR[95%CI] = 1.66 [1.37,2], 
p<0.00001; phet=0.13; ST: OR[95%CI]= 2.47[1.72,3.45], p<0.00001; phet=0.12), however, 
counterbalanced by a significant reduction in major bleedings (OR[95%CI]=0.60[0.47,0.76], 
p<0.0001; phet=0.38) and a trend in lower mortality. Thus, among selected patients undergoing 
DES implantation, a shorter DAPT strategy is associated with reduction in mortality and major 
bleedings but a higher risk of myocardial infarction and ST. A short duration (3-6 months) of DAPT 
appears as the safest strategy while a prolonged duration (24-36 months) reduces thrombotic 
complications, but with an excess in major bleeding complications 
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Background 
 
Optimal platelet inhibition represents a key point in the treatment of patients undergoing 
Percutaneous Coronary Interventions (PCI), and especially in the era of drug-eluted stents (DES) 
(1). The introduction of new, more potent antiplatelet agents and the identification of patients 
with high residual platelet reactivity led to better short and long-term clinical outcomes of patients 
with coronary artery disease (2-4). 
Still debated is the ideal duration of Dual Antiplatelet Therapy (DAPT) after coronary stenting 
especially after the introduction of second generation DES, associated with a consistent reduction 
of stent thrombosis as compared to first generation DES (5). A reduced DAPT duration could be 
considered safe, and also effective, reducing the risk of bleeding complications, which have been 
demonstrated to impact on mortality (6). On the other hand, very late (> 12 months) stent 
thrombosis reported after DES implantation suggest that DAPT may be extended beyond the 
recommended duration of 6 to 12 months (7). 
Several studies have been conducted so far to define the optimal duration of dual antiplatelet 
therapy after DES implantation. However they were not powered enough to evaluate hard 
endpoint such as mortality and stent thrombosis (ST), and therefore could not provide any 
conclusive recommendation for the optimal timing of DAPT discontinuation after DES implantation 
(8). 
Therefore, the aim of present meta-analysis was to compare the effectiveness in terms of 
mortality and bleeding complications of a shorter DAPT strategy versus an extended DAPT 
strategy in patients undergoing DES implantation. 
 
 
METHODS 
 
Eligibility and search strategy. The literature was scanned by formal searches  of electronic 
databases (MEDLINE, Cochrane and EMBASE) for clinical studies and furthermore the scientific 
session abstracts, searched on the TCT (www.tctmd.com), EuroPCR   (www.europcr.com),   
ACC   (www.acc.org),   AHA   (www.aha.org),   and     ESC (www.escardio.org) websites, for 
oral presentations and/or expert slide presentations from January 1990 to November 2014. The 
following key words were used: “dual antiplatelet therapy”, “clopidogrel”, “ticagrelor”, ”prasugrel”,  
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“duration”, “drug-eluting stent”, “DES”, “randomized”. 
No language restrictions were enforced. Inclusion criteria were: 1) Patients undergoing PCI with 
stent implantation; 2) availability of complete clinical data; 3) randomized treatment allocation. 
Exclusion criteria were: 1) follow-up data in less than 90% of patients and 2) ongoing studies or 
irretrievable data. 
Data extraction and validity assessment. Data were independently abstracted by two investigators 
(MV, AS). In case of incomplete or unclear data, authors were contacted. Disagreements were 
resolved by consensus. Data were managed according to the intention- to-treat principle. Data on 
cardiovascular mortality were collected if data on overall mortality were not available. 
Outcome measures. Primary endpoint was overall mortality. Secondary endpoints were: 1) 
cardiovascular mortality; 2) recurrent myocardial infarction; 3) stent thrombosis (ST; definite or 
probable according to ARC definition). Safety endpoint was the rate of major bleeding 
complications (according to protocol definition). 
 
Data analysis. Statistical analysis was performed using the Review Manager 4.27 freeware 
package, SPSS 17.0 statistical package. Odds ratio (OR) and 95% confidence intervals (95% CI) 
were used as summary statistics. The pooled odds ratio was calculated by using a fixed effect 
model (Mantel-Haensel). The Breslow-Day test was used to examine the statistical evidence of 
heterogeneity across the studies (p < 0.1). Potential publication bias was examined by constructing 
a “funnel plot”, in which sample size was plotted against odds ratios (for the primary endpoint). The 
study quality was evaluated by the same two investigators according to a score, that was 
expressed on a ordinal scale, allocating 1 point for the presence of each of the following: 1) 
statement of objectives; 2) explicit inclusion  and exclusion criteria; 3) description of intervention; 4) 
objective means of follow-up; 5) description of adverse events; 6) power analysis; 7) description of 
statistical methods; 8) multicenter design; 9) discussion of withdrawals; 10) details on medical 
therapy. 
A prespecificed analysis was performed according to the type of trial (trials comparing DAPT < 12 
months vs standard 12 months; trials comparing 6-12 months vs extended DAPT up to 24-36 
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months). 
A meta-regression analysis was carried out to evaluate the relationship between benefits in 
mortality (expressed as Log Odds Ratio) from shorter DAPT duration and  patient’s risk profile 
(expressed as log Odds for the event in control arm), the rate of acute coronary syndrome at 
presentation in control arm, or the risk in major bleeding complications (expressed as log Odds for 
the event in the control arm). The study was performed in compliance with the Preferred Reporting 
Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines (7). 
 
RESULTS 
 
Eligible studies. Out of 2215 citations, 13 trials were initially identified (6, 8-19). Two trials were 
excluded because of duplicates (15,19). Therefore, 11 randomized trials were finally included in 
our meta-analysis with a total of 32372 patients (6,8-14,16-19; Figure 1). 
A total of 5 trials (6, 8-10,16) evaluated the benefits of short DAPT (6023 patients randomized to 3-
6 months and 6055 patients to 12 months) and 6 trials (11-14,17,18) evaluated the benefits of 
extended DAPT (beyond 1 year) (10093 patients randomized to 6- 12 months and 10201 patients 
randomized to 18-36 months). 
Antiplatelet agents were mainly acetylsalicylic acid and clopidogrel at standard dose of 75 mg. In 4 
trials new P2Y12 inhibitors (prasugrel, ticagrelor) were also used in a group of patients 
(10,11,17,18). In one trial clopidogrel was administered at the dose of 150 mg daily in patients with 
pre-randomization high platelet reactivity at aggregation tests (11). 
Study characteristics of included trials are shown in Table 1. Mean follow-up was 18.7±8.3 months, 
ranging from 12 months (6,8-10,16) to 24-36 months (11-14,17-18). 
Table 2 displays the characteristics of enrolled patients, who had a mean age of 63.8±2.4 years, 
included about 72% males, 31.1% of diabetics, 49% of patients with stable CAD and 44.7% of 
patients with multivessel disease. New generation DES were used in the majority of patients, with  
BMS being implanted in < 25 % of patients in one trial (14). 
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Figure 1
194  2209 records identified by 
litterature search
73 full-lenght articles 
assessed for elegibility 
2142 citations excluded in case of: 1)  not full –lenght articles; 2) no 
original data; 3) meta-analysis
194  
60 studies excluded after
inclusion/exclusion criteria
application
(outcome endpoints, randomized
design, treatment completion
>90% of study population)
11 randomized trials  included in 
final meta-analysis
6 additional unpublished records 
identified  by manual search
2 trials excluded because were 
duplicates
194  13 randomized trials  
initially identified
 
Figure 1. Flow diagram of the systematic overview process. 
 
 
 
Clinical outcome 
 
Primary endpoint. Data on mortality were available in 30582 patients (94.4 % of total population). 
Three trials provided only cardiovascular mortality (10, 13, 16). A total of 559 patients (1.8%) 
had died at follow-up, with a significant reduction in mortality with shorter vs longer DAPT  duration 
(1.7  % (256/15233) vs  1.9% (303/15349),  OR[95%CI]=0.85[0.71,1],p=0.05; phet=0.91, Figure 2). 
Greatest benefits were obtained in trials on extended DAPT duration (<12 vs > 12 months; 2% 
(190/9270) vs 2.3% (225/9357), OR[95%CI]= 0.85   [0.69,1], p=0.10; phet=0.66), while trends in 
similar magnitude were found between 3 to 6 months and 12 months DAPT (1.1% (66/ 5963) vs 
1.3% (78/5992), OR[95%CI]= 0.84 [0.61, 1.18], p=0.32; phet=0.85, p interaction=0.99). 
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Table 1. Characteristics of included randomized studies. 
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Table 2. Clinical features of patients in included studies. 
 
 
 
 
By the use of meta-regression analysis, we found no relationship between the benefits in overall 
mortality from shorter DAPT and patients’ risk profile (r=0.27 (-0.30, 0.83), p=0.36), or the 
prevalence of acute coronary syndrome at presentation (r=-0.002 (-0.007, 0.01), p=0.68), and  the  
risk  of  bleedings  (r=-0.04  (-0.064,  0.55),  p=0.89),     (Figure  3  A,  B  and C, respectively). 
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Figure 2 Overall mortality
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Figure 2. Shorter versus longer DAPT (dual antiplatelet therapy) duration on mortality with odds ratios and 95% 
confidence intervals (CI). The size of the data markers (squares) is approximately proportional to the statistical weight 
of each trial. 
* Defined as cardiovascular mortality. 
 
 
 
Secondary endpoints 
 
Cardiovascular mortality 
 
 
Data on cardiovascular mortality were available in 25323 (78.2%) of patients. A total of 309 (1.2%) of 
patients had this event with no difference with respect to DAPT duration strategy (1.2% (149/12612) 
vs 1.2% (160/12711), OR[95%CI]= 0.94 [0.75,1.17], p= 0.57,  phet=0.95, Figure 4). Similar results 
were obtained in trials on short-term DAPT (3-6 months with 12 months; 0.9% (39/3966) vs 1.1% 
(45/3989), OR[95%CI]= 0.87 [0.56,1.34], p=0.52, phet=0.89), and extended DAPT (1.2%(110/8871) 
vs 1.3% (115/8958), OR[95%CI]=0.96 [0.74, 1.26], p=0.79, phet=0.76, p interaction=0.68).  
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Figure 4. Shorter versus longer DAPT (dual antiplatelet therapy) duration on cardiovascular mortality with odds ratios 
and 95% confidence intervals (CI). The size of the data markers (squares) is approximately proportional to the statistical 
weight of each trial. 
 
 
 
Myocardial infarction 
 
Data on recurrent myocardial infarction were available in 30582 patients (94.4%); among 
them, 643 (2.1%) experienced an event. A significant increase in the risk of non-fatal myocardial 
infarction was observed with a shorter vs longer DAPT strategy (2.5% (379/15233) vs 1.7% 
(264/15349), OR [95%CI]= 1.45 [1.24, 1.70], p<0.00001; phet=0.07, 
Figure 5), mainly driven by trials with extended DAPT duration (≤12 to > 12 months; 3.1% 
(281/9270)  vs  1.8%  (171/9357),  OR[95%CI]=  1.66  [1.37,  2],  p<0.00001;       phet=0.13), 
whereas similar results were obtained between the two treatment groups in trials on short- term 
DAPT (3-6 months with 12 months; 1.6% (98/5963) vs 1.5% (93/5992), OR[95%CI]= 
1.06 [0.80, 1.42], p=0.67, phet=0.65, p interaction=0.01). 
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Figure 5 Myocardial infarction
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Figure 5. Shorter versus longer DAPT (dual antiplatelet therapy) duration on myocardial infarction with odds ratios 
and 95% confidence intervals (CI). The size of the data markers (squares) is approximately proportional to the 
statistical weight of each trial. 
 
 
Stent thrombosis (ST). 
 
Data on definite/probable stent thrombosis were available in 30582 patients (94.4 %) (one 
study (14) evaluated only definite ST). A total of 188 (0.6 %) experienced such an event. The risk 
of ST was significantly doubled with shorter vs longer DAPT duration (0.8% (126/15233) vs 0.4% 
(62/15349), OR [95%CI]= 2.04 [1.52, 2.75], p<0.00001; phet=0.12, Figure 6). The 
results were mainly driven by a significant benefit in ST from extended (beyond 1 year) DAPT 
duration ((≤12 to > 12 months; 1.1% (101/9495) vs 0.4% (41/9594), OR[95%CI] = 2.47 [1.72, 
3.55], p<0.00001; phet=0.12;), while no significant difference was observed in trials on short 
DAPT duration (3-6 months vs 12 months; 0.5% (29/5963) vs 0.4% (23/5992), OR[95%CI]= 1.27 
[0.73, 2.19], p=0.40; phet=0.59, p interaction=0.05). 
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Figure 6 Stent thrombosis
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Figure 6. Shorter versus longer DAPT (dual antiplatelet therapy) duration on stent thrombosis (definite/probable) with 
odds ratios and 95% confidence intervals (CI). The size of the data markers (squares) is approximately 
proportional to the statistical weight of each trial. 
 
 
 
Safety endpoint. 
 
Data on major bleedings were available in 10 studies including 30400 patients (92.9%), of 
whom 339 patients (1.1%) experienced such an event. TIMI Major definition was used in 7 
studies (6, 8, 10, 12, 14, 15, 17). 
As displayed in Figure 7, shorter DAPT duration significantly reduced the rate of major 
bleeding events (0.8%, (127/15145) vs 1.4% (212/15255), OR [95%CI]= 0.61 [0.49, 0.76], 
p<0.00001; phet=0.86). The reduction in bleeding events was significant in trials evaluating 
extended DAPT duration (≤12 months vs > 12 months; 1.2%(104/9182) vs 1.9% (179/9263), 
OR[95%CI] = 0.60 [0.47, 0.76], p<0.0001; phet=0.38), while trials evaluating short DAPT duration 
showed a consistent and similar trend as indicated by the OR and the interaction value (3 to 
6 vs 12 months; 0.4% (23/5963) vs 0.6% (33/5992), OR[95%CI]= 0.70 [0.41,1.20], p=0.19, 
phet=0.99, p interaction=0.59). 
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Figure 7 Major bleedings
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Figure 7. Shorter versus longer DAPT (dual antiplatelet therapy) duration on major bleedings with odds ratios and 
95% confidence intervals (CI). The size of the data markers (squares) is approximately proportional to the statistical 
weight of each trial 
 
 
 
DISCUSSION 
 
Present study represents the largest meta-analysis of randomized trials comparing the safety and 
efficacy in terms of ischemic and bleeding complications of different DAPT duration strategies in 
patients undergoing percutaneous coronary revascularization with DES. 
Our meta-analysis showed that among patients undergoing DES implantation, a shorter DAPT 
duration is safer and associated with a significant reduction in overall mortality, a significant 
reduction in major bleeding, but associated with higher risk of late thrombotic complications, 
including stent thrombosis. The results were consistent for bleeding complications in the 2 
comparisons (shorter and longer than 1 year, p for interaction = NS). A significant reduction in 
thrombotic events was only observed in trials with prolonged DAPT (p for interaction = 0.01). 
Percutaneous coronary intervention (PCI) represents the preferred treatment for patients with  
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coronary artery disease, especially after the improvement in stent technologies, that have  
further contributed to enlarge the indication of percutaneous revascularization to a larger 
proportion of high-risk anatomical and clinical subsets, although potentially increasing the 
thrombotic complications (22). 
Therefore, achievement of quick and optimal platelet inhibition has become crucial for these 
patients, and mainly in those with acute presentation, where the use of potent antiplatelet 
agents has allowed to reduce the risk of periprocedural complications and improve outcome (2). 
However, controversy still exists about the optimal duration of DAPT after DES implantation. 
In fact, several concerns were raised with first generation DES with respect to the risk of stent 
thrombosis (ST) even long after PCI. A pooled analysis of over 6800 STEMI patients with up to 6 
years follow-up, showed that 1st generation DES were associated with a significantly higher risk of 
very late stent thrombosis as compared to BMS (23). Similarly, the International Drug-Eluting Stent 
Event Registry of Thrombosis (DESERT) Registry, reported that the majority of ST events occurred 
after 1 year (75%) and continued to occur for as long as 7.3 years (24). 
In the large National Heart, Lung, and Blood Institute Dynamic Registry, reported a significant 4-
year reduction of mortality in patients with extended DAPT after DES implantation (25). 
Opposite findings have been observed in the Patterns of non-Adherence to anti-platelet Regimens 
In Stented patients (PARIS-2) registry conducted mainly with new  generation DES. In fact, DAPT 
interruption was associated with a significantly increased rate of major cardiovascular events only 
within the first 7 days after PCI, and progressively decreased with time (26). The potentiality and 
safety of short DAPT duration has been suggested in some recent registries and meta-analysis of 
mainly observation studies (27). 
Moreover, a significant increase in bleedings may be expected in case of DAPT prolongation over 
12 months. In fact, in a large non-randomized registry, the Coronary Revascularization 
Demonstrating Outcome (CREDO)-Kyoto Registry Cohort-2 (28), prolonged thienopyridine therapy 
beyond 1 year did not reduce ischemic events, but showed a trend toward increased bleedings, that 
have been demonstrated to negatively influence in-hospital and long-term outcome after PCI (5). 
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However, few trials have evaluated so far the feasibility and efficacy of different DAPT duration 
strategies after DES implantation and the indications of current guidelines (29) are still contrasting, 
suggesting 6-12 months DAPT duration, but considering a premature discontinuation in high-
bleeding risk subjects or a prolongation in high-thrombotic risk patients, thus leaving room for 
operator’s choice. In a previous meta-analysis, including  only 4 randomized trials, Cassese et al. 
(30) concluded that the extension of DAPT after percutaneous coronary interventions could 
increase the risk of bleedings without reducing ischaemic events, as more recently reported in the 
Assessment by a Double Randomization of a Conventional Antiplatelet Strategy versus a 
Monitoring-guided Strategy for Drug-Eluting Stent Implantation and of Treatment Interruption versus 
Continuation One Year  after Stenting (ARCTIC) Interruption trial (13). However, in the meta-
analysis by Cassese et al. the power of each trial and of their pooled analysis was severely 
conditioned by the very small number of adverse events observed. Several additional large trials 
have been recently conducted (12, 14, 18-20), including also new antiplatelet agents, such as 
prasugrel and ticagrelor, but none of these was adequately powered to confidently evaluate low 
incidence endpoints such as mortality or stent thrombosis. 
In particular, the DAPT study, (19) including almost 10000 patients, showed a significant reduction 
in recurrent ischemic events associated with usage of ASA plus thienopyridines for 
30 months, and 55% of the benefits in preventing new onset of myocardial infarction was not 
related to stent thrombosis. It should be emphasized that less pronounced benefits were observed 
with Everolimus-Eluting stent, with a significant interaction among stents concerning the overall 
MACCE occurrence. A significant interaction was also observed for type of thienopyridine, with 
larger benefits in MACCE from prolonged DAPT in patients treated prasugrel than clopidogrel. 
Furthermore, these benefits in ischemic complications were counterbalanced by an increased 
rate of hemorrhagic bleedings. 
Indeed, according to a recent mathematic model proposed by Garg and colleagues (31), a 
“small” absolute difference in ischemic events with longer DAPT, would have been sufficient to 
outweigh the known bleeding risk associated with such a strategy, although expecting a 2- 5% 
reduction in major cardiovascular events from extended DAPT to worth, that is still much higher  
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than the absolute events rate observed in major trials. In fact, this model has not so far been 
confirmed in clinical practice, where hemorrhagic complications have been associated to an 
increased mortality in patients with cardiovascular disease (5). 
Several meta-analyses have been so far conducted to explore the optimal duration of DAPT after 
DES implantation. However, all of them failed to include all available randomized trials (32-37), or 
included a large spectrum of cardiovascular disorders beyond coronary DES implantation (38). 
Therefore, this is the largest, most comprehensive meta-analysis of randomized trials on DAPT 
duration after DES implantation. On a population of over 33000 PCI patients, about 50% elective 
and 50% acute patients, treated mainly with newer DES, we demonstrated that short DAPT 
duration, and in particular 3 to 6 months duration, appears as safe and effective as the standard of 
care of 12 months DAPT, while extended DAPT beyond 1 year is associated with an increased 
rate of major bleeding complications and a trend in higher mortality, despite a significant 
reduction in thrombotic events. While these results were not influenced by the percentage of 
ACS patients, and   therefore suggest that a strategy of short-term DAPT could be feasible in 
the setting of ACS, these data certainly need further confirmation from ongoing trials dedicated to 
this high risk clinical subsets (39). 
 
 
LIMITATIONS 
 
Certain limitations should be acknowledged. The most important one relates to the synthesis of 
data from different trials. However, no significant heterogeneity was found in our primary efficacy 
and safety endpoint, although the definitions of major bleedings differed among trials. 
The use of different DES generations in several studies is another important limitation, with still 
large quote of first generation DES in some major trials on prolonged DAPT duration (19). 
Improvement in DES technologies, leading to faster complete re-endothelization (40) accounts 
for MACE, including stent thrombosis. 
It might be argued that the use of new ADP-antagonists, which can more significantly reduce 
mortality or increase bleedings, could have modified our results. Indeed, clopidogrel was used 
in the majority of the included trials, however, similar findings were reported in the trials allowing  
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prasugrel administration (19), and even in the ARCTIC Interruption (13), where prasugrel was 
administered in poor clopidogrel responders. 
Finally, some caution should be exercised in the extension of these results to the daily 
practice, due to the method of patient selection in some of the trials included in this meta- 
analysis. The delayed randomization strategy used in some trials (13,14,16,18-20) restricting the 
inclusion to patients who were event-free at the end of the minimum planned DAPT duration, 
may have excluded major high-risk patients who might have potentially obtained larger benefits 
from prolonged DAPT. Furthermore, high-risk patients such as those with STEMI, left main 
disease, impaired ejection fraction or cardiogenic shock, were excluded in the majority of trials. 
 
CONCLUSIONS 
 
This meta-analysis showed that, among selected patients undergoing coronary DES implantation, 
a shorter DAPT strategy is associated with reduction in mortality and major bleeding 
complications but a higher risk of myocardial infarction and stent thrombosis. A short duration 
(3-6 months) of DAPT appears as the safest strategy and could be recommended, while a 
prolonged duration (24-36 months) reduces the incidence of thrombotic complications, but with an 
excess in major bleeding complications. 
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Summary and conclusions 
 
In this thesis we have addressed the several aspects of thrombosis in patients with coronary artery 
disease, analysing the markers and predictors of platelet hyper reactivity, with a particular focus on 
special, high-risk subsets of patients such as those suffering from diabetes mellitus. 
 
Chapter 1 explored the mechanisms linking platelet to the pathogenesis of acute 
spontaneous cardiovascular events or to periprocedural complications during percutaneous 
coronary interventions, providing an overview on the existing antithrombotic strategies and on 
the still burning unsolved problems. 
 
In Part 2 we evaluated the role of different platelet indexes on periprocedural myocardial 
infarction (PMI) in patients undergoing percutaneous coronary revascularization with stent 
implantation. 
 
Chapter 2, in particular, considered the impact of mean platelet volume (MPV) on PMI in a 
cohort of 1056 consecutive patients undergoing non-urgent PCI. Larger sized platelets, defined as 
tertiles values of MPV, did not increase the risk of periprocedural myonecrosis (adjusted p=0.64) or 
PMI (adjusted p=0.20). Subgroup analysis confirmed no impact of MPV on periprocedural MI also 
in high-risk subsets of patients, such as those with ACS at presentation, diabetes, elderly patients 
(age > 75 years), renal failure or according to gender. 
 
In Chapter 3, we assessed the role of the single nucleotide polymorphism Le33Pro of glycoprotein 
IIbIIIa (platelet PlA1/PlA2 or HPA-1 a/b antigen) on PMI and myonecrosis in 422 patients 
undergoing elective PCI. The 136 carriers of the Leu33Pro polymorphism were younger and more 
frequently dyslipidemic, PCI-related complications did not differ according to genotype, with the 
only exception of higher rate of distal embolization in polymorphic patients. However, in 
carriers of this GpIIIa polymorphism, the risk of periprocedural myonecrosis  and PMI  was not  
increased even after  correction for  baseline differences.  At subgroup analyses, however, in 
diabetics the Leu33Pro substitution was associated with over 4 fold-increased risk of PMI 
(Adjusted OR = 4.46 [1.12 –17.76] (p =0.03). 
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In Chapter 4 we demonstrated that the same platelet Leu33Pro genetic polymorphism did not 
affect the risk of periprocedural myocardial damage in 478 consecutive patients undergoing 
coronary angioplasty for non ST-segment elevation myocardial infarction. Although the patients in 
this study experienced more frequently PMI complications, as compared to the elective patients 
displayed in Chapter 3, no role of Le33Pro genetic polymorphism was confirmed even in special 
subgroups of patients. 
 
In Part 3 we discussed the challenging matter of diabetic patients with coronary artery 
disease. 
Chapter 5 evaluated the relationship between platelet size and coronary artery disease or 
platelet aggregation in diabetic patients. Among 1016 consecutive diabetic patients undergoing 
coronary angiography, larger Mean Platelet Volume (MPV) did not emerge as a predictor of the 
prevalence or extent of coronary artery disease at angiography. In addition, in 50 diabetic patients 
without history of coronary artery disease, we demonstrated by  the use of light transmission 
aggregometry that an increased MPV did not translate into a higher platelet reactivity. 
 
Chapter 6 addressed another interesting biomarker, uric acid, that has been  largely proposed as a 
mirror of the strict association between metabolic disorders, inflammation and atherosclerosis. We 
included a population of 3280 patients, 35.7% of them had diabetes. No significant difference was 
found in uric acid levels between diabetic and non diabetic patients (p=0.09). In fact, we identified 
age, renal failure, hypertension, smoking, BMI, use  of diuretics, statins, haemoglobin, triglycerides 
and HDL cholesterol levels as independent predictors of higher levels of uric acid (3rd tertile, ≥ 6.7 
mg/dl or 0.39 mmol/l). Among diabetic patients, no relationship was found between uric acid and 
the extent of coronary artery disease (adjusted p = 0.48), or severe CAD (adjusted p=0.94). 
Furthermore, uric acid   levels did not influence platelet reactivity in a subgroup of 50 diabetic 
patient without cardiovascular history. 
 
In Chapter 7 we documented that the well-known platelet hyper reactivity of diabetic patients can 
persist even despite dual antiplatelet therapy with the use of new, more potent, antiplatelet agents 
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as ticagrelor. Among 224 patients treated with a dual antiplatelet therapy with maintenance 
dosages of ASA and ticagrelor for a recent acute coronary syndrome (30- 90 days), diabetic status 
was associated to a higher platelet reactivity in response to different activating stimuli (p=0.046 for 
ASPI test, p=0.013 for COL test, p=0.04 for TRAP test and p=0.002 for ADP test), with a direct 
linear relationship between ADP-mediated aggregation and glycosylated hemoglobin, as a 
parameter of chronic glycemic control, (r=0.15, p=0.029). The rate of ticagrelor poor-responders 
was 12.9%. In addition, an almost double rate of patients with high-on treatment platelet 
reactivity during ticagrelor was observed in diabetics as compared to non-diabetics (p=0.025). 
 
Part 4 provided an overview on the major recent innovations in the field of antithrombotic 
therapies. 
Chapter 8 displayed the most updated and largest meta-analysis of randomized trials comparing 
bivalirudin with heparin (with or without Glycoprotein IIbIIIa inhibitors) in patients undergoing PCI, 
including over 40,000 patients. Considering the differential thrombotic and haemorrhagic risk in 
acute and elective settings, a prespecified analysis was conducted according to presentation 
(elective, ACS or STEMI). The primary endpoint, overall mortality, was observed in 1100 (2.8%) 
patients, with no difference between bivalirudin and heparin. Indeed bivalirudin, as compared with 
heparin, was associated with a significant reduction in major bleeding complications (p<0.00001) 
that, however, did not translate into mortality benefits. Furthermore, a higher rate of 30-days stent 
thrombosis and recurrent MI was observed among STEMI patients treated with bivalirudin, 
suggesting that its use should be confined to those sicker patients at higher of bleeding 
complications. 
In Chapter 9 we performed a meta-analysis of randomized trials comparing the new ADP 
antagonists prasugrel, ticagrelor and cangrelor with the traditional clopidogrel, in patients with 
stable angina or ACS undergoing mainly invasive management. We demonstrated that the new 
ADP-antagonists are associated with significant reduction in mortality, reinfarction, recurrent 
ischemia and stent thrombosis respect to clopidogrel, without a significant increase in bleeding 
complications, therefore providing further evidence for their use especially in higher-risk 
subsets of patients. 
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In Chapter 10, finally we addressed the debated matter of the optimal duration of dual 
antiplatelet therapy (DAPT) in patients undergoing percutaneous coronary interventions with drug 
eluting stents implantation. We performed a meta-analysis of 11 randomized trials comparing 3-6 
vs 12 months DAPT, or 6-12 months vs extended DAPT treatment. A shorter DAPT duration 
reduced mortality (p=0.05), and major bleedings but was associated with a higher risk of 
myocardial infarction and stent thrombosis, especially when compared with a prolonged 24-36 
months treatment. Therefore, a short duration (3-6 months) of DAPT appeared as the safest 
strategy while a prolonged duration (24-36 months) reduced thrombotic complications, but with an 
excess in major bleeding complications. 
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Future directions in the management of platelets reactivity and antithrombotic therapies in 
coronary artery disease 
 
 
1) Despite the great efforts focused on the identification of markers of enhanced thrombotic 
risk, the results on this topic are still unsatisfactory. The enthusiasm of inflammatory 
markers, platelet volume indexes and genetic variants,  has progressively decreased, after 
several studies, including those reported in this thesis, failed to identify any role of these 
markers in predicting platelet reactivity or cardiovascular risk. Nevertheless, the principle of 
identifying rapid, bedside indicators allowing to stratify patients’ thrombotic risk still 
maintains its forcefulness. Technological innovations have allowed to move towards the 
detection of infinitesimal levels of substances circulating in the bloodstream and to identify 
microscopic particles playing a crucial regulatory role in pathophysiology, as miRNA. 
Several miRNAs such as miR-92a and miR-712, which modulate endothelial cells 
proliferation and inflammation, are up-regulated by flow disturbance and contribute to 
atherosclerosis. In macrophages, miR-342-5p induces the expression of miR-155 during 
the progression of atherosclerosis, which promotes inflammatory gene expression and 
contributes to necrotic core formation (1). However, large scale data on these miRNA are 
still to be provided. 
 
 
2) A large number of assays has been developed and used in daily practice in order to 
evaluate platelet function, especially for those easy-to-perform whole blood aggregation 
tests, confirming the complexity of reproducing in vitro the phenomenon of aggregation. In 
fact, the test of choice and the cut-off points for assessing platelet reactivity are still matter 
of debate. More recently, the Multiplate impedance aggregometry has gained ground on 
other assays, after the positive results of the ISAR-ASPI trial (2) and the MADONNA 
trial (3). However, most randomized trials have so far failed to demonstrate an outcomes 
benefit from tailoring antiplatelet therapy based on aggregation tests (4). Therefore, a 
consensus on the definition of high platelet reactivity and poor response to antiplatelet 
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agents should be advocated based on data from larger scale studies. In addition, future 
trials should share light on the correct management of these patients poorly responding to 
antiplatelet agents, demonstrating whether switching between antiplatelet drugs could 
represent a valid option, especially in those subjects at higher thrombotic risk, as in 
diabetics, without safety concerns. 
 
3) In addition, the use of more potent antiplatelet agents should be advised, especially in 
higher risk settings, such as in complex percutaneous  interventions,  or in patients with 
intrinsic higher platelet reactivity. Glycoprotein IIbIIIa inhibitors are indeed the most 
effective platelet inhibitors, however, despite their undoubted  benefits, especially in the 
context of acute myocardial infarction and primary PCI (5), they have been set aside, in the 
last years, for a prevailing fear of potential bleeding complications (6). The emerging need 
of overcoming platelet hyper reactivity and oral drugs resistance, should perhaps lead to a 
new rise of these drugs, even, maybe with a more focused use in selected patients at 
higher thrombotic and lower hemorrhagic risk. 
 
 
4) Great advances in research have been accomplished also in the field of non anti- 
platelet agents. Particular attention should be deserved to statins, whose benefits in 
cardiovascular prevention can go far beyond their lipid-lowering effect. In fact, several trials 
have demonstrated that statins could provide protective effects from periprocedural 
myocardial injury or contrast induced nephropathy in patients undergoing PCI (7,8). In 
addition, their anti-inflammatory and anti –oxidant “pleiotropic effects” have been suggested 
to positively modulate platelets reactivity. 
However, the underlying mechanism of these pleiotropic effects still needs to be elucidated. 
An intriguing hypothesis, but yet to be verified, connects these non-lipid effects of statins 
ith vitamin D (9). In fact, Vitamin D is also a pro-hormone with potential anti-
inflammatory, anti-thrombotic and atheroprotective effects. Therefore, future studies should 
address the statins-vitamin D interaction and the role of their administration in 
cardiovascular prevention. 
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5) Finally, increasing complexity of patients being treated with stents implantation for 
coronary artery disease renders more difficult to identify the exact balance between 
thrombotic and bleeding complications. Therefore, dedicated studies including special 
higher-risk patients, such as elderly or patients with end-stage renal failure or requiring non-
deferrable surgery should be conducted, in order to define the best treatment options in 
these patients, that are not usually represented in large randomized trials. However, until 
new data become available, case by case decision, and the selection of the most commonly 
experienced strategies, whose complications we are more accustomed to manage, should 
be preferred in these subset. 
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Samenvatting en conclusies 
 
In dit proefschrift komen verschillende aspecten van trombose aan de orde bij patiënten met 
coronairlijden, waarbij markers en voorspellers van plaatjeshyperreactiviteit worden geanalyseerd. 
Daarbij ligt de focus op speciale, hoog-risico subgroepen van patiënten, zoals bijvoorbeeld 
patiënten met diabetes mellitus. 
 
Hoofdstuk 1 beschrijft de mechanismen via welke bloedplaatjes gerelateerd kunnen worden aan 
spontane cardiovasculaire events en aan periprocedurele complicaties tijdens een percutane 
coronaire interventie (PCI). Er wordt een overzicht gegeven van de huidige antitrombotische 
strategieën, en er wordt ingegaan op nog onopgeloste problemen. 
 
In Deel 2 wordt de rol beschreven van verschillende karakteristieken van plaatjes en de kans op 
een periprocedureel myocardinfarct (PMI) bij patiënten die een PCI ondergaan. 
 
In Hoofdstuk 2 werd de rol van het gemiddelde bloedplaatjes volume (mean platelet volume, MPV) 
bestudeerd in relatie tot een PMI in een cohort van 1056 patiënten die een niet- urgente PCI 
ondergingen. Het gemiddelde volume van de bloedplaatjes, ingedeeld in tertielen, was niet 
gerelateerd aan de het risico op periprocedurele necrose (gecorrigeerde p- waarde 0.64) of een PMI 
(gecorrigeerde p-waarde 0.20). Subgroep analyse liet evenmin een relatie zien in subgroepen met 
een hoog risico, zoals patiënten met een ACS bij presentatie, diabetes en ouderen (>75 jaar). Ook 
werd er geen geslachtsafhankelijk verschil waargenomen. 
 
In Hoofdstuk 3, onderzochten wij de rol van het “single nucleotide”-polymorfisme Leu33Pro van 
glycoproteine IIb/IIIa (het zogenaamde plaatjes PlA1/A2 of HPA-1 a/b antigeen) op PMI en 
myonecrosis in 422 patiënten met een electieve PCI. De 136 carriers van het “Leu33Pro 
polymorphism” waren jonger en er was vaker sprake van dyslipidemie. PCI-gerelateerde 
complicaties verschilden niet per genotype, met als enige uitzondering een hoger percentage distale 
embolisatie in patiënten met het polymorfisme. Echter, in carriers van dit GpIIIa polymorfisme, was 
het risico op periprocedural myonecrosis and PMI niet verhoogd, ook niet 
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na correctie voor verschillen in basis karakteristieken. Bij subgroup analyses, echter, bleek de 
Leu33Pro substitutie geassocieerd te zijn met een ruim 4 keer verhoogd risico op PMI in geval van 
diabetes mellitus (Adjusted OR = 4.46 [1.12 –17.76] (p =0.03). 
 
Hoofdstuk 4 beschrijft 478 opeenvolgende patiënten die een PCI ondergingen ivm een non- ST 
elevatie myocardinfarct: het risico op periprocedurele myocardiale schade was niet gerelateerd 
aan het bovenbeschreven genetische polymorfisme (Leu33Pro). Hoewel bij de patiënten in deze 
studie vaker een periprocedureel myocardinfarct optrad in vergelijking met de electieve patienten 
in de studie van Hoofdstuk 3, speelde het polymorfisme geen rol van betekenis, ook niet in 
bepaalde subgroepen van patienten. 
 
In Deel 3 wordt nader ingegaan op de intrigerende materie rondom coronairlijden bij diabeten. 
Hoofdstuk 5 beschrijft de relatie tussen het volume van de bloedplaatjes en aggregatie van 
bloedplaatjes in patienten met diabetes, evenals de relatie met coronairlijden. Bij 1016 
opeenvolgende diabetici die een coronair angiografie ondergingen, bleek het MPV (Mean Platelet 
Volume) niet gecorreleerd met de aanwezigheid of de uitgebreidheid van angiografisch bewezen 
coronairlijden. Daarnaast werd middels LTA (light transmission aggregometry) in 50 diabeten 
zonder voorgeschiedenis van coronairlijden aangetoond dat een toegenomen MPV niet 
gerelateerd was aan een hogere activiteit van de bloedplaatjes. 
 
Hoofdstuk 6 handelt over een andere interessante marker, urinezuur. Het wordt beschouwd als 
een algemene weerspiegeling van de metabole disregulatie, inflammatie en atherosclerose. Wij 
bestudeerden een populatie van 3280 patienten, 35.7% met diabetes. Er werd geen significant 
verschil gevonden in urinezuur spiegels tussen diabeten en niet diabeten (p=0.09). Als 
onafhankelijke voorspellers voor hogere spiegels van urinezuur (≥ 3e tertile, d.w.z. 6.7 mg/dl of 
0.39 mmol/l) kwamen de volgende variabelen naar voren : leeftijd, nierinsufficientie, hypertensie, 
roken, BMI, gebruik van diuretica, statines, hemoglobine, triglyceriden and HDL cholesterol. Onder 
de diabeten werd geen relatie gevonden tussen het 
urinezuur en de uitgebreidheid van coronairlijden (gecorrigeerde p = 0.48), en evenmin   met 
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ernstig coronairlijden (gecorrigeerde p=0.94). Daarnaast bleken urinezuur concentraties niet 
gerelateerd met de reactiviteit van de bloedplaatjes in een subgroup van 50 diabeten zonder 
cardiovasculaire voorgeschiedenis. 
 
In Hoofdstuk 7 wordt aangetoond dat de bij diabeten welbekende hyperreactiviteit van de 
bloedplaatjes zelfs onder gebruik van dubbele anti-plaatjes therapie kan persisteren, ook bij 
gebruik van het nieuwe, meer potente middel ticagrelor. Onder 224 patienten met een recent acuut 
coronair syndroom (30-90 dagen) behandeld met duale anti-plaatjes therapie in de vorm van 
een onderhoudsdosering aspirine en ticagrelor, was diabetes geassocieerd met hogere plaatjes 
reactiviteit in respons op verschillende activerende stimuli (p=0.046 for ASPI test, p=0.013 for 
COL test, p=0.04 for TRAP test and p=0.002 for ADP test); er was een directe lineaire relatie 
tussen ADP-gemedieerde aggregatie en geglycosyleerd hemoglobine, een proxy voor de 
chronische glycemische controle, (r=0.15, p=0.029). De proportie van “poor-responders” was 
12.9%. Bovendien werd er ten opzichte van niet diabeten een bijna verdubbeling van het aantal 
patienten gezien met hoge plaatjes reactiviteit, terwijl ze behandeld werden met ticagrelor 
(p=0.025). 
 
Deel 4 verschaft een overzicht mbt de belangrijkste ontwikkelingen op het gebied van 
antitrombotische therapie. 
Hoofdstuk 8 beschrijft de recentste update en grootste meta-analyse van gerandomiseerde trials 
die bivalirudine vergelijken met heparine (met of zonder glycoproteine IIb/IIIa remmers) in 
patiënten die een PCI ondergaan, met in totaal meer dan 40,000 patienten. Gezien het verschil 
in het risico op trombose en bloeden in een acute setting en in een electieve setting, werd er een 
vooraf gespecificeerde analyse verricht, afhankelijk van de klinische presentatie (electief, ACS, 
STEMI). Het primaire eindpunt, sterfte agv alle mogelijke oorzaken, werd waargenomen in 
1100 (2.8%) patienten, zonder verschil tussen bivalirudine en heparine. Zoals verwacht, 
resulteerde het gebruik van bivalirudine in een significante reductie in grote bloedingen, in 
vergelijking met heparine (p<0.00001). Dit verschil vertaalde zich echter niet in een voordeel in 
termen van overleving. Bovendien, werd er een hoger percentage stent 
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tromobse en reinfarct waargenomen, op 30 dagen bij de STEMI patiënten op bivalirudine, wat 
suggereert dat het gebruik ervan gereserveerd dient te worden voor de patiënten met een 
hoger risico op bloedingscomplicaties. 
 
In Hoofdstuk 9 wordt een meta-analysis beschreven van de gerandomiseerde studies naar de 
nieuwe ADP antagonisten prasugrel, ticagrelor and cangrelor, in vergelijking met het 
traditionele clopidogrel : dit alles in patienten met stabiele angina of ACS, waarbij er nadruk lag op 
een invasieve behandelstrategie. Wij lieten zien dat de nieuwe ADP-antagonisten resulteren in 
een significante daling van de mortaliteit, reinfarct, terugkerende ischemie en stent thrombose 
in vergelijking met clopidogrel, zonder een significante toename van het bloedingsrisico. Dit 
vormt aanvullend bewijs voor het gebruik van deze middelen, in het bijzonder in geval van 
patiënten die behoren tot een hoger-risico subgroep. 
 
In Hoofdstuk 10, tenslotte, komt de immer nog prangende kwestie aan de orde wat de 
optimale duur van dubbele antiplaatjestherapie is (DAPT) bij patiënten na een PCI met 
implantatie van een drug eluting stent (DES). Wij verrichtten een meta-analyse van 11 
gerandomiseerde trials die 3-6 vs 12 maanden DAPT vergeleken, dan wel 6-12 maanden vs 
langduriger DAPT. Een kortere duur van DAPT reduceerde de mortaliteit (p=0.05), en de kans 
op grote bloedingen, maar was geassocieerd met een hoger risico op een myocard infarct and 
stent trombose, vooral wanneer dit vergeleken werd met een regime van langdurige DAPT (24-36 
maanden). Samenvattend, een kortere duur (3-6 maanden) van DAPT leek de veiligste strategie, 
daar waar een verlengd regime (24-36 maanden) thrombotische complicaties reduceerde, zij het 
ten koste van een verhoogd risico op grote bloedingen. 
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Nieuwe ontwikkelingen op het gebied plaatjes reactiviteit en antitrombotische therapie in het 
kader van coronairlijden 
 
1) Ondanks de grote inspanningen om markers te identificeren die gepaard gaan met een 
verhoogd trombotisch risico, zijn de resultaten op dit gebeid tot dusver nog 
onbevredigend. Het enthousiasme in het onderzoek naar inflammatoire markers, 
bloedplaatjes volume indices en genetische varianten is progressief afgenomen. Dit, nadat 
er in verschillende studies, zoals ook in de onderzoeken in deze thesis, geen belangrijke 
rol lijkt weggelegd in het voorspellen van bloedplaatjes acitiviteit en coronairlijden. 
Desalniettemin is het potentieel van snelle, bedside identificatie  van het trombotisch risico 
van een patient enorm, wat toekomstig onderzoek op dit gebied onderhoudt. 
Technologische innovaties geven momenteel de  mogelijkheid tot detectie van oneindig 
kleine hoeveelheden in de bloedstroom circulerende substanties, en tot de identificatie van 
micropartikels die een cruciale regulatoire rol spelen in de pathofysiologie, zoals miRNA. 
Verscheidene miRNAs zoals miR-92a en miR-712, die endotheelcel proliferatie en 
inflammatie moduleren, worden ge- upreguleerd door veranderingen in de bloedstroom en 
dragen bij aan atherosclerose. In macrofagen induceert miR-342-5p de expressie van miR-
155 tijdens de progressie van atherosclerose, wat inflammatoire genexpressie stimuleert 
en bijdraagt aan formatie van een necrotische kern (1). Echter, grootschalig bewijs op het 
gebied van deze miRNA’s moet nog geleverd worden. 
2) Er is een groot aantal verschillende assays ontwikkeld dat in de dagelijkse praktijk gebruikt 
wordt om plaatjesfunctie te evaluereen, in het bijzonder aggregatie testen die gemakkelijk 
zijn in gebruik en waarbij met volbloed gewerkt kan worden. De verscheidenheid 
weerspiegelt de complexiteit om een representatieve in vitro test te ontwikkelen voor een 
proces als bloedplaatjes aggregatie. Nog steeds is er geen eenduidigheid mbt de te 
prefereren test; hetzelfde geldt overigens voor de bijbehorende normaalwaarden en 
afkapwaarden om plaatjes reactiviteit te bepalen. 
Recent  heeft  de  Multiplate  impedance  aggregometry  terrein  gewonnen,  na     de 
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positieve resultaten van de ISAR-ASPI trial (2) en de MADONNA trial (3). Echter, de 
meeste gerandomiseerde studies hebben tot dusver geen verbeteringen  in uitkomsten 
opgeleverd middels aangepaste antitrombotische therapie op basis van uitslagen van 
aggregatie testen (4). In het licht van bovenstaande, is er behoefte aan een consensus met 
betrekking tot de definitie van begrippen als ‘hoge bloedplaatjes reactiviteit’ en ‘slechte 
respons op antiplaatjes therapie’, op basis van data van grootschalige studies. Daarnaast 
moeten toekomstige studies uitwijzen in hoeverre het wisselen naar een ander 
antiplaatjes middel de uitkomst kan verbeteren, bij patienten die slecht reageren op een 
bepaalde vorm van antiplaatjes  therapie. Daarbij lijken patiënten met een a priori hoog 
trombotisch risico, zoals diabetici, de geschikte kandidaten, waarbij naast effectiviteit ook 
veiligheid in het onderzoek betrokken dient te worden. 
3) Bovendien zal zeker in hoog risico settings als complexe PCIs en in geval van verhoogde 
plaatjes reactiviteit een advies, dan wel voorkeur, voor meer potente antiplaatjes middelen 
te dienen worden opgesteld. Glycoproteine IIb/IIIa remmers zijn zonder meer het sterkst 
qua remming van de bloedplaatjes aggregatie, maar zijn geleidelijk aan steeds minder 
gebruikt ondanks evidente voordelen in de setting van een primaire PCI bij het acute 
myocardinfarct (5), wat voornamelijk wordt gedreven door de kans op 
bloedingscomplicaties (6). Gezien de nog immer prangende vraag naar oplossingen op 
het gebied van ‘verhoogde plaatjesactiviteit’ en ‘ongevoeligheid voor antiplaatjes 
medicatie’, lijkt een hernieuwd initiatief tot vaker gebruik van deze medicatie op zijn 
plaats, waarbij de focus dan mogelijk meer moet liggen  op de patiënt met een hoog 
trombotisch ririsco en een wat lager bloedingsrisico. 
4) Naast de ontwikkelingen in antiplaatjestherapie, zijn er ook andere grote stappen 
gemaakt in het onderzoek naar hart- en vaatziekten. In het bijzonder verdienen de 
statines, waarvan de voordelen op het terrein van cardiovasculaire preventie veel verder 
reiken dan een puur op lipiden verlaging gebaseerd effect. Verscheidene studies hebben 
aangetoond dat het gebruik van statines voor een PCI protectief 
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werkt mbt de kans op periprocedurele myocardinfarcten en constrastnefropathie. (7,8). 
Daarnaast lijkt plaatjes reactiviteit gunstig beinvloed te worden als gevolg van anti-
inflammatoire en anti-oxidatieve eigenschappen, de zogenaamde ‘pleiotrope effecten’ van 
statines. Het exacte mechanisme dat ten grondslag ligt aan deze pleiotrope effecten dient 
nader ontrafeld te worden. Een intrigerende hypothese, die nog verificatie vereist, legt een 
verband tussen vitamine D en deze niet van lipiden verlaging afhankelijke effecten (9). 
Vitamine D fungeert ook als een pro-hormoon met potentielel anti-inflammatoire, anti-
trombotische en atheroprotectieve effecten. Er wordt derhalve uitgezien naar studies die 
de interactie tussen statines en vitamin D nader beschrijven, en de invloed op 
cardiovasculaire protectie. 
5) Tenslotte zal in de loop der jaren een steeds complexere populatie patienten aangeboden 
worden voor percutane interventies met stenting. Hierdoor zal  het steeds moeilijker worden 
om de juiste balans tussen trombotisch risico en bloedingsrisico in te schatten. Er is 
derhalve behoefte aan studies puur toegewijd aan hoog-risico patienten zoals de oudere 
patient en patienten met eindstadium nierinsufficientie. Ook patienten die op afzienbare 
termijn (niet cardiale) chirurgie dienen te ondergaan die niet uitgesteld kan worden 
vormen een belangrijke groep voor nader onderzoek. Deze patiënten zijn vaak niet 
vertegenwoordigd in de gerandomiseerde studies. Niet voordat er nieuwe studiedata 
beschikbaar komen, zal er, per individu, telkens opnieuw, moeten worden afgewogen wat 
te doen. Daarbij verdient de strategie de voorkeur waarmee men het meest vertrouwd en 
ervaren is, en waarbij ook de ervaring en het gemak mbt het management van de 
eventuele complicaties dient te worden meegenomen in het besluit. 
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